0001683168-21-001967.txt : 20210513 0001683168-21-001967.hdr.sgml : 20210513 20210513164321 ACCESSION NUMBER: 0001683168-21-001967 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210513 DATE AS OF CHANGE: 20210513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medicine Man Technologies, Inc. CENTRAL INDEX KEY: 0001622879 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 465289499 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55450 FILM NUMBER: 21920300 BUSINESS ADDRESS: STREET 1: 4880 HAVANA STREET STREET 2: SUITE 201 SOUTH CITY: DENVER STATE: CO ZIP: 80239 BUSINESS PHONE: 303-371-0387 MAIL ADDRESS: STREET 1: 4880 HAVANA STREET STREET 2: SUITE 201 SOUTH CITY: DENVER STATE: CO ZIP: 80239 10-Q 1 medman_10q-033121.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________.

Commission File Number 000-55450

MEDICINE MAN TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada

46-5289499

(State or other jurisdiction of

Incorporation or organization)

(I.R.S. Employer Identification No.)

4880 Havana Street

Suite 201

Denver, Colorado 80239

(Address of principal executive offices, zip code)

(303) 371-0387

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name on each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated filer ☒	Smaller reporting company ☒
		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 10, 2021, the Registrant had 42,331,595 shares of Common Stock outstanding.

TABLE OF CONTENTS

		Page
Part I – FINANCIAL INFORMATION

Item 1.	Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	29
Item 4.	Controls and Procedures	29

Part II – OTHER INFORMATION

Item 1.	Legal Proceedings	31
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
Item 3.	Defaults upon Senior Securities	31
Item 4.	Mine Safety Disclosures	32
Item 5.	Other Information	32
Item 6.	Exhibits	32

Signatures		33

NOTE ABOUT FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), adopted pursuant to the Private Securities Litigation Reform Act of 1995. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, business strategy and plans, and objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual events or our actual results, performance, or achievements to be materially different from the future events, results, performance or achievements expressed or implied by any forward-looking statements. There can be no assurance that future events, results, performance or achievements will be in accordance with our expectations or that the effect of future events, results, performance or achievements will be those anticipated by us.

Factors and risks that may cause or contribute to actual events, results, performance or achievements differing from these forward-looking statements include, but are not limited to, for example:

regulatory limitations on our products and services;

our ability to complete and integrate announced acquisitions;

general industry and economic conditions;

our ability to access adequate capital upon terms and conditions that are acceptable to us;

volatility in credit and market conditions;

other risks and uncertainties related to the cannabis market and our business strategy.

We operate in very competitive and rapidly changing markets. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

Stockholders and potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this Quarterly Report on Form 10-Q are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved.

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Considering these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements concerning other matters addressed in this Quarterly Report on Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Quarterly Report on Form 10-Q.

All forward-looking statement speak only as of the date of this Quarterly Report on Form 10-Q. Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether because of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Part I. FINANCIAL INFORMATION

Item 1. Financial Statements

MEDICINE MAN TECHNOLOGIES, INC.

CONDENSED BALANCE SHEETS

Expressed in U.S. Dollars

	March 31, 2021			December 31, 2020
	(Unaudited)			(Audited)
Assets
Current assets
Cash and cash equivalents	$	22,966,320		$	1,231,235
Accounts receivable, net of allowance for doubtful accounts		2,365,063			1,270,380
Accounts receivable – related party		–			80,494
Inventory		5,588,257			2,619,145
Notes receivable – related party		40,231			181,911
Prepaid expenses		627,016			614,200
Total current assets		31,586,887			5,997,365
Non-current assets
Fixed assets, net accumulated depreciation of $1,032,211 and $872,579, respectively		3,089,027			2,584,798
Goodwill		40,532,910			53,046,729
Intangible assets, net accumulated amortization of $1,796,386 and $200,456, respectively		97,589,114			3,082,044
Marketable securities, net of unrealized gain (loss) of $214,630 and ($129,992), respectively		491,412			276,782
Accounts receivable – litigation		3,063,968			3,063,968
Other noncurrent assets		423,710			51,879
Operating lease right of use assets		4,242,124			2,579,036
Total non-current assets		149,432,265			64,685,236
Total assets	$	181,019,152		$	70,682,601

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	2,481,572		$	3,508,478
Accounts payable – related party		41,123			48,982
Accrued expenses		8,298,446			2,705,445
Derivative liabilities		2,301,295			1,047,481
Deferred revenue		–			50,000
Notes payable – related party		–			5,000,000
Total current liabilities		13,122,436			12,360,386
Long-term liabilities
Long term debt		54,250,000			13,901,759
Lease liabilities		4,342,018			2,645,597
Total long-term liabilities		58,592,018			16,547,356
Total liabilities		71,714,454			28,907,742


Shareholders’ equity
Common stock $0.001 par value. 250,000,000 authorized, 42,819,815 shares issued and 42,331,595 outstanding as of March 31, 2021 and 42,601,773 shares issued and 42,169,041 outstanding as of December 31, 2020, respectively.		42,820			42,602
Preferred stock $0.001 par value. 10,000,000 authorized. 87,266 shares issued and outstanding as of March 31, 2021 and 19,716 shares issued and outstanding as of December 31, 2020, respectively.		87			20
Additional paid-in capital		157,530,563			85,357,835
Accumulated deficit		(46,823,076	)		(42,293,098	)
Common stock held in treasury, at cost, 488,220 shares held as of March 31, 2021 and 432,732 shares held as of December 31, 2020.		(1,445,696	)		(1,332,500	)
Total shareholders' equity		109,304,698			41,774,859
Total liabilities and stockholders’ equity	$	181,019,152		$	70,682,601

See accompanying notes to the financial statements

MEDICINE MAN TECHNOLOGIES, INC.

CONDENSED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)

For the Three Months Ended March 31, 2021 and 2020

Expressed in U.S. Dollars

	Three Months Ended March 31,
	2021			2020
Operating revenues
Retail	$	11,816,200		$	–
Wholesale		7,446,265			2,528,931
Other		77,650			674,203
Total revenue		19,340,115			3,203,134
Cost of goods and services
Cost of goods and services		12,087,111			2,148,535
Total cost of goods and services		12,087,111			2,148,535
Gross profit		7,253,004			1,054,599
Operating expenses
Selling, general and administrative		3,189,638			666,919
Professional services		2,195,108			1,248,988
Salaries		1,869,358			1,997,036
Stock-based compensation		1,483,806			1,252,731
Total operating expenses		8,737,910			5,165,674
Loss from operations		(1,484,906	)		(4,111,075	)
Other income (expense)
Interest income (expense), net		(961,282	)		48,042
Gain on forfeiture of contingent consideration		–			1,462,636
Unrealized gain (loss) on derivative liabilities		(1,253,814	)		1,191,963
Gain (loss) on sale of assets		292,479			–
Unrealized gain (loss) on investment		214,630			29,124
Total other income (expense)		(1,707,987	)		2,731,765
Loss before income taxes		(3,192,893	)		(1,379,310	)
Provision for income tax (benefit) expense		456,614			–
Net loss	$	(3,649,507	)	$	(1,379,310	)

Loss per share attributable to common shareholders
Basic and diluted loss per share	$	(0.09	)	$	(0.03	)
Weighted average number of shares outstanding, basic and diluted		42,616,309			39,952,628

Comprehensive loss	$	(3,649,507	)	$	(1,379,310	)

See accompanying notes to the financial statements

MEDICINE MAN TECHNOLOGIES, INC.

STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

For the Three Months Ended March 31, 2021 and 2020

Expressed in U.S. Dollars

	Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Treasury Stock					Total Stockholders’
	Shares		Value		Shares		Value		Capital		Deficit			Shares		Cost			Equity
Balance at, December 31, 2019		–		–		39,952,628	$	39,953	$	50,356,469	$	(22,816,477	)		257,732	$	(1,000,000	)	$	26,579,945
Net income (loss)		–		–		–		–		–		(1,379,310	)		–		–			(1,379,310	)
Stock based compensation expense related to common stock options		–		–		–		–		1,252,731		–			–		–			1,252,731
Balance, March 31, 2020		–		–		39,952,628	$	39,953	$	51,609,200	$	(24,195,787	)		257,732	$	(1,000,000	)	$	26,453,366

	Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Treasury Stock					Total Stockholders’
	Shares		Value		Shares		Value		Capital		Deficit			Shares		Cost			Equity
Balance at, December 31, 2020		19,716		20		42,601,773	$	42,602	$	85,357,835	$	(42,099,098	)		432,732	$	(1,332,500	)	$	41,774,859
Net income (loss)		–		–		–		–		–		(3,649,507	)		–		–			(3,649,507	)
Issuance of stock as payment for acquisitions		20,240		20		–		–		20,239,980		–			–		–			20,240,000
Return of common stock as compensation to employees, officers and/or directors		–		–		–		–		–		–			–		–			–
Issuance of common stock as compensation to employees, officers, and/or directors		–		–		218,042		218		444,588		–			–		–			444,806
Issuance of stock in connection with sales made under private or public offerings		47,310		47		–		–		50,449,160		–			–		–			50,449,207
Dividends declared		–		–		–		–		–		(880,471	)		–		–			(880,471	)
Return of common stock		–		–		–		–		–		–			55,488		(113,196	)		(113,196	)
Stock based compensation expense related to common stock options		–		–		–		–		1,039,000		–			–		–			1,039,000
Balance, March 31, 2021		87,266		87		42,819,815	$	42,820	$	157,530,563	$	(46,823,076	)		488,220	$	(1,445,696	)	$	109,304,698

See accompanying notes to the financial statements

MEDICINE MAN TECHNOLOGIES, INC.

STATEMENT OF CASH FLOWS (UNAUDITED)

For the Three Months Ended March 31, 2021 and 2020

Expressed in U.S. Dollars

	For the Three Months Ended March 31,
	2021			2020
Cash flows from operating activities
Net loss for the period	$	(3,649,507	)	$	(1,379,310	)
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization		1,790,568			6,113
Gain on forfeiture of contingent consideration		–			(1,462,636	)
(Gain) loss on change in derivative liabilities		1,253,814			(1,191,963	)
(Gain) loss on investment, net		(214,630	)		(29,124	)
Stock based compensation		1,483,806			1,252,731
Changes in operating assets and liabilities
Accounts receivable		(1,014,189	)		(107,426	)
Accrued interest receivable		–			(1,248	)
Inventory		225,878			42,251
Prepaid expenses and other current assets		(12,816	)		–
Other assets		(371,831	)		(178,290	)
Operating lease right of use assets and liabilities		33,334			5,053
Accounts payable and other liabilities		2,224,092			572,827
Deferred revenue		(50,000	)		–
Net cash provided by (used in) operating activities		1,698,519			(2,471,022	)

Cash flows from investing activities
Purchase of fixed assets		(633,114	)		(307,178	)
Cash consideration for acquisition of business		(65,109,039	)		–
Issuance of notes receivable		141,680			–
Net cash (used in) investing activities		(65,600,473	)		(307,178	)

Cash flows from financing activities
Proceeds from issuance of debt, net		40,348,241			–
Repayment of notes payable		(5,000,000	)		–
Proceeds from issuance of stock, net of issuance costs		50,282,798			–
Net cash provided by financing activities		85,631,039			–

Net (decrease) increase in cash and cash equivalents		21,729,085			(2,778,200	)
Cash and cash equivalents at beginning of period		1,237,235			11,853,627
Cash and cash equivalents at end of period	$	22,966,320		$	9,075,427

Supplemental disclosure of cash flow information:
Cash paid for interest	$	897,247		$	–

See accompanying notes to the financial statements

MEDICINE MAN TECHNOLOGIES, INC.

NOTES TO UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS

Organization and Nature of Operations

Medicine Man Technologies, Inc. (“we,” “us,” “our” or the “Company”) was incorporated in Nevada on March 20, 2014. On May 1, 2014, we entered into a non-exclusive Technology License Agreement with Futurevision, Inc., f/k/a Medicine Man Production Corp., dba Medicine Man Denver (“Medicine Man Denver”) pursuant to which Medicine Man Denver granted us a license to use all of the proprietary processes that they had developed, implemented and practiced at their cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future) (the “License Agreement”) for 10 years.

In 2017, the Company acquired additional cultivation intellectual property through the acquisition of Success Nutrients™ and Pono Publications, including the rights to the book titled “Three A Light” and its associated cultivation techniques, which have been part of the Company’s products and services offerings since the acquisition. The Company acquired Two J’s LLC d/b/a The Big Tomato (“The Big Tomato”) in 2018, which operates a retail location in Aurora, Colorado. It has been a leading supplier of hydroponics and indoor gardening supplies in the metro Denver area since May 2001. The Company was focused on cannabis dispensary and cultivation consulting and providing equipment and nutrients to cannabis cultivators until its first plant touching acquisition in April of 2020. In 2019, due to the changes in Colorado law permitting non-Colorado resident and publicly traded investment into “plant-touching” cannabis companies, the Company made a strategic decision to move toward direct plant-touching operations. The Company developed a plan to roll up a number of direct plant-touching dispensaries, manufacturing facilities, and cannabis cultivations with a target to be one of the largest seed to sale cannabis businesses in Colorado. In April 2020, the Company acquired its first plant-touching business, Mesa Organics Ltd. (“Mesa Organics”), which consists of four dispensaries and one manufacturing infused products facility (“MIP”), d/b/a Purplebee’s.

On April 20, 2020, the Company rebranded and conducts its business under the trade name, Schwazze. The corporate name of the Company continues to be Medicine Man Technologies, Inc. Effective April 21, 2020, the Company commenced trading under the OTC ticker symbol SHWZ.

On December 17, 2020, the Company closed on the acquisition of (i) Starbuds Pueblo LLC; and (ii) Starbuds Alameda LLC. On December 18, 2020, the Company closed on the acquisition of (i) Starbuds Commerce City LLC; (ii) Lucky Ticket LLC; (iii) Starbuds Niwot LLC; and (iv) LM MJC LLC under the applicable Asset Purchase Agreements (“APAs”).

On February 4, 2021, the Company acquired the assets of Colorado Health Consultants LLC and Mountain View 44th LLC under the applicable APAs.

On March 2, 2021, the Company acquired the assets of (i) Starbuds Aurora LLC, (ii) SB Arapahoe LLC; (iii) Citi-Med LLC; (iv) Starbuds Louisville LLC; and (v) KEW LLC under the applicable APAs.

From December 2020 through March 2021 the Company completed a private placement of Series A Cumulative Convertible Preferred Stock (“Series A Preferred Stock”) for aggregate gross proceeds of $57.7 million dollars. In the private placement, the Company issued and sold an aggregate of 57,700 shares of Series A Preferred Stock at a price of $1,000 per share under securities purchase agreement with Dye Capital Cann Holdings II, LLC (“Dye Cann II”) and CRW Cann Holdings, LLC (“CRW”) as well as subscription agreements with unaffiliated investors. Among other terms, each share of Series A Preferred Stock (i) earns an annual dividend of 8% on the “preference amount,” which initially is equal to the $1,000 per-share purchase price and subject to increase, by having such dividends automatically accrete to, and increase, the outstanding preference amount; (ii) is entitled to a liquidation preference under certain circumstances, (iii) is convertible into shares of the Company’s common stock by dividing the preference amount by $1.20 per share under certain circumstances, and (iv) is subject to a redemption right or obligation under certain circumstances.

In addition, on December 16, 2020, the Company issued and sold a Convertible Promissory Note and Security Agreement in the original principal amount of $5,000,000 to Dye Capital & Company, LLC (“Dye Capital”). On February 26, 2021, Dye Capital converted all outstanding amounts under the note into 5,060 shares of Preferred Stock.

The Company is focused on growing through internal growth, acquisition, and new licenses in the Colorado cannabis market. The Company is focused on building the premier vertically integrated cannabis company in Colorado. The company's leadership team has deep expertise in mainstream consumer packaged goods, retail, and product development at Fortune 500 companies as well as in the cannabis sector. The Company has a high-performance culture and a focus on analytical decision making, supported by data. Customer-centric thinking inspires the Company’s strategy and provides the foundation for the Company’s operational playbooks.

The Company’s operations are organized into three different segments as follows: (i) retail, consisting of retail locations for sale of cannabis products, (ii) wholesale, consisting of manufacturing and sale of wholesale cannabis products, nutrients for cannabis, and hydroponics and indoor gardening supplies, and (iii) other, consisting of all other income and expenses, including those related to licensing and consulting services, facility design services, facility management services, and corporate operations.

1.	Liquidity and Capital Resources:

During the quarters ended March 31, 2021 and 2020, the Company primarily used revenues from its operations to fund its operations.

Cash and cash equivalents are carried at cost and represent cash on hand, deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date. The Company had $22,966,320 and $1,231,235 classified as cash and cash equivalents as of March 31, 2021 and December 31, 2020, respectively.

The Company maintains its cash balances with a high-credit-quality financial institution. At times, such cash may be more than the insured limit of $250,000. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on its cash and cash equivalents.

To mitigate credit risk, the Company may purchase highly liquid investments with an original maturity of three months or less. As of March 31, 2020, the Company had one United States Treasury Bill with a maturity date of April 7, 2020 and bearing interest at a rate of approximately 0.65%. The Company did not have any such United States Treasury Bills as of March 31, 2021.

2.	Critical Accounting Policies and Estimates

Management’s Representation of Interim Financial Statements

The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of the Company’s financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of December 31, 2020 and 2019, as presented in the Company’s Annual Report on Form 10-K filed on March 31, 2021 with the SEC.

Basis of Presentation

These accompanying financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the SEC for interim financial statements. All intercompany accounts and transactions are eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Reclassifications

During the quarter ended March 31, 2021, we changed our segments based on the way management discusses and reviews financial information. Certain prior year amounts have been reclassified to conform to the current year presentation. These reclassifications had no impact on the Company’s net (loss) earnings and financial position.

Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments include cash, accounts receivable, notes receivable, accounts payables and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. The Company’s derivative liability was adjusted to fair market value at the end of the year, using Level 3 inputs.

The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2021 and December 31, 2020, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):

March 31,

2021

December 31,

2020

Level 1 – Marketable Securities Available-for-Sale – Recurring

491,412

276,782

Marketable Securities at Fair Value on a Recurring Basis

Certain assets are measured at fair value on a recurring basis. The Level 1 position consists of an investment in equity securities held in Canada House Wellness Group, Inc., a publicly-traded company whose securities are actively quoted on the Toronto Stock Exchange.

Fair Value of Financial Instruments

The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available-for-sale securities are recorded at current market value as of the date of this report.

Accounts Receivable

The Company extends unsecured credit to its customers in the ordinary course of business. This accounts receivable relates to the Company’s wholesale and other revenue segments. Accounts receivable is recorded when a milestone is reached at point in time resulting in funds being due for delivered goods or services, and where payment is reasonably assured. Wholesale revenues are generally collected within 14 to 30 days after invoice is sent. Consulting revenues are generally collected from 30 to 60 days after the invoice is sent.

The following table depicts the composition of our accounts receivable as of March 31, 2021, and December 31, 2020:

	March 31, 2021			December 31, 2020
Accounts receivable – trade	$	2,524,718		$	1,315,188
Accounts receivable – related party		–			80,494
Accounts receivable – litigation, non-current		3,063,968			3,063,968
Allowance for doubtful accounts		(159,656	)		(44,808	)
Total accounts receivable	$	5,429,031		$	4,414,842

The Company establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade receivables. A considerable amount of judgment is required in assessing the amount of the allowance. The Company makes judgments about the creditworthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the customers were to deteriorate, resulting in their inability to make payments, a specific allowance will be required. As of March 31, 2021 and December 31, 2020, the Company recorded an allowance for doubtful accounts of $159,656 and $44,808, respectively.

Notes Receivable

On July 17, 2018, the Company entered into an intellectual property license agreement with Abba Medix Corp. (“AMC”), a wholly owned subsidiary of publicly traded Canada House Wellness Group, Inc.. The Company agreed to provide a lending facility to AMC in CAD$125,000 increments of up to CAD$500,000. The lending facility is for a term of 36 months and bears interest at a rate of 2%. As of March 31, 2021 and December 31, 2020, the outstanding balance, including accrued interest, on the notes receivable with AMC totaled $248,025 and $246,765, respectively. As of March 31, 2021 and December 31, 2020, the Company has recorded a full allowance on the note receivable balance.

Other Assets (Current and Non-Current)

Other assets as of March 31, 2021 and December 31, 2020 were $1,050,726 and $666,079, respectively. As of March 31, 2021, this balance included $627,016 in prepaid expenses and $423,710 in security deposits. As of December 31, 2020, other assets included $345,777 in prepaid expenses, $268,423 in tax receivable, and $51,879 in security deposits. Prepaid expenses were primarily comprised of insurance premiums, membership dues, conferences and seminars, and other general and administrative costs.

Goodwill and Intangible Assets

Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from the Company’s acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. The Company’s amortizable intangible assets consist of licensing agreements, product licenses and registrations, and intellectual property or trade secrets. Their estimated useful lives range from 10 to 15 years.

Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. The Company performs an annual impairment assessment for goodwill during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, the Company determines fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, the Company relies on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, the Company’s risk relative to the overall market, the Company’s size and industry and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.

Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that the Company’s estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause the Company to perform an impairment test prior to scheduled annual impairment tests.

The Company performed its annual fair value assessment as of December 31, 2020, on its subsidiaries with material goodwill and intangible asset amounts on their respective balance sheets and determined that no impairment exists. No additional factors or circumstances existed as of March 31, 2021 that would indicate impairment.

Long-Lived Assets

The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances have indicated that an asset may not be recoverable. The long-lived asset is grouped with other assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows is less than the carrying value of the assets, the assets are written down to the estimated fair value.

The Company evaluated the recoverability of its long-lived assets on December 31, 2020 on its subsidiaries with material amounts on their respective balance sheets and determined that no impairment exists.

Accounts Payable

Accounts payable as of March 31, 2021 and December 31, 2020 were $2,522,695 and $3,557,460, respectively and were comprised of trade payables for various purchases and services rendered during the ordinary course of business.

Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities as of March 31, 2021 and December 31, 2020 were $8,298,446 and $2,705,445, respectively. As of March 31, 2021, this was comprised of customer deposits of $24,958, accrued payroll of $1,402,814, and operating expenses of $6,870,674. As of December 31, 2020, accrued expenses and other liabilities was comprised of customer deposits of $26,826, accrued payroll of $1,154,887, and operating expenses of $1,523,732.

Revenue Recognition and Related Allowances

The Company’s revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until is the criteria are met. When consideration is received in advance of the delivery of goods or services, a contract liability is recorded. Revenue contracts are identified when accepted from customers and represent a single performance obligation to sell the Company’s products to a customer.

The Company has three main revenue streams: retail; wholesale; and other.

Retail and wholesale sales are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, the Company considers several indicators, including significant risks and rewards of products, its right to payment, and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to customers.

Other revenue consists of other income and expenses, including related to, licensing and consulting services, facility design services, facility management services, the Company’s Three A Light™ publication, and corporate operations. Revenue is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved and target harvest yields are exceeded or earned upon the completion of the seminar. The Company also recognizes expense reimbursement from clients as revenue for expenses incurred during certain jobs.

Costs of Goods and Services Sold

Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of the Company’s products and services.

General and Administrative Expenses

General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred and were $111,685 and $129,267 during the quarter ended March 31, 2021 and 2020, respectively.

Stock Based Compensation

The Company accounts for share-based payments pursuant to ASC 718, Stock Compensation and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model.

Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and Emerging Issues Task Force (“EITF”) 96-18 when stock or options are awarded for previous or current service without further recourse.

Share-based expense paid to through direct stock grants is expensed as occurred. Since the Company’s common stock is publicly traded, the value is determined based on the number of shares of common stock issued and the trading value of the common stock on the date of the transaction.

On June 20, 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-07 which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. Previously, share-based payment arrangements to nonemployees were accounted for under ASC 718, while nonemployee share-based payments issued for goods and services were accounted for under ASC 505-50. Before the amendment, the major difference for the Company (but not limited to) was the determination of measurement date, which generally is the date on which the measurement of equity classified share-based payments becomes fixed. Equity classified share-based payments for employees was fixed at the time of grant. Equity-classified nonemployee share-based payment awards are no longer measured at the earlier of the date which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. They are now measured at the grant date of the award, which is the same as share-based payments for employees. The Company adopted the requirements of the new rule as of January 1, 2019, the effective date of the new guidance.

The Company recognized $1,483,806 in expense for stock-based compensation from common stock options and common stock issued to employee, officers, and directors during the three months ended March 31, 2021, and $1,252,731 in expense for stock-based compensation from common stock options issued to employees during the three months ended March 31, 2020.

Income Taxes

ASC 740, Income Taxes requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.

Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.

The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability, and the tax benefit to be recognized is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.

As the Company operates in the cannabis industry, it is subject to the limits of the Internal Revenue Code (IRC) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.

Right of Use Assets and Lease Liabilities

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard requires lessees to recognize almost all leases on the balance sheet as a Right-of-Use (“ROU”) asset and a lease liability and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840. The Company elected the package of practical expedients permitted under the standard, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.

Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in determining the present value of lease payments. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.

Operating leases are included in operating lease ROU assets and operating lease liabilities, current and non-current, on the Company's consolidated balance sheets.

3.	Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations except as noted below:

In January 2017 the FASB issued ASU 2017-01, Clarifying the Definition of a Business (Topic 805), which changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. The guidance also requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described in ASC 606. The ASU is effective for annual reporting periods beginning after December 15, 2017, and for interim periods within those years. Adoption of this ASU did not have a significant impact on the Company’s consolidated results of operations, cash flows and financial position.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), which enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. The amendment became effective for public companies with fiscal years beginning after December 15, 2020. The Company is evaluating the impact of this amendment on its consolidated financial statements.

In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements.

4.	Property and Equipment

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:

	March 31, 2021			December 31, 2020
Furniture and fixtures	$	294,204		$	228,451
Leasehold improvements		656,314			90,314
Machinery and Tools		1,401,752			1,456,752
Office equipment		69,983			104,059
Software		1,308,387			1,308,387
Work in process		390,598			269,414
	$	4,121,239		$	3,457,377
Less: Accumulated depreciation		(1,032,211	)		(872,579	)
Total property and equipment, net of depreciation	$	3,089,027		$	2,584,798

Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.

Furniture and fixtures	3 years
Leasehold improvements	Lesser of the lease term or estimated useful life
Vehicles	3 years
Office equipment	3 years

Depreciation expense for the three months ended March 31, 2021 and 2020 was $194,637 and $4,465 respectively.

5.	Intangible Asset

Intangible assets as of March 31, 2021 and December 31, 2020 were comprised of the following:

	March 31, 2021			December 31, 2020
Licenses	$	88,745,700		$	1,667,000
Tradename		4,270,000			350,000
Customer relationships		5,150,000			1,055,000
Non-compete		1,130,000			120,000
Product license and registration		57,300			57,300
Trade secret – intellectual property		32,500			32,500
	$	99,385,500		$	3,282,500
Less: accumulated amortization		(1,796,386	)		(200,456	)
Total intangible assets, net of amortization	$	97,589,114		$	3,082,044

Amortization expense for the three months ended March 31, 2021 and 2020 was $1,595,931 and $1,648, respectively.

6.	Derivative Liability

In 2019, the Company entered into certain employment agreements with key officers that contained contingent consideration provisions based upon the achievement of certain market condition milestones. The Company determined that each of these vesting conditions represented derivative instruments.

On January 8, 2019, the Company granted the right to receive 500,000 shares of restricted common stock to an officer and director, which will vest at such time that the Company’s stock price appreciates to $8.00 per share with defined minimum average daily trading volume thresholds.

On April 23, 2019, the Company granted the right to receive 1,000,000 shares of restricted common stock to an officer and director, which will vest at such time that the Company’s stock price appreciates to $8.00 per share with defined minimum average daily trading volume thresholds. On February 25, 2020, the director resigned from his remaining positions with the Company and forfeited his right to the contingent consideration. As a result, the Company recorded a gain of $1,462,636 as a component of other income (expense), net on its financial statements.

On June 11, 2019, the Company granted the right to receive 1,000,000 shares of restricted common stock to an officer, which will vest at such time that the Company’s stock price appreciates to $8.00 per share with defined minimum average daily trading volume thresholds.

The Company accounts for derivative instruments in accordance with the US GAAP accounting guidance under ASC 815, Derivatives and Hedging Activities. The Company estimated the fair value of these derivatives at the respective balance sheet dates using the Black-Scholes option pricing model based upon the following inputs: (i) stock price on the date of grant ranging between $1.32 - $3.75, (ii) a risk-free interest rate ranging between 1.87% - 2.57%, and (iii) an expected volatility of the price of the underlying common stock ranging between 145% - 158%.

As of March 31, 2021, the fair value of these derivative liabilities is $2,301,295. The change in the fair value of derivative liabilities for the three months ended March 31, 2021 was $1,253,814 resulting in an aggregate unrealized loss on derivative liabilities.

7.	Related Party Transactions

Transactions Involving Former Directors, Executive Officers or Their Affiliated Entities

During the year ended December 31, 2020, the Company recorded sales to Medicine Man Denver, totaling $997,262. The Company had an accounts receivable balance with Medicine Man Denver totaling $72,109 as of December 31, 2020. The Company’s former Chief Executive Officer, Andy Williams, maintains an ownership interest in Medicine Man Denver. Effective February 25, 2020 he was no longer an officer of the Company and therefore no longer a related party. As such, he is not included as a related party with respect to sales and accounts receivable from Medicine Man Denver during the period ended March 31, 2021.

During the year ended December 31, 2020, the Company recorded sales to MedPharm Holdings LLC (“MedPharm”) totaling $73,557. The Company had a net accounts receivable balance with MedPharm totaling $5,885 as of December 31, 2020. The Company’s former Chief Executive Officer, Andy Williams, maintains an ownership interest in MedPharm. Effective February 25, 2020 he was no longer an officer of the Company and therefore no longer a related party. As such, he is not included as a related party with respect to sales and accounts receivable from MedPharm during the period ended March 31, 2021.

Also, during the year ended December 31, 2019, the Company issued various notes receivable to MedPharm totaling $767,695 with original maturity dates ranging from September 21, 2019 through January 19, 2020 and all bearing interest at 8% per annum. All notes extended to May 2020 by mutual agreement between the Company and noteholder. On August 1, 2020, the Company entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with MedPharm. Pursuant to the terms of the Settlement Agreement, the Company and MedPharm agreed that the amount of the settlement to be furnished to the Company by MedPharm shall be $767,695 in principal and $47,161 in accrued interest. The Company received a $100,000 cash payment from MedPharm on August 1, 2020. On September 4, 2020, Andrew Williams, a member of the MedPharm Board of Directors and the Company’s former Chief Executive Officer, returned 175,000 shares of the Company’s common stock to the Company, as equity consideration at a price of $1.90 per share, a mutually agreed upon price per share. These shares are held in treasury. The remaining outstanding principal and interest of $181,911 due and payable by MedPharm under the Settlement Agreement will be paid out in bi-weekly installments of product by scheduled deliveries through March 31, 2021. As of March 31, 2021, the remaining outstanding principal and interest was $40,231.

During the year ended December 31, 2020, the Company recorded sales to Baseball 18, LLC (“Baseball”) totaling $14,605, to Farm Boy, LLC (“Farm Boy”) totaling $16,125, to Emerald Fields LLC (“Emerald Fields”) totaling $16,605, and to Los Sueños Farms (“Los Sueños”) totaling $52,244. As of December 31, 2020 the Company had net accounts payable balances with Baseball of $31,250, and with Farm Boy of $93,944. One of the Company’s former directors, Robert DeGabrielle, owns the Colorado retail marijuana cultivation licenses for Farm Boy, Baseball, Emerald Fields, and Los Sueños. Effective June 19, 2020 he was no longer an officer of the Company and therefore no longer a related party. As such, he is not included as a related party with respect to sales and accounts receivable from Baseball, Farm Boy, Emerald Fields, or Los Sueños during the period ended March 31, 2021.

Transactions with Entities Affiliated with Justin Dye

The Company has participated in several transaction involving Dye Capital, Dye Capital Cann Holdings, LLC (“Dye Cann I”) and Dye Cann II. Justin Dye, the Company’s Chief Executive Officer, one of our directors, and the largest beneficial owner of the Company’s common stock and Series A Preferred Stock, controls Dye Capital and Dye Capital controls Dye Cann I and Dye Cann II. Dye Cann I is the largest holder of the Company’s outstanding common stock. Dye Cann II is a significant holder of the Series A Preferred Stock. Mr. Dye has sole voting and dispositive power over the securities held by Dye Capital, Dye Cann I, and Dye Cann II.

The Company entered into a Securities Purchase Agreement with Dye Cann I on June 5, 2019, (as amended, the “Dye Cann I SPA”) pursuant to which the Company agreed to sell to Dye Cann I up to between 8,187,500 and 10,687,500 shares of the Company’s common stock in several tranches at $2.00 per share and warrants to purchase 100% of the number of shares of common stock sold at a purchase price of $3.50 per share. At the initial closing on June 5, 2019, the Company sold to Dye Cann I 1,500,000 shares of common stock and warrants to purchase 1,500,000 shares of common stock for gross proceeds of $3,000,000, and the Company has consummated subsequent closings for an aggregate of 9,287,500 shares of common stock and warrants to purchase 9,287,500 shares of common stock for aggregate gross proceeds of $18,575,000 to the Company. The terms of the Dye Cann I SPA are disclosed in the Company’s Current Report on Form 8-K filed on June 6, 2019. The Company and Dye Cann I entered into a first amendment to the Dye Cann I SPA on July 15, 2019, as described in the Company’s Current Report on Form 8-K filed on July 17, 2019, a second amendment to the Dye Cann I SPA on May 20, 2020, as described in the Company’s Current Report on Form 8-K filed on May 22, 2020, and a Consent, Waiver and Amendment on December 16, 2020, as described in the Company’s Current Report on Form 8-K filed on December 23, 2020. At the time of the initial closing under the Dye Cann I SPA, Justin Dye became a director and the Company’s Chief Executive Officer.

The Company granted Dye Cann I certain demand and piggyback registration rights with respect to the shares of common stock sold under the Dye Cann I SPA and issuable upon exercise of the warrants sold under the Dye Cann I SPA. The Company also granted Dye Cann I the right to designate one or more individuals for election or appointment to the Company’s board of directors (the “Board”) and Board observer rights. Further, under the Dye Cann I SPA, until June 5, 2022, if the Company desires to pursue debt or equity financing, the Company must first give Dye Cann I an opportunity to provide a proposal to the Company with the terms upon which Dye Cann I would be willing to provide or secure such financing. If the Company does not accept Dye Cann I’s proposal, the Company may pursue such debt or equity financing from other sources but Dye Cann I has a right to participate in such financing to the extent required to enable Dye Cann I to maintain the percentage of the Company’s common stock (on a fully-diluted basis) that it then owns, in the case of equity securities, or, in the case of debt, a pro rata portion of such debt based on the percentage of the Company’s common stock (on a fully-diluted basis) that it then owns.

The Company entered into a Securities Purchase Agreement (as amended, the “Dye Cann II SPA”) with Dye Cann II on November 16, 2020 pursuant to which the Company agreed to sell to Dye Cann II shares of Series A Preferred Stock in one or more tranches at a price of $1,000 per share. The terms of the Dye Cann II SPA are disclosed in the Company’s Current Report on Form 8-K filed on December 23, 2020. The Company and Dye Cann II entered into an amendment to the Dye Cann II SPA on December 16, 2020, as described in the Company’s Current Report on Form 8-K filed on December 23, 2020, a second amendment to the Dye Cann II SPA on February 3, 2021, as described in the Company’s Form 8-K filed on February 9, 2021, and a third amendment to the Dye Cann II SPA on March 30, 2021, as described under Item 9B of this Report. The Company issued and sold to Dye Cann II 7,700 shares of Series A Preferred Stock on December 16, 2020, 1,450 shares of Series A Preferred Stock on December 18, 2020, 1,300 shares of Series Preferred Stock on December 22, 2020, 3,100 shares of Series A Preferred Stock on February 3, 2021, 3,800 shares of Series A Preferred Stock on March 2, 2021 and 4,000 shares of Series A Preferred Stock on March 30, 2021. As a result, the Company issued and sold an aggregate of 21,350 shares of Series A Preferred Stock to Dye Cann II for aggregate gross proceeds of $21,350,000.

The Company granted Dye Cann II certain demand and piggyback registration rights with respect to the shares of common stock issuable upon conversion of the Series A Preferred Stock under the Dye Cann II SPA. Further, the Company granted Dye Can II the right to designate one or more individuals for election or appointment to the Board and Board observer rights.

On December 16, 2020, the Company entered into a Secured Convertible Note Purchase Agreement with Dye Capital and issued and sold to Dye Capital a Convertible Note and Security Agreement in the principal amount of $5,000,000 as described in the Company’s Current Report on Form 8-K filed on December 23, 2020. On February 26, 2021, Dye Capital elected to convert the $5,000,000 principal amount and the $60,250 of accrued but unpaid interest under the Convertible Promissory Note and Security Agreement under its terms and Dye Capital and the Company entered into a Conversion Notice and Agreement pursuant to which the Company issued 5,060 shares of Series A Preferred Stock to Dye Capital and also paid Dye Capital $230.97 in cash in lieu of issuing any fractional shares of Series Preferred Stock upon conversion, as described in the Company’s Current Report on Form 8-K filed on March 4, 2021.

The Company previously reported the terms of the Series A Preferred Stock in the Company’s Current Report on Form 8-K filed on December 23, 2020 and under Item 1 of this Report, which disclosure is incorporated herein by reference.

During the year ended December 31, 2020, the Company recorded expenses of $66,264 with Tella Digital. During the quarter ended March 31, 2021, the Company recorded expenses of $170,119 with Tella Digital. Tella Digital provides on-premise digital experience solutions for our retail dispensary locations. Mr. Dye serves as Chairman of Tella Digital and has super majority rights.

Transactions with CRW and Affiliated Entities

On February 26, 2021, the Company entered into a Securities Purchase Agreement (the “CRW SPA”) with CRW pursuant to which the Company issued and sold 25,350 shares of Series A Preferred Stock to CRW at a price of $1,000 per share for aggregate gross proceeds of $25,350,000. The transaction made CRW a beneficial owner of more than 5% of the Company’s common stock. The Company granted CRW certain demand and piggyback registration rights with respect to the shares of common stock issuable upon conversion of the Series A Preferred Stock under the CRW SPA. On the same date, the Company entered into a letter agreement with CRW, granting CRW the right to designate one individual for election or appointment to the Board and Board observer rights. Under the letter agreement, for as long as CRW has the right to designate a Board member, if the Company, directly or indirectly, plans to issue, sell or grant any securities or options to purchase any of its securities, CRW has a right to purchase its pro rata portion of such securities, based on the number of shares of Series A Preferred Stock beneficially held by CRW on the applicable date on an as-converted to common stock basis divided by the total number of shares of common stock outstanding on such date on an as-converted, fully-diluted basis (taking into account all outstanding securities of the Company regardless of whether the holders of such securities have the right to convert or exercise such securities for common stock at the time of determination). Further, under the letter agreement, the Company will pay CRW Capital, LLC, the sole manager of CRW and a holder of a carried interest in CRW, a monitoring fee equal to $150,000 in monthly installments of $10,000. On March 14, 2021, the Board appointed Jeffrey A. Cozad as a director to fill a vacancy on the Board. Mr. Cozad is a manager and owns 50% of CRW Capital, LLC, and he shares voting and disposition power over the shares of Series A Preferred Stock held by CRW. Mr. Cozad and his family members indirectly own membership interests in CRW. The Company previously reported the terms of the CRW SPA and the CRW letter agreement in the Company’s Current Report on Form 8-K filed March 4, 2021.

Transactions with Entities Affiliated with Brian Ruden

The Company has participated in several transactions involving entities owned or affiliated with Brian Ruden, one of its directors and a beneficial owner of more than 5% of the Company’s common stock and a beneficial owner of more than 5% of the Series A Preferred Stock.

Between December 17, 2020 and March 2, 2021, the Company’s wholly-owned subsidiary SBUD, LLC acquired the Star Buds assets. The Company previously reported the terms of the applicable purchase agreements and related amendments in the Company’s Current Reports on Form 8-K filed June 8, 2020, September 21, 2020, December 22, 2020, and March 8, 2021.

The aggregate purchase price for the Star Buds assets was $118,000,000, paid as follows: (i) $44,250,000 in cash at the applicable closings, (ii) $44,250,000 in deferred cash, also referred to in this Report as “seller note(s),” (iii) 29,500 shares of Series A Preferred Stock, of which 25,075 shares were issued at the applicable closings and 4,425 shares are held in held in escrow and will be released post-closing to either Star Buds or the Company depending on post-closing adjustments to the purchase price. In addition, the Company issued warrants to purchase an aggregate of 5,531,250 shares of the Company’s common stock to the sellers. As of March 31, 2021, the Company owed an aggregate principal amount of $44,250,000 under the seller notes and accrued but unpaid interest of $425,162. The Company has not paid any principal and has paid an aggregate of $810,887 of interest on the seller notes as of March 31, 2021. Mr. Ruden’s interest in the aggregate purchase price for the Star Buds assets is as follows: (i) $13,727,490 in cash at the applicable closings, (ii) $13,727,490 in seller notes, (iii) 9,152 shares of Series A Preferred Stock, of which 7,779 shares were issued at the applicable closings and 1,373 shares are held in held in escrow and will be released post-closing to either Mr. Ruden or the Company depending on post-closing adjustments to the purchase price. In addition, the Company issued warrants to purchase an aggregate of 1,715,936 shares of the Company’s common stock to Mr. Ruden and paid Mr. Ruden an aggregate of $111,824 in interest on his seller notes.

Mr. Ruden was a part-owner of each of the Star Buds companies that sold assets to SBUD, LLC. Mr. Ruden owned 50% of Colorado Health Consultants LLC, 50% of Starbuds Aurora LLC, 50% of Starbuds Pueblo LLC, 50% of Starbuds Alameda LLC, 48% of SB Arapahoe LLC, 36% of Starbuds Commerce City LLC, 30% of Starbuds Louisville LLC, 25% of Starbuds Niwot LLC, 16.66% of Lucky Ticket LLC, 15% of KEW LLC, and 10% of LM MJC LLC.

In connection with acquiring the Star Buds assets for our Pueblo West and Commerce City locations, SBUD LLC entered into a lease with each of 428 S. McCulloch LLC and 5844 Ventures LLC on substantially the same terms.

Each of the leases is for an initial three-year term. The lease with 428 S. McCulloch LLC is for the Company’s Pueblo West Star Buds location and was effective on December 17, 2020. The lease with 45844 Ventures LLC is for the Company’s Commerce City Star Buds location and was effective on December 18, 2020. Each lease provides for a monthly rent payment of $5,000. SBUD LLC expect to pay each landlord an aggregate of $180,000 during the initial term of the leases. During 2020, SBUD LLC made aggregate rent payments of $10,000. Between January 1, 2021 and March 31, 2021, SBUD LLC made aggregate rent payments of $30,000. In addition, SBUD LLC must pay each landlord’s expenses and disbursements incurred in connection with the ownership, operation, maintenance, repair and replacement of the premises. SBUD LLC has the option to renew each lease for two additional three-year terms. The rent increase to $5,500 per month during the first three-year renewal period, and to $6,050 during the second three-year renewal period. The Company has an option to purchase the premises at fair market value at any time during the lease term and also has a right of first refusal if the landlords desire to sell the premises to a third party.

On December 17, 2020, SBUD, LLC entered into a Trademark License Agreement with Star Brands LLC under which Star Brands LLC licenses certain trademarks to SBUD, LLC effective as of the closing of the acquisitions of all of the Star Buds assets. SBUD LLC has no payment obligation under this agreement. Mr. Ruden is a part-owner of Star Brands LLC.

In connection with the Star Buds acquisitions, the Company granted Mr. Ruden and Naser Joudeh the right designate individuals for election or appointment to the Board.

8.	Inventory

As of March 31, 2021, and December 31, 2020, respectively, the Company had $3,345,353 and $2,090,887 of finished goods inventory. As of March 31, 2021 the Company had $911,246 of work in process and $1,331,658 of raw materials. As of December 31, 2020, the Company had $500,917 of work in process and $27,342 of raw materials. The Company uses the FIFO inventory valuation method. As of March 31, 2021 and December 31, 2020, the Company did not recognize any impairment for obsolescence within its inventory.

9.	Goodwill

On June 3, 2017, the Company issued an aggregate of 7,000,000 shares of its common stock for 100% ownership of both Success Nutrients and Pono Publications. The Company utilized purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in $6,301,080 of goodwill.

On July 21, 2017, the Company issued 2,258,065 shares of its common stock for 100% ownership of Denver Consulting Group (“DCG”). The Company utilized purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in $3,003,226 of goodwill.

On September 17, 2018, we closed the acquisition of The Big Tomato. The Company issued an aggregate of 1,933,329 shares of its common stock for 100% ownership of The Big Tomato. The Company utilized purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in the Company valuing the investment as $3,000,000 of goodwill.

On April 20, 2020, the Company closed the acquisition of Mesa Organics. The aggregate purchase price after working capital adjustments was $2,609,500 of cash and 2,554,750 shares of the Company’s Common Stock. The Company accounted for the transaction utilizing purchase price accounting stating that the book value approximates the fair market value of the assets acquired. The purchase price accounting resulted in the Company valuing the investment as $2,147,613 of goodwill.

From December 2020 through March 2021, the Company closed the acquisition of thirteen Star Buds dispensaries and one cultivation facility. The aggregate purchase price was $118,000,000. The Company accounted for the transaction utilizing purchase price accounting stating that the book value approximates the fair market value of the assets acquired. The purchase price accounting resulted in the Company valuing the investment as $26,080,991 of goodwill.

As of March 31, 2021, the Company had $40,532,910 of goodwill which consisted of $6,301,080 from Success Nutrients and Pono Publications, $3,003,226 from DCG, $3,000,000 from The Big Tomato, $2,147,613 from Mesa Organics, and $26,080,991 from Star Buds.

10.	Leases

Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Leases with a term greater than one year are recognized on the balance sheet at the time of lease commencement or modification of an ROU operating lease asset and a lease liability, initially measured at the present value of the lease payments. Lease costs are recognized in the income statement over the lease term on a straight-line basis. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.

The Company's leases consist of real estate leases for office spaces. The Company elected to combine the lease and related non-lease components for its operating leases.

The Company’s operating leases include options to extend or terminate the lease, which are not included in the determination of the ROU asset or lease liability unless reasonably certain to be exercised. The Company's operating leases have remaining lease terms of less than two years. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

As the Company's leases do not provide an implicit rate, we used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The discount rate used in the computations ranged between 6% and 12%.

Balance Sheet Classification of Operating Lease Assets and Liabilities

	Balance Sheet Line	March 31, 2021
Asset
Operating lease right of use assets	Noncurrent assets	$	4,242,124
Liabilities
Lease liabilities	Noncurrent liabilities	$	4,342,018

Lease Costs

The table below summarizes the components of lease costs for the three months ended March 31, 2021.

		Three Months Ended March 31, 2021
Operating lease costs		$	278,117

Maturities of Lease Liabilities

Maturities of lease liabilities as of March 31, 2021 are as follows:

2021 fiscal year	$	4,418,867
Less: Interest		(76,848	)
Present value of lease liabilities	$	4,342,018

The following table presents the Company’s future minimum lease obligation under ASC 840 as of March 31, 2021:

2021 fiscal year			1,109,215
2022 fiscal year			1,479,393
2023 fiscal year			1,354,595
2024 fiscal year			723,590
2025 fiscal year			333,356
2026 fiscal year			178,648
Total			5,178,796

11.	Stockholders’ Equity

The Company is authorized to issue two classes of stock, designated preferred stock and common stock.

Preferred Stock

The number of shares of preferred stock authorized is 10,000,000, par value $0.001 per share. The preferred stock may be divided into such number of series as the Company’s Board of Directors may determine. The Board is authorized to determine and alter the rights, preferences, privileges and restrictions granted and imposed upon any wholly unissued series of preferred stock, and to fix the number and designation of shares of any series of preferred stock. The Board, within limits and restrictions stated in any resolution of the Board, originally fixing the number of shares constituting any series may increase or decrease, but not below the number of such series then outstanding, the shares of any subsequent series.

The Company had 87,266 shares of Series A Preferred Stock issued and outstanding as of March 31, 2021 and 19,716 shares of Series A Preferred Stock issued and outstanding as of December 31, 2020. Among other terms, each share of Series A Preferred Stock (i) earns an annual dividend of 8% on the “preference amount,” which initially is equal to the $1,000 per-share purchase price and subject to increase, by having such dividends automatically accrete to, and increase, the outstanding preference amount; (ii) is entitled to a liquidation preference under certain circumstances, (iii) is convertible into shares of the Company’s common stock by dividing the preference amount by $1.20 per share under certain circumstances, and (iv) is subject to a redemption right or obligation under certain circumstances.

Common Stock

The Company is authorized to issue 250,000,000 shares of common stock at a par value of $0.001. The Company had 42,819,815 shares of common stock issued and 42,331,595 shares of common stock outstanding as of March 31, 2021, and 42,601,773 shares of common stock issued and 42,169,041 shares of common stock outstanding as of December 31, 2020.

Common Stock Issued in Private Placements

During the year ended December 31, 2020, the Company issued 187,500 shares of common stock and warrants to purchase 187,500 shares of common stock, for gross proceeds of $375,000.

Common Stock Issued as Compensation to Employees, Officers, and Directors

On April 3, 2020, the Company cancelled 500,000 shares of common stock, with vesting conditions represented as derivative instruments. These shares were incorrectly issued as restricted shares instead of restricted stock units to an officer of the Company, Paul Dickman, on January 8, 2019.

During the year ended December 31, 2020, the Company issued 406,895 shares of common stock valued at $497,301 to employees, officers, and directors as compensation.

During the quarter ended March 31, 2021, the Company issued 218,042 shares of common stock valued at $444,806 to employees, and directors as compensation.

Common and Preferred Stock Issued as Payment for Acquisitions

On April 20, 2020, the Company issued 2,554,750 shares of common stock valued at $4,167,253 for the acquisition of Mesa Organics, Ltd.

On December 17, 2020, the Company issued 2,862 shares of Series A Preferred Stock valued at $2,861,994 and on December 18, 2020, the Company issued 6,404 shares of Series A Preferred Stock valued at $6,403,987 for the acquisition of Star Buds assets.

On February 3, 2021, the Company issued 2,319 shares of Series A Preferred Stock valued at $2,318,998 and on March 3, 2021, the Company issued 17,921 shares of Series A Preferred Stock valued at $17,920,982 for the acquisition of Star Buds assets.

Warrants

The Company accounts for common stock purchase warrants in accordance with ASC 480, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity. The Company estimates the fair value of warrants at date of grant using the Black-Scholes option pricing model. There is a moderate degree of subjectivity involved when using option pricing models to estimate the warrants, and the assumptions used in the Black Scholes option-pricing model are moderately judgmental.

During the quarter ended March 31, 2021, the Company issued warrants to purchase an aggregate of 3,793,530 shares of common stock as purchase consideration for the acquisition of certain Star Buds assets. These warrants have an exercise price of $1.20 per share and expiration dates five years from the date of issuance. In addition, the Company issued a warrant to purchase an aggregate 1,500,000 shares of common stock to an accredited investor in connection with entering into a loan agreement. This warrant has an exercise price of $2.50 per share and expires five years from the date of issuance. The Company estimated the fair value of these warrants at date of grant using the Black-Scholes option pricing model using the following inputs: (i) stock price on the date of grant of $1.20 of $2.50, respectively, (ii) the contractual term of the warrant of 5 years, (iii) a risk-free interest rate ranging between 0.46% - 0.75% and (iv) an expected volatility of the price of the underlying common stock ranging between 192.71% - 195.00%.

The following table reflects the change in common stock purchase warrants for the three months ended March 31, 2021.

	Number of shares
Balance as of January 1, 2021		11,725,220
Warrants exercised		–
Warrants forfeited		–
Warrants issued		5,293,530
Balance as of March 31, 2021		17,018,750

Option Repricing

On December 15, 2020, the Board repriced certain outstanding stock options issued to the Company’s current employees. The repriced stock options had original exercise prices ranging from $1.52 per share to $3.83 per share. All of these stock options to current employees were repriced to have an exercise price of $1.26 per share, which was the closing price of the Company’s common stock on December 15, 2020. Each of the options has a new 10-year term from the repricing date.

12.	Segment Information

The Company has three identifiable segments as of March 31, 2021; (i) retail, (ii) wholesale and (iii) and other. The retail segment represents our dispensaries which sell merchandise directly to customers via retail locations and e-commerce portals. The wholesale segment represents our manufacturing and wholesale business which sell merchandise to customers via e-commerce portals, a retail location, and manufacturing facility. The other segment derives its revenue from licensing and consulting agreements with cannabis related entities, in addition to fees from seminars and expense reimbursements included in other revenue on the Company’s financial statements.

The following information represents segment activity for the three-month periods ended March 31, 2021 and March 31, 2020:

	For the Three Months Ended March 31,
	2021												2020
	Retail			Wholesale			Other			Total			Retail		Wholesale			Other			Total

Revenues	$	11,816,200			7,446,265			77,650			19,340,115		$	–	$	2,528,931		$	674,203		$	3,203,134
Cost of goods and services	$	(7,500,757	)		(4,483,694	)		(102,660	)		(12,087,111	)	$	–	$	(1,896,226	)	$	(252,309	)	$	(2,148,535	)
Gross profit	$	4,315,443			2,962,571			(25,010	)		7,253,004		$	–	$	633,705		$	421,894		$	1,054,599
Intangible assets amortization	$	1,594,302			1,497			133			1,595,931		$	–	$	1,513		$	135		$	1,648
Depreciation	$	84,298			3,641			106,699			194,637		$	–	$	1,233		$	3,232		$	4,465
Net income (loss)	$	1,398,651			2,814,014			(7,862,172	)		(3,649,507	)	$	–	$	446,499		$	(1,825,809	)	$	(1,379,310	)
Segment assets	$	132,931,035			21,326,258			26,761,858			181,019,151		$	–	$	12,935,074		$	17,094,217		$	30,029,291

13.	Tax Provision

The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended March 31, 2021 and March 31, 2020:

	Three Months Ended March 31,
	2021			2020
Income (Loss) before Income Taxes		(3,192,891	)		(1,379,310	)
Income Tax Expense		456,614			–
Effective Tax Rate		-14.30%			0%

The Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. We believe that, at this time, the use of this discrete method is more appropriate than the annual effective tax rate method as the estimated annual effective tax rate method is not reliable due to the high degree of uncertainty in estimating annual pre-tax income due to the early growth stage of the business.

Due to its cannabis operations, the Company is subject to the limitations of Internal Revenue Code (“IRC”) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.

The effective tax rate for the three months ended March 31, 2021 varied from the three months ended March 31, 2020 primarily due to IRC Section 280E. The Company acquired plant-touching cannabis operations during 2020 and 2021 and these plant-touching operations are subject to the limitations of IRC Section 280E. As of March 31, 2020, the Company had not yet acquired these cannabis plant-touching operations and the Company was not subject to IRC Section 280E.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company's valuation allowance represents the amount of tax benefits that are likely to not be realized. Management assesses the need for a valuation allowance each period and continues to have a full valuation allowance on its deferred tax assets as of March 31, 2021.

The Federal statute of limitation remains open for the 2017 tax year to present. The state statute of limitation remains open for the 2016 tax year to present.

14.	Subsequent Events

In accordance with FASB ASC 855-10, Subsequent Events, the Company has analyzed its operations subsequent to March 31, 2021 to the date these unaudited consolidated financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these unaudited consolidated financial statements, except as follows:

During the year ended December 31, 2019, the Company issued various notes receivable to MedPharm Holdings totaling $767,695 with original maturity dates ranging from September 21, 2019 through January 19, 2020 and all bearing interest at 8% per annum. All notes extended to May 2020 by mutual agreement between the Company and noteholder. On August 1, 2020, the Company entered into the Settlement Agreement with MedPharm. As of March 31, 2021, the remaining outstanding principal and interest was $40,231. This amount was paid off on April 19, 2021.

On June 11, 2019, the Company granted the right to receive 1,000,000 shares of restricted common stock to an officer (former officer as of December 4, 2019), which would have vested at such time that the Company’s stock price appreciated to $8.00 per share with defined minimum average daily trading volume thresholds. On May 3, 2021, the former officer and the Company entered into a separation agreement under which the former officer agreed to forfeit the 1,000,000 shares of restricted common stock. The former officer was entitled to $75,000 in bonus payments under the separation agreement. This payment was made on May 4, 2021.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our unaudited consolidated financial statements and notes thereto included herein and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC. In addition to our historical unaudited condensed consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A, “Risk Factors.” See also, “NOTE ABOUT FORWARD-LOOKING INFORMATION.”

Overview

We were incorporated in Nevada on March 20, 2014. On May 1, 2014, we entered into an exclusive Technology License Agreement with Medicine Man Denver whereby Medicine Man Denver granted us a license to use all of their proprietary processes they have developed, implemented and practiced at their cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical marijuana and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future).

In 2017, the Company acquired additional cultivation intellectual property through the acquisition of Success Nutrients™ and Pono Publications, including the rights to the book titled “Three A Light” and its associated cultivation techniques, which have been part of the Company’s products and services offerings since the acquisition. The Company acquired Two J’s LLC d/b/a The Big Tomato (“Big T or The Big Tomato”) in 2018, which operates a retail location in Aurora, Colorado. It has been a leading supplier of hydroponics and indoor gardening supplies in the metro Denver area since May 2001. The Company was focused on cannabis dispensary and cultivation consulting and providing equipment and nutrients to cannabis cultivators until its first plant touching acquisition in April of 2020. In 2019, due to the changes in Colorado law permitting non-Colorado resident and publicly traded investment into “plant-touching” cannabis companies, the Company made a strategic decision to move toward direct plant-touching operations. The Company developed a plan to roll up a number of direct plant-touching dispensaries, manufacturing facilities, and cannabis cultivations with a target to be one of the largest seed to sale cannabis businesses in Colorado. In April 2020 the Company acquired its first plant-touching business, Mesa Organics, which consists of four dispensaries and one MIP, d/b/a Purplebee’s.

On February 4, 2021, the Company acquired the assets of Colorado Health Consultants LLC and Mountain View 44th LLC under the applicable APAs.

On March 2, 2021, the Company acquired the assets of (i) Starbuds Aurora LLC, (ii) SB Arapahoe LLC, (iii) Citi-Med LLC, (iv) Starbuds Louisville LLC and (v) KEW LLC under the applicable APAs.

From December 2020 through March 2021 the Company completed a private placement of Series A Preferred Stock for aggregate gross proceeds of $57.7 million dollars. In the private placement, the Company issued and sold an aggregate of 57,700 shares of Series A Preferred Stock at a price of $1,000 per share under securities purchase agreement with Dye Capital and CRW as well as subscription agreements with unaffiliated investors. Among other terms, each share of Series A Preferred Stock (i) earns an annual dividend of 8% on the “preference amount,” which initially is equal to the $1,000 per-share purchase price and subject to increase, by having such dividends automatically accrete to, and increase, the outstanding preference amount; (ii) is entitled to a liquidation preference under certain circumstances, (iii) is convertible into shares of the Company’s common stock by dividing the preference amount by $1.20 per share under certain circumstances, and (iv) is subject to a redemption right or obligation under certain circumstances.

In addition, on December 16, 2020, the Company issued and sold a Convertible Promissory Note and Security Agreement in the original principal amount of $5,000,000 to Dye Capital. On February 26, 2021, Dye Capital converted all outstanding amounts under the note into 5,060 shares of Series A Preferred Stock.

Results of Operations

Comparison of Results of Operations for the three months ended March 31, 2021 and 2020

Revenues

Revenues for the three months ended March 31, 2021 totaled $ 19,340,115 including (i) retail of $11,816,200, (ii) wholesale $7,446,265, and (iii) other of $77,650, compared to $3,203,134 including (i) wholesale of $2,528,931 and (ii) other of $674,203 during the three months ended March 31, 2020, representing an increase of $16,136,981 or 503.79%. This increase was due to increased sale of our products as well as growth through acquisition.

Cost of Services

Cost of goods and services for the three months ended March 31, 2021 totaled $12,087,111, compared to cost of goods and services of $2,148,535 during the three months ended March 31, 2020 representing an increase of $9,938,576 or 462.57%. This increase was due to increased sale of our products as well as growth through acquisition and includes a $2.2 million inventory purchase price valuation adjustment.

Operating Expenses

Operating expenses for the three months ended March 31, 2021 totaled $8,737,910, compared to operating expenses of $5,165,674 during the three months ended March 31, 2020 representing an increase of $3,572,253 or 69.15%. This increase was due to increased selling, general and administrative expenses, professional service fees, and non-cash, stock-based compensation offset by a decrease in salaries, benefits and related employment costs.

Other Income (Expense), Net

Net other expense for the three months ended March 31, 2021 totaled $1,707,988, compared to net other income of $2,731,765 during the three months ended March 31, 2020. The increase in other expenses, net was primarily due to an unrealized loss recognized on the change in fair value of certain derivative liabilities and interest expense, offset by an unrealized gain on investments and a gain on sale of assets. In addition, there was a gain on forfeiture of contingent consideration during the three months ended March 31, 2020 that was not present during the three months ended March 31, 2021.

Net Income (Loss)

As a result, we generated a net loss during the three months ended March 31, 2021 of $3,649,507 or approximately $0.09 per share, compared to a net loss of $1,379,310 or approximately $0.03 per share during the three months ended March 31, 2020.

Liquidity and Capital Resources

As of March 31, 2021, we had $22,966,320 in cash on hand. Net cash provided by operating activities was $1,698,519 during the three months ended March 31, 2021, compared to cash used in operating activities of $2,471,022 for the three months ended March 31, 2020, representing an increase in cash used of $4,169,541. Cash flows used for investing activities was $65,600,473 during the three months ended March 31, 2021, compared to cash used of $307,178 for the three months ended March 31, 2020, representing a decrease of $65,293,295. Cash flows provided by financing activities was $85,631,039 during the three months ended March 31, 2021, compared to $0 for the three months ended March 31, 2020, representing an increase of $85,631,039.

We will likely need to raise additional capital to fund our growth acquisition strategy. We may explore capital raising transactions in the form of debt, equity or both. At this time, we are unable to state how much additional capital we may need. As of the date of this Quarterly Report on Form 10-Q, we have a $5 million commitment to lend from a lender provided we close on certain assets. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company can obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing. Failure to obtain this additional financing may have a material negative impact on our ability growth the company at the pace we anticipate.

Upon successfully integrating our recently acquired operations into our own operations, we believe we will generate positive cash flow from our operations. If we are successful in achieving this objective, we do not believe we will need to raise additional capital to execute the ongoing business operations, as we anticipate that the revenue generated from the fully integrated acquisitions will be sufficient to allow us to implement our current business plan. However, if we do not experience a positive impact on our operations from our completed acquisitions we may consummate or if unforeseen developments occur that negatively impact our cash flow, we may need to raise additional capital to execute our business strategy.

Off-Balance Sheet Arrangements

We had no off-balance sheet arrangements as of March 31, 2021 and December 31, 2020.

Critical Accounting Estimates

Our financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended December 31, 2020 in the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

On June 7, 2019, the Company filed a complaint against ACC Industries Inc. (“ACC”) and Building Management Company B, L.L.C., in state district court located in Clark County, Nevada, alleging, amongst other causes of action, breach of contract, conversion, and unjust enrichment and seeking general, special and punitive damages in the amount of $3,876,850. On July 17, 2019, the parties stipulated to stay the case in favor of arbitration. On February 25, 2020 ACC filed a counterclaim alleging breach of contract, which the Company believes is without merit. The Company discovered new facts that lead it to believe that a related entity not previously named as a party to the arbitration should be brought in as a party to the arbitration. Based upon the new facts, the Company filed a motion to amend the complaint to add new claims and the related entity as a party. On September 1, 2020, the court ruled in favor of the Company and permitted the Company to amend the complaint to add the related entity. On September 1, 2020, the Company filed an amended complaint naming the related entity a party and added intentional misrepresentation, fraudulent inducement, civil conspiracy, aiding and abetting, successor liability and fraudulent concealment claims. The Company began arbitration proceedings on November 2, 2020. The Company completed arbitration in February 2021 and is still awaiting a decision.

On July 6, 2018, the Company filed a complaint in the Eight Judicial Court, Clark County, Nevada against Vegas Valley Growers (“VVG”). In the complaint, the Company alleges breach by VVG of the Technologies License Agreement dated April 27, 2017 between the parties and seeks general, special and punitive damages in the amount of $3,876,850. On August 28, 2018, VVG filed an Answer and Counterclaim against the Company. On August 2, 2019, a jury found in favor of the Company and awarded the Company damages totaling $2,773,321. In March 2020, VVG filed its opening appeal brief. The Company’s response brief was due on May 15, 2020. After VVG filed its opening brief in March 2020, the Company filed a Motion to Strike portions of the brief and record. Because a successful ruling on the Company’s motion may strike portions of VVG’s brief or require VVG to refile it, the Company asked the court for an extension of the deadline to file the Company’s answering brief until the court renders its decision on the motion, which VVG did not oppose. The Company will have 30 days to file its answering brief once the court enters an order on the Motion to Strike or 30 days from when VVG files an amended opening brief and record. On August 27, 2020, the court ordered VVG to supplement its brief and the record. The Company filed its answering brief on October 15, 2020. On October 27, 2020, the Company, in a joint request with VVG, filed a motion to extend its time to file its answering brief. The Company filed its answering brief in January 2021. VVG’s reply brief was due on or before February 4, 2021. Once VVG’s reply brief is filed, the appeal will be fully briefed and the parties will await either a notice of oral argument or a decision on the appeal.

On March 6, 2020, the Company’s former Chief Operating Officer, Joe Puglise, issued an arbitration demand against the Company claiming breach of contract and seeking equity compensation and cash damages. The Company counterclaimed with breach of contract and breach of fiduciary duty claims for unspecified damages. The ultimate resolution of the matter could result in a Company loss of up to $3,500,000 in stock-based compensation. The parties commenced arbitration on January 25, 2021 and concluded it in March 2021.

Item 1A. Risk Factors

There have been no material changes in the risk factors applicable to us from those identified in the Annual Report on Form 10-K for the period ended December 31, 2020 filed with the Securities and Exchange Commission on March 31, 2021.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

3.1		Certificate of Amendment to Designation, dated March 1, 2021 (Incorporated by reference to Exhibit 3.1 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed March 4, 2021 (Commission File No. 000-55450))
4.1		Warrant to Purchase Common Stock, dated February 26, 2021, issued by Medicine Man Technologies, Inc. to SHWZ Altmore, LLC (Incorporated by reference to Exhibit 4.1 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed March 4, 2021 (Commission File No. 000-55450))
10.1		Second Amendment to Securities Purchase Agreement, dated February 3, 2021, between Medicine Man Technologies, Inc. and Dye Capital Cann Holdings II, LLC (Incorporated by reference to Exhibit 10.1 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed February 9, 2021 (Commission File No. 000-55450))
10.2		Securities Purchase Agreement, dated February 26, 2021, between Medicine Man Technologies, Inc. and CRW Capital Cann Holdings, LLC (Incorporated by reference to Exhibit 10.1 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed March 4, 2021 (Commission File No. 000-55450))
10.3*		Letter Agreement, dated February 26, 2021, between Medicine Man Technologies, Inc. and CRW Capital Cann Holdings, LLC
10.4		Conversion Notice and Agreement, dated February 26, 2021, between Medicine Man Technologies, Inc. and Dye Capital & Company, LLC (Incorporated by reference to Exhibit 10.3 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed March 4, 2021 (Commission File No. 000-55450))
10.5		Loan Agreement, dated February 26, 2021, among Mesa Organics Ltd., Mesa Organics II Ltd., Mesa Organics III Ltd., Mesa Organics IV Ltd, SCG Holding, LLC and PBS Holdco LLC, as borrowers, SHWZ Altmore, LLC, as lender, and GGG Partners LLC, as collateral agent (Incorporated by reference to Exhibit 10.4 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed March 4, 2021 (Commission File No. 000-55450))
10.6		Promissory Note, dated February 26, 2021, issued by Mesa Organics Ltd., Mesa Organics II Ltd., Mesa Organics III Ltd., Mesa Organics IV Ltd, SCG Holding, LLC and PBS Holdco LLC, as borrowers, to SHWZ Altmore, LLC, as lender (Incorporated by reference to Exhibit 10.5 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed March 4, 2021 (Commission File No. 000-55450))
10.7		Security Agreement, dated February 26, 2021, between Mesa Organics Ltd., Mesa Organics II Ltd., Mesa Organics III Ltd., Mesa Organics IV Ltd, SCG Holding, LLC and PBS Holdco LLC, as grantors, and GGG Partners LLC, as collateral agent (Incorporated by reference to Exhibit 10.6 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed March 4, 2021 (Commission File No. 000-55450))
10.8		Parent Guaranty, dated February 26, 2021, between Medicine Man Technologies, Inc, as guarantor, and GGG Partners LLC, as collateral agent (Incorporated by reference to Exhibit 10.7 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed March 4, 2021 (Commission File No. 000-55450))
10.9		Third Amendment to Securities Purchase Agreement, dated March 30, 2021, between Medicine Man Technologies, Inc. and Dye Capital Cann Holdings II, LLC (Incorporated by reference to Exhibit 10.25 to Medicine Man Technologies, Inc.’s Annual Report on Form 10-K filed March 31, 2021 (Commission File No. 000-55450))
10.10*		Severance Agreement and Release between Leonardo Riera and Medicine Man Technologies, Inc.
31.1*		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2*		Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32**		Chief Executive Officer and Chief Financial Officer Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document*
101.SCH		XBRL Schema Document*
101.CAL		XBRL Calculation Linkbase Document*
101.DEF		XBRL Definition Linkbase Document*
101.LAB		XBRL Label Linkbase Document*
101.PRE		XBRL Presentation Linkbase Document*

______________________

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 13, 2021	MEDICINE MAN TECHNOLOGIES, INC.

	By: /s/ Justin Dye
	Justin Dye, Chief Executive Officer (Authorized Officer)


	By: /s/ Nancy Huber
	Nancy Huber, Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-10.3 2 medman_10q-ex1003.htm LETTER AGREEMENT BETWEEN MEDICINE MAN TECHNOLOGIES, INC. AND DYE CAPITAL & COMPANY

Exhibit 10.3

MEDICINE MAN TECHNOLOGIES, INC.

February 26, 2021

CRW Capital Cann Holdings, LLC
25 Highland Park Village, Suite 100-868

Dallas, TX 75205

Ladies and Gentlemen:

This letter agreement (this “Agreement”) will confirm our agreement that pursuant to and effective upon the closing of your purchase (the “Purchase”) of up to 30,000 shares of Series A Preferred Stock of Medicine Man Technologies, Inc. (the “Company”), CRW Capital Cann Holdings, LLC (the “Investor”) shall be entitled to the contractual rights set forth below, in addition to the rights specifically set forth in the Securities Purchase Agreement dated as of the date hereof by and between the Company and the Investor (the “Purchase Agreement”) and the Certificate of Designation of the Company that is referenced in the Purchase Agreement (the “Certificate of Designation”). The offering of the Series A Preferred Stock of the Company contemplated by the Purchase Agreement and the Confidential PPM (as defined in the Purchase Agreement) is sometimes referred to herein as the “Offering.” Capitalized terms that are used but not defined herein shall have the meaning given to them in the Purchase Agreement or, if applicable, the Certificate of Designation.

1. Board Nomination Rights.

(a) The Company shall take all actions to ensure that from and after the Closing and for so long as the Investor meets the Ownership Threshold (as defined below) as of the date of determination, the Company shall use its best efforts to appoint one individual designated by the Investor (an “Investor Designee”) to the board of directors of the Company (the “Board”). The Investor’s initial Investor Designee shall be Jeff Cozad (the “Initial Designee”). Following the Closing, the Company shall use its best efforts to cause the appointment to the Board of the Initial Designee and thereafter, for so long as the Investor’s Board nomination right under this Section 1 continues, the Company will use its best efforts to cause the Investor Designee to be elected to the Board (including recommending that the Company’s stockholders vote in favor of the election of such designee, soliciting proxies and contesting any proxy contest and otherwise supporting such designee for election in a manner no less rigorous and favorable than the manner in which the Company supports its other nominees); provided that if the Investor determines to designate a different individual (“Replacement Designee”) as the Investor Designee, such obligation shall instead apply to the Replacement Designee. If the Investor Designee ceases to be a director of the Company, the Company shall use its best efforts to cause the appointment to the Board of a Replacement Designee nominated by the Investor to fill the vacancy and thereafter the Company will use its best efforts to cause the election of such an individual to the Board, subject to the same conditions and limitations as set forth in the foregoing sentence. During such time as the Investor Designee is a member of the Board, the Investor Designee shall be entitled to the same level of compensation, directors’ and officers’ indemnity insurance coverage and indemnity and exculpation protection (including under any indemnification agreement) as the other independent members of the Board. For purposes hereof, “Ownership Threshold” means that the Investor owns, in the aggregate, at least $15,000,000 of Preferred Stock, on an as-converted to Common Stock basis, as of any date of determination, based on the 30-Day Trailing VWAP (as defined below); provided, however, that the Ownership Threshold shall automatically be deemed to be satisfied at any time the Investor holds at least 15,000 (as such amount may be adjusted for stock splits, subdivisions, combinations and the like) shares of Preferred Stock. For purposes hereof, “30-Day Trailing VWAP” means, as of any date of determination, the volume-weighted average price per share of Common Stock on the exchange on which the Common Stock is then traded during the regular trading session (and excluding pre-market and after-hours trading) over the thirty (30) consecutive trading days prior to and including such determination date.

(b) For so long as the Investor is entitled to designate an Investor Designee for election to the Board under this letter agreement, each committee of the Board shall include the Investor Designee as a member or, if the Investor so elects, as an observer; provided, however, that if the Investor Designee is not eligible for membership on any given committee of the Board under then applicable listing and corporate governance standards of a trading exchange or any Applicable Law, then such committee shall include the Investor Designee as an observer only; provided, further, that the Company shall exercise all authority under Applicable Law to permit the inclusion of the Investor Designee on such committee, including, without limitation, by causing an increase in the number of directors on such committee.

(c) The Investor Designee shall take all action reasonably requested by the Company, at the Company’s cost and expense, to comply with applicable state cannabis laws and regulations, including, without limitation, making all requisite filings under such laws and regulations as and when requested by the Company and the Investor Designee shall, at the Company’s cost and expense, reasonably cooperate with the Company with respect to any report, filing, notification or other communication with or to any state governmental authority related to the Company’s licenses, approvals, consents or obligations under state cannabis laws and regulations related to such Investor Designee’s capacity as a director of the Company, including, without limitation, any investigation or inquiry by a state governmental authority related to any of the foregoing. If the Investor Designee is determined to be unsuitable or disqualified to serve on the Board by a state governmental authority, including, without limitation, the Colorado Marijuana Enforcement Division, such Investor Designee shall immediately resign from the Board and the Investor shall be entitled to appoint a Replacement Designee in accordance with the provisions of Section 1(a) above.

2. For so long as the Investor is entitled to designate an Investor Designee for election to the Board under this letter agreement, the Investor may examine the books and records of the Company and inspect its facilities and may request information at reasonable times and intervals concerning the general status of the Company’s financial condition and operations, provided that the Investor may be excluded from access to any information or facilities if the Company determines in good faith, upon advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential proprietary information, or for other similar reasons; provided, however, that if any of the foregoing information constitutes or contains material, non-public information, the Company shall provide the Investor a statement asking whether the Investor is willing to accept material non-public information and provide such information to the Investor solely if the Investor consents to receive such information.

3. For so long as the Investor is entitled to designate an Investor Designee for election to the Board under this letter agreement, if the Investor is not represented on the Board, the Company shall, concurrently with delivery to the Board, give a representative of the Investor copies of all notices, minutes, consents and other material that the Company provides to its directors, except that the representative may be excluded from access to any material or meeting or portion thereof if the Board determines in good faith, upon advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential proprietary information, or for other similar reasons; provided, however, that if any of the foregoing material constitutes or contains material, non-public information, the Company shall provide the Investor a statement asking whether the Investor is willing to accept material nonpublic information and provide such information to the Investor solely if the Investor consents to receive such information. Upon reasonable notice and at a scheduled meeting of the Board or such other time, if any, as the Board may determine in its sole discretion, such representative may address the Board with respect to the Investor’s concerns regarding significant business issues facing the Company.

4. If, on or after the Closing, the Company issues any rights or benefits containing provisions (including, without limitation, any of the terms of pricing, conversion price, exercise price, anti-dilution, liquidation, distributions, and registration rights) that are more favorable than those set forth in the Purchase Agreement and Certificate of Designation to any other holder of the Preferred Stock issued in the Offering who acquires an amount of Preferred Stock that is less than or equal to the amount of Preferred Stock acquired by the Investor pursuant to the Purchase Agreement, the Company will make such provisions (or any more favorable portion thereof) available to the Investor and will use best efforts to enter into amendments necessary to confer such rights on the Investor.

5. Right to Participate.

(a) From and after the Closing and for so long as the Investor meets the Ownership Threshold, the Company will not, directly or indirectly, issue, sell or grant any securities or options to purchase any of its securities (any such issuance, sale or grant being referred to as a “Placement”), unless the Company shall have first complied with this Section 5.

(b) At least five Trading Days prior to any proposed or intended Placement, the Company shall deliver to the Investor a written notice (each such notice, a “Pre-Notice”), which Pre-Notice shall not contain any information (including, without limitation, material, non-public information) other than: (i) if the proposed Offer Notice (as defined below) constitutes or contains material, non-public information, a statement asking whether the Investor is willing to accept material non-public information or (ii) if the proposed Offer Notice does not constitute or contain material, non-public information, (x) a statement that the Company proposes or intends to effect a Placement, (y) a statement that the statement in clause (x) above does not constitute material, nonpublic information and (z) a statement informing the Investor that it is entitled to receive an Offer Notice with respect to such Placement upon its written request. Upon the written request of the Investor within three Trading Days after the Company’s delivery to the Investor of such Pre-Notice, and only upon a written request by the Investor, the Company shall promptly, but no later than one Trading Day after such request, deliver to the Investor an irrevocable written notice (the “Offer Notice”) of any proposed or intended issuance, sale or grant (the “Offer”) of the securities being offered (the “Offered Securities”) in a Placement, which Offer Notice shall (A) identify and describe the Offered Securities, (B) describe the price and other terms upon which they are to be issued, sold or granted, and the number or amount of the Offered Securities to be issued, sold or granted, (C) identify the Persons (if known) to which or with which the Offered Securities are to be issued, sold or granted and (D) offer to issue and sell to the Investor in accordance with the terms of the Offer the Investor’s pro rata portion of the Offered Securities, provided that the number of Offered Securities which the Investor shall have the right to subscribe for under this Section 5 shall be equal to a percentage of the Offered Securities determined as follows: the number of shares of Preferred Stock beneficially held by the Investor on the date of the Offer Notice on an as-converted to Common Stock basis shall be divided by the total number of shares of Common Stock outstanding on the date of the Offer Notice on an as-converted, fully-diluted basis (taking into account all outstanding securities of the Company regardless of whether the holders of such securities have the right to convert or exercise such securities for Common Stock at the time of determination).

(c) To accept an Offer, the Investor must deliver a written notice to the Company prior to the end of the fifth Trading Day after the Investor’s receipt of the Offer Notice (the “Offer Period”), setting forth whether the Investor elects to purchase all or none (but not some) of the Offered Securities the Investor is eligible to purchase pursuant to this Section 5 (the “Notice of Acceptance”). Notwithstanding the foregoing, if the Company desires to modify or amend the terms and conditions of the Offer prior to the expiration of the Offer Period, the Company may deliver to the Investor a new Offer Notice and the Offer Period shall expire on the fifth Trading Day after the Investor’s receipt of such new Offer Notice.

(d) The Company shall have ten Trading Days from the expiration of the Offer Period above to issue, sell or grant all or any part of such Offered Securities as to which a Notice of Acceptance has not been given by the Investor (the “Refused Securities”) pursuant to a definitive agreement(s), but only upon terms and conditions that are not more favorable to the acquiring Person or Persons or less favorable to the Company than those set forth in the Offer Notice.

(e) Upon the closing of the issuance, sale or grant of the Offered Securities, the Investor shall acquire from the Company, and the Company shall issue to the Investor, the number or amount of Offered Securities specified in its Notice of Acceptance. Any Offered Securities not acquired by the Investor or other Persons in accordance with this Section 5 may not be issued or sold until they are again offered to the Investor under the procedures specified in this Section 5.

(f) Notwithstanding anything to the contrary in this Section 5 and unless otherwise agreed to in writing by the Investor, the Company shall either confirm in writing to the Investor that the transaction with respect to the Placement has been abandoned or shall publicly disclose its intention to issue the Offered Securities, in either case, in such a manner such that the Investor will not be in possession of any material, non-public information, by the fifth Trading Day following delivery of the Offer Notice. If by such fifth Trading Day, no public disclosure regarding a transaction with respect to the Offered Securities has been made, and no notice regarding the abandonment of such transaction has been received by the Investor, such transaction shall be deemed to have been abandoned and the Investor shall not be in possession of any material, non-public information with respect to the Company or any of its Subsidiaries. Should the Company decide to pursue a transaction with respect to the Offered Securities which had been deemed to have been abandoned pursuant to the preceding sentence, the Company shall provide the Investor with another Offer Notice and the Investor will again have the right of participation set forth in this Section 5.

(g) The participation rights contained in this Section 5 shall not apply to (i) securities issued to any employee, officer, director or consultant pursuant to any incentive equity plan that has been approved by the Board, (ii) any securities issued upon exercise, conversion or exchange of securities issued pursuant to clause (i) of this Section 5(g), (iii) any securities issues upon exercise, conversion or exchange of any securities that are outstanding on the Original Issue Date; provided, that any issuance of securities upon exercise, conversion or exchange of any securities that are outstanding on the Original Issue Date is made pursuant to the terms of such securities in effect on the Original Issue Date and such securities are not amended, modified or changed on or after the Original Issue Date in any manner that materially and adversely affects the Investor, (iv) securities issued by the Company in connection with acquisitions, joint ventures or debt financing of the Company, (v) any proportional subdivision of Common Stock or Preferred Stock (including any dividend or stock split), any combination of Common Stock or Preferred Stock or any other proportional recapitalization, or (vi) any securities issued as a dividend or other distribution made on the Preferred Stock or otherwise on a pro rata basis to all stockholders of the Company.

6. From and after the Closing and for so long as the Investor meets the Ownership Threshold, the Company shall not issue any Senior Securities without the written consent of the Investor, which the Investor may grant or withhold in its sole discretion.

7. The Company shall pay CRW Capital, LLC, the manager of the Investor, a monitoring fee equal to $150,000, which such monitoring fee shall be paid in monthly installments of $10,000 commencing on the date of the Closing.

8. This Agreement and the rights, privileges and obligations herein are personal to the Investor and may not be assigned, transferred, subcontracted or delegated (in whole or in part) by the Investor, including by operation of law, without the prior written consent of the Company to any Person other than an Affiliate of the Investor.

9. Unless earlier terminated pursuant to the terms hereof, this Agreement and the rights described herein shall terminate and be of no further force or effect upon the earlier of: (a) such time as no shares of the Company’s stock are held by the Investor; (b) the Listing Event; or (c) completion of a Change of Control Transaction; provided, however, that this Agreement and the rights described herein shall not terminate solely as a result of the Common Stock ceasing to be listed on any Trading Market but, for the avoidance of doubt, this Agreement and the rights described herein shall terminate if any other element of the definition of Change of Control Transaction set forth in the Certificate of Designation (i.e., clause (a), (b) or (c) of such definition) occurs.

The parties acknowledge and agree that this Agreement is a Transaction Document as such term is defined under the Purchase Agreement and the provisions of Section 7 of the Purchase Agreement are incorporated herein by reference and shall apply hereto mutatis mutandis.

[Signature Page Follows]

Very truly yours,	Agreed and Accepted:

CRW CAPITAL CANN HOLDINGS, LLC	MEDICINE MAN TECHNOLOGIES, INC.


By /s/Jeff Cozad	By: /s/Justin Dye
Name:Jeff Cozad	Name: Justin Dye
Title: Managing Member of GP	Title: CEO

EX-10.1 3 medman_10q-ex1010.htm SEVERANCE AGREEMENT AND RELEASE

Exhibit 10.10

SEVERANCE AGREEMENT AND RELEASE

This Full and Final General Release (referred to herein as “Agreement”) dated October 23, 2020 (“Effective Date”) is made and entered into by LEONARDO RIERA (“Consultant”) and MEDICINE MAN TECHNOLOGIES, INC. (MMT) DBA SCHWAZZE, a corporation duly organized under the laws of the state of Nevada and having its principal place of business at 4880 Havana Street, Suite 201 South, Denver, Colorado 80239 (hereinafter referred to as the “Contractor” “MMT” “Schwazze” or “the Company”). The parties to this Agreement are referred to collectively herein as the “Parties” or individually as a “Party” to this Agreement.

RECITALS

WHEREAS Consultant has been contracted by the Company since February 2020 and has served as consultant and Board Member of the Company since June of 2019;

WHEREAS Consultant and the Company desire to mutually agree to terminate Consultant’s contractual relationship pursuant to Section 8(b) of Consultant’s February 15, 2020 Agreement;

WHEREAS Consultant has been a member of the Company’s Board of Directors (“Board”) since 2019;

WHEREAS Consultant and the Company desire to mutually agree to terminate Consultant’s service on the Company’s Board of Directors;

WHEREAS the effective date (“Effective Date”) of this Agreement will commence immediately upon the expiration of the seven-day revocation period described in Paragraph 18 below; and

AGREEMENT

NOW, THEREFORE, for and in consideration of the premises, agreements, covenants and conditions contained herein, the adequacy and sufficiency of which are hereby expressly acknowledged, Consultant agrees as follows:

SEPARATION AND ACCRUED WAGES

A. Consultant’s active contractual relationship with the Company ended on October 1, 2020 (“Separation Date”). The Company reimbursed Consultant for all approved expenses made on behalf of the Company. Consultant agrees that upon receipt of his final payment , Consultant has received all wages, bonus, and benefits owed to him by the Company.

B. Subject to the approval of the board, having previously been negotiated and approved in good faith with the CEO and Chairman, Mr. Riera will receive fifty thousand value in shares of common stock for his board service, which shall be delivered to Consultant within five days of board approval. The Company requires that Mr. Riera continue his Board services on the special committee and on the Board up to January 31^st. 2021, but could end his service sooner at the sole discretion of the Chairman. Mr. Riera will continue to exercise his fiduciary and loyalty duties to the Company while remaining on the Board.

C. Consultant will execute a letter of resignation from his role on the Board, effective immediately but exercisable by the Company at its sole discretion. A copy of Consultants’ resignation letter is herein attached as Exhibit A.

Payment AND TAX Liability

A. In consideration for the covenants undertaken and releases given herein by Consultant, and provided that Consultant executes and does not revoke this Agreement, is not in breach or default of this Agreement, and has performed all of his obligations under this Agreement, the Company agrees that it shall provide Consultant with the following:

(i) Severance Payment: One Hundred and Fifty Thousand Dollars ($150,000.00), that will be payable in four payments: a lump sum of Fifty Thousand Dollars ($50,000.00) on October 26, 2020, a lump sum of Fifty Thousand Dollars ($50,000.00) on November 16, 2020, a lump sum of Twenty Five Thousand Dollars ($25,000.00) on November 30, 2020, and a lump sum of Twenty Five Thousand Dollars ($25,000.00) on December 15, 2020.

(ii) Interim cash payment and assistance with moving expenses: The Company has agreed to advance Consultant three payments of $10,000.00 each to assist Consultant in covering living expenses while consultant remains in Denver for the months of November 2020, December 2020 and January 2021. These payments shall be made on November 20, December 20, and January 20, plus $10,500.00 for moving expenses back to Florida that shall be paid together with the December 2020 payment.

(iii) Subject to approval by the Board, having previously been negotiated and approved in good faith with the CEO and Chairman, the Company shall grant Consultant the option to purchase three hundred and twenty-five thousand (325,000) shares of the Company’s common stock, which shall vest immediately upon their issuance, subject to the terms and conditions set forth in a Stock Option Agreement and the Company’s 2017 Equity Incentive Plan (hereafter collectively referred to as the “Stock Option Agreements”), which are set forth in Exhibit B and incorporated by reference herein. The strike price shall be set at $1.17 which was the strike price on the Date of Separation.

B. Consultant shall be responsible for any and all tax liabilities resulting from the payments that are being provided by the Company to Consultant, as outlined above.

This consideration is over and above all payments due, and Consultant agrees that he is not otherwise entitled to receive a severance sum from the Company and that the severance sum is above and in addition to all wages owed to him. Consultant further agrees that the consideration set forth above constitutes the entire consideration provided to her under this Agreement and that he shall not seek any further compensation or consideration (including additional stock options) from the Releasees (defined below) for claimed damages, costs, or attorneys’ fees in connection with any claim released here.

General Release

A. In exchange for the payment described in Paragraph 2A and the other promises contained herein, Consultant and the Company hereby forever release and discharge the other Party, its affiliates, owners, predecessors, successors, parents, subsidiaries, divisions, heirs, assigns, executives, present and former representatives, present and former Consultants, consultants, agents, insurers and attorneys from any and all claims, federal or state actions, appeals, demands, causes of action, liabilities, damages, interest, attorneys’ fees and expenses whatsoever, whether in law or equity or otherwise, and whether known or unknown.

All of the released entities described above are collectively referred to as the “Releasees.”

This release includes, but is not limited to, all claims, demands, federal or state administrative actions, appeals, and causes of action arising out of or in any way related to: (a) all federal, state, and local laws, including, without limitation, the following federal and state statutes, as amended, and their corresponding regulations: the Americans with Disabilities Act Amendments Act of 2008 and any subsequent amendments, the Civil Rights Act of 1991, the Civil Rights Acts of 1866 and 1871, 42 U.S.C. § 1981, 42 U.S.C. § 1983, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act of 1967 and any subsequent amendments, the Fair Labor Standards Act, the Consultant Retirement Income Security Act, the Americans with Disabilities Act of 1990, the Equal Pay Act of 1963, the Family and Medical Leave Act of 1993 and any subsequent amendments, the National Labor Relations Act, the Labor Management Relations Act, the Occupational Safety and Health Act of 1970, the Older Workers Benefit Protection Act of 1990, the Rehabilitation Act of 1973t; and (b) any claim or action under the common law of the State of Colorado including but not limited to, any claim for compensation, damages, tort, breach of express or implied employment contract, breach of duty of good faith, discrimination, intentional interference with contractual relations, fraud, misrepresentation, outrageous conduct, slander, libel, negligent and/or intentional infliction of emotional distress, violation of public policy, negligent supervision, assault, battery, breach of contract, implied breach of good faith and fair dealing, promissory estoppel, wrongful discharge, harassment, or retaliation, and for any other damages or injuries incurred on the job; and (c) any claim under the constitution of the United States or the State of Colorado; in relation to Consultant’s employment or incurred as a result of loss of employment. However, nothing in this Agreement including but not limited to the release of claims, proprietary information, confidentiality, and non-disparagement provisions, prevent Consultant from filing a charge or complaint with or from participating in an investigation or proceeding conducted by the EEOC, NLRB or any other any federal, state or local agency charged with the enforcement of any laws, or from exercising Consultant’s rights under Section 7 of the NLRA to engage in joint activity with other Consultants, although by signing this release Consultant is waiving rights to individual relief based on claims asserted in such a charge or complaint, except where such a waiver of individual relief is prohibited.

B. Released Claims. The claims, charges, causes of actions, appeals, demands, losses, damages, attorneys’ fees, expenses, costs and liabilities released in Paragraph 3A shall be referred to collectively herein as the “Released Claims.”

PROMISE NOT TO PROSECUTE

Consultant and the Company further agree that they shall not, at any time hereafter, commence, maintain or prosecute any action, suit, proceeding, investigation, complaint, claim, grievance or charge with any court, administrative agency, arbitrator or any other body or person, whether Federal, State, contractual or otherwise, or aid or assist others in prosecuting such action, suit, proceeding, investigation, complaint, claim, grievance or charge on their behalf, except in response to governmental agency or court inquiries or as compelled by legal process, against the other, or any of them, based in whole or in part upon, or arising out of or in an way connected with, any of the claims released or any of the matters referred to in this Agreement. Consultant and the Company further agree to indemnify each other and hold the other Party harmless from and against any and all claims, demands, causes of action, damages or liability of any kind, including the cost of defense and reasonable attorneys’ fees arising out of or in connection with, any action, suit, proceeding, investigation, complaint, claim, grievance or charge commenced, maintained, or prosecuted by them contrary to the terms of this Agreement.

Release IncludeS Unknown Claims

A. The Parties understand and agree that the Released Claims are intended to and do include any and all claims of every nature and kind whatsoever, whether known, unknown, suspected, or unsuspected.

B. The Parties further acknowledge that they may hereafter discover facts different from or in addition to those that they now know or believe to be true with respect to the Released Claims and agree that, in such event, this Agreement shall nevertheless be and remain effective in all respects, notwithstanding such different or additional facts, or the discovery thereof.

C. The Parties represent and acknowledge (i) that they have conducted whatever investigation was deemed necessary to ascertain all facts and matters related to this Release; (ii) that they have had the opportunity to consult with and to receive advice from legal counsel concerning this Release; and (iii) that they are not relying in any way on any statement or representation by the other party or that party’s attorneys, except as expressly stated herein, in reaching his decision to enter into this Agreement.

No Assignment or Transfer of Released Claims

The Parties represent and warrant that they have not assigned, transferred, or hypothecated, or purported to assign, transfer, or hypothecate, to any person, firm, corporation, association, or entity whatsoever any of the Released Claims.

No Admission of Liability

Consultant and the Company understand and agree that this Agreement is a release of any disputed claims and does not constitute an admission of liability on the part of any of the Parties, as to any matters whatsoever and that the Parties intend by this Agreement to avoid further proceedings and buy peace. The Parties specifically deny liability for any harm allegedly suffered by the other Party.

8. RETURN OF PROPERTY AND RECORDS

Consultant agrees to return all property belonging to the Company that Consultant has in his possession. Consultant understands that he is not entitled to keep or preserve records of the Company. This prohibition does not include any relevant Consultant files or records of Consultant.

9. Confidentiality

A. Consultant agrees he will keep this Agreement confidential, and that the Agreement and its terms and conditions, including the fact of Release and the facts and circumstances underlying any potential claims, shall not be discussed with, or revealed to, any person other than Consultant’s spouse, attorneys, accountants, or tax or financial advisors, except as otherwise required by law or by order of a court. Consultant agrees that if he discusses or reveals the terms or conditions of the Release to or with any of the aforementioned persons or entities, he will instruct those persons or entities that the terms and conditions of the Agreement are confidential, and that such persons or entities shall be under the same confidentiality obligations as to Consultant and the Company. Consultant understands and agrees that confidentiality is a material provision of this Agreement.

B. Company agrees it will keep this Agreement confidential, and that the Agreement and its terms and conditions, including the fact of Release and the facts and circumstances underlying any potential claims, shall not be discussed with, or revealed to, any person other than Company’s Board of Directors, attorneys, accountants, tax or financial advisors or those required for processing the payment described above in Paragraph 2, except as otherwise required by law or by order of a court. Company agrees that if it discusses or reveals the terms or conditions of the Release to or with any of the aforementioned persons or entities, it will instruct those persons or entities that the terms and conditions of the Agreement are confidential, and that such persons or entities shall be under the same confidentiality obligations as to Consultant and the Company. Company understands and agrees that confidentiality is a material provision of this Agreement.

10. non-disparagement

A. Consultant and the Company agree not to make any statements to any third party that disparages the Company, Consultant, or other Releasees. Nothing in the foregoing sentence, however, is intended to nor shall it be construed to prevent Consultant from making true statements to a third party pursuant to a valid subpoena or under oath and penalty of perjury in a deposition or other court proceeding. Consultant and the Company understand and agree that non-disparagement is a material provision of this Agreement.

11. COOPERATION

Consultant and the Company agree to cooperate with each other with respect to the prosecution and/or defense of legal claims which arose during Consultant’s tenure as a Consultant of the Company, or which relate to events which occurred during Consultant’s tenure as a Consultant of the Company or to which Consultant has any information. Such cooperation shall include, but is not limited to, making each other available for interview by each other and/or its counsel, reviewing and/or identifying documents, giving testimony and/or testifying at trial, and further that the Parties shall immediately notify the each other in writing if a Party to this Agreement is ever subpoenaed or otherwise requested to testify in any matter involving the other Party..

12. NON-COMPETE AND NON-SOLICITATION

Consultant acknowledges that the business and products of Company as embodied in Company’s Confidential Information are unique and of significant importance to the commercial viability and continuity of Company, as well as providing Company with a significant competitive advantage and as a result, Consultant agrees:

	A.	Non-Compete. Consultant covenants and agrees that for one (1) year after the Effective Date of this Agreement that Consultant will not, directly or indirectly, anywhere in the states in which Company operates or is contemplating operating, provide consulting services on behalf of any business that is competitive with Company.

	B.	Non-Solicitation of Employees. Consultant covenants and agrees that for one (1) year after the Effective Date of this Agreement that Consultant shall not, directly or indirectly, employ, solicit, recruit, or encourage for employment, or otherwise contract for or hire, the services of any individual who is then an employee of the Company or who was an employee of the Company within the previous twelve (12) months of the Effective Date.

NonSolicitation of Customers, Customer Prospects and Vendors. Consultant covenants and agrees that for one (1) year after the Effective Date of this Agreement that Consultant shall not, directly or indirectly, solicit any person or entity who paid or engaged the Company for services, or who received the benefit of Company’s services, or with whom Consultant had any substantial dealing with. This Section also applies to assisting any employer or other third party in the non-solicitation of customers, customer prospects and vendors. Consultant shall not, directly or indirectly, disclose to any person, firm or corporation the names or addresses of any of the customers or clients of the Company or any other information pertaining to them. Consultant shall not call on, solicit, take away, or attempt to call on or solicit any customer of the Company with whom Consultant has personally knowledge of.

13. parties to bear their own costs

Consultant understands that he and the Company will each bear their own costs, expenses, and attorneys’ fees, if any, in relation to this Agreement.

14. REPRESENTATIONS

Each signatory hereto warrants that s/he/it is legally competent and/or authorized to execute this Agreement and has not relied on any statements or explanations in connection therewith. Moreover, each party hereby acknowledges that s/he/it has been afforded the opportunity to be advised by legal counsel regarding the terms of this Agreement, including the release of all claims and waiver of rights.

15. KNOWLEDGE, CAPACITY, AND AUTHORITY

Consultant represents and warrants that he had the opportunity to have counsel explain the contents of this Agreement to him. Consultant represents that he understands the contents of this Agreement and that he executed it knowingly and voluntarily and understands that after executing it he cannot proceed against any Releasee on account of the matters referred to herein. Each party to this Agreement represents and warrants that s/he/it has the authority and capacity to execute this Agreement.

16. Modification

No provision of this Release may be changed, altered, modified or waived except in writing signed by both Consultant and the Company or other Releasees, which writing shall specifically reference this Release and the provision that the parties intend to waive or modify.

17. NON-WAIVER

No provision of this Agreement may be waived unless in writing and signed by all the parties to this Agreement. Waiver of any one provision shall not constitute waiver of any other provision. A delay of failure by either party to exercise a right under this Agreement, or a partial or single exercise of that right, shall not constitute a waiver of that or any other right herein.

18. Severability

In the event any provision of this Agreement should be held to be unenforceable, each and all of the other provisions of this Agreement shall remain in full force and effect.

19. WAIVER OF CLAIMS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT

The Severance Sum is intended in part as consideration for Consultant’s release and waiver of any and all claims under the ADEA. Consultant should consult with his attorneys about this release and waiver before executing this Agreement. Further, Consultant has twenty-one (21) calendar days from her receipt of this Agreement to consider the release and waiver of any and all claims (including those arising under the ADEA), and, for a period of seven (7) calendar days following execution of the Agreement by him, Consultant may revoke this release and waiver in a writing received by counsel for the Company on or before the expiration of the seven (7) calendar day period. This Agreement shall not become effective or enforceable until the seven (7) calendar day revocation period set forth herein has expired without Consultant having exercised her right of revocation (defined herein as the “Effective Date”). Notice should be sent in writing to the following: Daniel Pabon, Medicine Man Technologies, Inc. 4801 Havana Street, Suite 201, Denver, Colorado 80239.

20. Applicable Law

This Agreement shall be construed and enforced according to the laws of the State of Colorado.

21. Counterparts Acceptable

This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.

22. ENTIRE AGREEMENT

Consultant acknowledges that this Release constitutes a full, final, and complete settlement of the parties’ differences and supersedes and replaces any and all other written or oral exchanges, agreements, understandings, employment contracts, arrangements, or negotiations between or among them relating to the subject matter hereof; and Consultant affirmatively represents that there are no other prior or contemporaneous exchanges, agreements, representations, arrangements, or understandings, written or oral, between or among the parties relating to the subject matter hereof other than that as set forth herein, and that this Release contains the sole and entire Release between them with respect to the subject matter hereof. Consultant further acknowledges and agrees that any language proposed for, deleted from, or otherwise changed in any drafts of this Release but not included herein shall not be considered in any way in the interpretation and application of this Release and shall not in any way affect the rights and obligations of Consultant, the Company, or Releasees.

PLEASE READ CAREFULLY.

THIS AGREEMENT INCLUDES A RELEASE OF ALL CLAIMS KNOWN AND UNKNOWN.

I, Leonard Riera, ACKNOWLEDGE THAT I HAVE READ THIS RELEASE, THAT I HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING THIS RELEASE, AND THAT I UNDERSTAND ALL OF THIS AGREEMENT’S TERMS AND EXECUTE THE AGREEMENT VOLUNTARILY WITH FULL KNOWLEDGE OF ITS SIGNIFICANCE AND CONSEQUENCES. CONSULTANT ACKNOWLEDGES THAT HE HAD SEVEN DAYS TO DECIDE IF HE WANT TO SIGN THIS AGREEMENT.

IN WITNESS WHEREOF, the Parties have executed this Agreement have set their hands the day and year set forth below their respective signatures.

/s/ Leonardo Riera
Date: 10/23/2020


Medicine Man Technologies, Inc. dba Schwazze


/s/ Justin Dye
By: Justin Dye	Date: 10/23/2020
Title: CEO

Exhibit A

________________, 2020

Executive Chairman and CEO Justin Dye

Directors of Medicine Man Technologies, Inc. dba Schwazze

4880 Havana Street Ste 201

Denver, CO 80239

Re: Resignation of Membership on Medicine Man Technologies, Inc. dba Schwazze Board of Directors

Dear Mr. Dye:

Please let this letter serve as notice that for personal reasons I have decided to resign as a Member of the Board of Directors of Medicine Man Technologies, Inc dba Schwazze. My resignation shall be effective at any time between the current date and no later than January 31, 2021, at the discretion of the Chairman of the Board. Until such time that my resignation to the Board becomes effective by means of written notification by the Chairman, I will continue to serve, at his request, as Director and as member of the Special Committee that is evaluating financing options in the form of preferred shares.

I have greatly enjoyed my time in Denver and as member of the Board of Schwazze. I am proud of the work we have done, and wish Schwazze all the best in the future.

Sincerely,

Leonardo Riera

Accepted on _____________________________.

_______________________________________

Medicine Man Technologies, Inc. dba Schwazze

Exhibit B

Stock Option Agreement

EX-31.1 4 medman_10q-ex3101.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Justin Dye, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Medicine Man Technologies, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 13, 2021	/s/ Justin Dye
	Justin Dye, Chief Executive Officer

EX-31.2 5 medman_10q-ex3102.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Nancy Huber, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Medicine Man Technologies, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 13, 2021	/s/ Nancy Huber
	Nancy Huber, Chief Financial Officer

EX-32 6 medman_10q-ex32.htm CERTIFICATION

Exhibit 32

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report of Medicine Man Technologies, Inc. (the “Company”) on Form 10-Q for the fiscal period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

	1.	The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 13, 2021	/s/ Justin Dye
	Justin Dye, Chief Executive Officer


Dated: May 13, 2021	/s/ Nancy Huber
	Nancy Huber, Chief Financial Officer

EX-101.INS 7 mdcl-20210331.xml XBRL INSTANCE FILE 0001622879 2021-01-01 2021-03-31 0001622879 2020-12-31 0001622879 2021-03-31 0001622879 2020-01-01 2020-03-31 0001622879 us-gaap:CommonStockMember 2020-12-31 0001622879 us-gaap:CommonStockMember 2021-03-31 0001622879 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001622879 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001622879 us-gaap:RetainedEarningsMember 2020-12-31 0001622879 us-gaap:RetainedEarningsMember 2021-03-31 0001622879 us-gaap:TreasuryStockMember 2020-12-31 0001622879 us-gaap:TreasuryStockMember 2021-03-31 0001622879 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001622879 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001622879 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001622879 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001622879 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001622879 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001622879 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001622879 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001622879 2021-05-10 0001622879 us-gaap:RetailMember 2021-01-01 2021-03-31 0001622879 us-gaap:RetailMember 2020-01-01 2020-03-31 0001622879 MDCL:WholesaleMember 2021-01-01 2021-03-31 0001622879 MDCL:WholesaleMember 2020-01-01 2020-03-31 0001622879 MDCL:OtherMember 2021-01-01 2021-03-31 0001622879 MDCL:OtherMember 2020-01-01 2020-03-31 0001622879 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001622879 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001622879 us-gaap:PreferredStockMember 2019-12-31 0001622879 us-gaap:PreferredStockMember 2020-03-31 0001622879 us-gaap:PreferredStockMember 2020-12-31 0001622879 us-gaap:PreferredStockMember 2021-03-31 0001622879 us-gaap:CommonStockMember 2019-12-31 0001622879 us-gaap:CommonStockMember 2020-03-31 0001622879 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001622879 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001622879 us-gaap:RetainedEarningsMember 2019-12-31 0001622879 us-gaap:RetainedEarningsMember 2020-03-31 0001622879 us-gaap:TreasuryStockMember 2019-12-31 0001622879 us-gaap:TreasuryStockMember 2020-03-31 0001622879 2019-12-31 0001622879 2020-03-31 0001622879 MDCL:ConvertiblePromissoryNoteMember MDCL:DyeCapitalMember 2020-12-16 0001622879 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember MDCL:MarketableSecuritiesMember 2021-03-31 0001622879 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember MDCL:MarketableSecuritiesMember 2020-12-31 0001622879 us-gaap:TradeAccountsReceivableMember 2021-03-31 0001622879 MDCL:AccountsReceivableRelatedPartyMember 2021-03-31 0001622879 MDCL:AccountsReceivableLitigationMember 2021-03-31 0001622879 us-gaap:TradeAccountsReceivableMember 2020-12-31 0001622879 MDCL:AccountsReceivableRelatedPartyMember 2020-12-31 0001622879 MDCL:AccountsReceivableLitigationMember 2020-12-31 0001622879 MDCL:IntellectualPropertyLicenseAbbaMember 2021-03-31 0001622879 MDCL:IntellectualPropertyLicenseAbbaMember 2020-12-31 0001622879 srt:MinimumMember 2021-01-01 2021-03-31 0001622879 srt:MaximumMember 2021-01-01 2021-03-31 0001622879 MDCL:CustomerDepositsMember 2021-03-31 0001622879 MDCL:AccruedPayrollMember 2021-03-31 0001622879 MDCL:OperatingExpensesMember 2021-03-31 0001622879 MDCL:PrepaidExpensesMember 2021-03-31 0001622879 MDCL:SecurityDepositsMember 2021-03-31 0001622879 MDCL:CustomerDepositsMember 2020-12-31 0001622879 MDCL:AccruedPayrollMember 2020-12-31 0001622879 MDCL:OperatingExpensesMember 2020-12-31 0001622879 MDCL:PrepaidExpensesMember 2020-12-31 0001622879 MDCL:TaxReceivableMember 2020-12-31 0001622879 MDCL:SecurityDepositsMember 2020-12-31 0001622879 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001622879 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001622879 us-gaap:MachineryAndEquipmentMember 2021-03-31 0001622879 us-gaap:OfficeEquipmentMember 2021-03-31 0001622879 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-03-31 0001622879 MDCL:WorkInProgressMember 2021-03-31 0001622879 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001622879 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001622879 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001622879 us-gaap:OfficeEquipmentMember 2020-12-31 0001622879 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0001622879 MDCL:WorkInProgressMember 2020-12-31 0001622879 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-03-31 0001622879 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-03-31 0001622879 us-gaap:VehiclesMember 2021-01-01 2021-03-31 0001622879 us-gaap:OfficeEquipmentMember 2021-01-01 2021-03-31 0001622879 us-gaap:LicenseMember 2021-03-31 0001622879 us-gaap:TradeNamesMember 2021-03-31 0001622879 us-gaap:CustomerRelationshipsMember 2021-03-31 0001622879 MDCL:ProductLicenseAndRegistrationMember 2021-03-31 0001622879 MDCL:TradeSecretMember 2021-03-31 0001622879 us-gaap:NoncompeteAgreementsMember 2021-03-31 0001622879 us-gaap:LicenseMember 2020-12-31 0001622879 us-gaap:TradeNamesMember 2020-12-31 0001622879 us-gaap:CustomerRelationshipsMember 2020-12-31 0001622879 us-gaap:NoncompeteAgreementsMember 2020-12-31 0001622879 MDCL:ProductLicenseAndRegistrationMember 2020-12-31 0001622879 MDCL:TradeSecretMember 2020-12-31 0001622879 MDCL:OfficerAndDirectorMember us-gaap:RestrictedStockMember 2019-01-01 2019-01-08 0001622879 MDCL:OfficerAndDirectorMember us-gaap:RestrictedStockMember 2019-01-01 2019-04-23 0001622879 MDCL:AnOfficerMember us-gaap:RestrictedStockMember 2019-01-01 2019-06-11 0001622879 MDCL:MedManDenverMember 2020-01-01 2020-12-31 0001622879 MDCL:MedManDenverMember 2020-12-31 0001622879 MDCL:MedPharmHoldingsMember 2020-01-01 2020-12-31 0001622879 MDCL:MedPharmHoldingsMember 2019-01-01 2019-12-31 0001622879 MDCL:MedPharmHoldingsMember 2020-12-31 0001622879 MDCL:MedPharmHoldingsMember 2021-03-31 0001622879 MDCL:Baseball18Member 2020-01-01 2020-12-31 0001622879 MDCL:FarmBoyMember 2020-01-01 2020-12-31 0001622879 MDCL:EmeraldFieldsMember 2020-01-01 2020-12-31 0001622879 MDCL:LosSuenosMember 2020-01-01 2020-12-31 0001622879 MDCL:Baseball18Member 2020-12-31 0001622879 MDCL:FarmBoyMember 2020-12-31 0001622879 MDCL:TellaDigitalMember 2021-01-01 2021-03-31 0001622879 MDCL:TellaDigitalMember 2020-01-01 2020-12-31 0001622879 MDCL:SuccessAndPonoMember 2017-06-03 0001622879 MDCL:DenverConsultingMember 2017-07-21 0001622879 MDCL:BigTomatoMember 2018-01-01 2018-09-17 0001622879 MDCL:MesaOrganicsMember 2020-04-20 0001622879 MDCL:SuccessAndPonoMember 2021-03-31 0001622879 MDCL:DenverConsultingMember 2021-03-31 0001622879 MDCL:BigTomatoMember 2021-03-31 0001622879 MDCL:MesaOrganicsMember 2021-03-31 0001622879 srt:MinimumMember 2021-03-31 0001622879 srt:MaximumMember 2021-03-31 0001622879 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001622879 us-gaap:WarrantMember 2020-12-31 0001622879 us-gaap:WarrantMember 2021-03-31 0001622879 MDCL:EmployeesOfficersDirectorsMember 2020-01-01 2020-12-31 0001622879 MDCL:MesaOrganicsLtdMember 2020-01-01 2020-04-20 0001622879 MDCL:SBUDLLCMember us-gaap:PreferredStockMember 2020-01-01 2020-12-17 0001622879 MDCL:SBUDLLCMember us-gaap:PreferredStockMember 2020-01-01 2020-12-18 0001622879 MDCL:SBUDLLCMember us-gaap:PreferredStockMember 2021-01-01 2021-02-03 0001622879 us-gaap:WarrantMember MDCL:VariousAccreditedInvestorMember srt:MaximumMember 2021-03-31 0001622879 us-gaap:WarrantMember MDCL:VariousAccreditedInvestorMember srt:MinimumMember 2021-03-31 0001622879 us-gaap:WarrantMember MDCL:VariousAccreditedInvestorMember 2021-01-01 2021-03-31 0001622879 us-gaap:WarrantMember MDCL:VariousAccreditedInvestorMember srt:MinimumMember 2021-01-01 2021-03-31 0001622879 us-gaap:WarrantMember MDCL:VariousAccreditedInvestorMember srt:MaximumMember 2021-01-01 2021-03-31 0001622879 MDCL:ProductsMember 2021-01-01 2021-03-31 0001622879 MDCL:LicensingAndConsultingMember 2021-01-01 2021-03-31 0001622879 MDCL:InfrastructureMember 2021-01-01 2021-03-31 0001622879 MDCL:ProductsMember 2020-01-01 2020-03-31 0001622879 MDCL:LicensingAndConsultingMember 2020-01-01 2020-03-31 0001622879 MDCL:InfrastructureMember 2020-01-01 2020-03-31 0001622879 MDCL:SeriesACumulativeConvertiblePreferredStockMember MDCL:DyeCannAndCrwCannMember 2020-12-01 2021-03-31 0001622879 MDCL:SeriesACumulativeConvertiblePreferredStockMember MDCL:DyeCannAndCrwCannMember 2021-03-31 0001622879 MDCL:ConvertiblePromissoryNoteMember MDCL:DyeCapitalMember 2021-01-01 2021-02-26 0001622879 MDCL:ConvertiblePromissoryNoteMember MDCL:DyeCapitalMember MDCL:SeriesACumulativeConvertiblePreferredStockMember 2021-01-01 2021-02-26 0001622879 MDCL:OfficerAndDirectorMember us-gaap:RestrictedStockMember MDCL:DirectorResignationMember 2020-01-01 2020-02-25 0001622879 MDCL:MedPharmHoldingsMember 2020-08-01 0001622879 MDCL:MedPharmHoldingsMember 2020-01-01 2020-07-31 0001622879 MDCL:MedPharmHoldingsMember MDCL:AndrewWilliamsMember 2020-01-01 2020-09-04 0001622879 MDCL:MedPharmHoldingsMember 2020-09-04 0001622879 MDCL:SecuritiesPurchaseAgreementMember MDCL:DyeCannIMember us-gaap:CommonStockMember 2019-01-01 2019-06-05 0001622879 MDCL:SecuritiesPurchaseAgreementMember MDCL:DyeCannIMember MDCL:WarrantsMember 2019-01-01 2019-06-05 0001622879 MDCL:SecuritiesPurchaseAgreementMember MDCL:DyeCannIMember 2019-01-01 2019-06-05 0001622879 MDCL:SecuritiesPurchaseAgreementMember MDCL:DyeCannIMember us-gaap:CommonStockMember 2019-06-06 2021-03-31 0001622879 MDCL:SecuritiesPurchaseAgreementMember MDCL:DyeCannIMember MDCL:WarrantsMember 2019-06-06 2021-03-31 0001622879 MDCL:SecuritiesPurchaseAgreementMember MDCL:DyeCannIMember 2019-06-06 2021-03-31 0001622879 MDCL:DyeCannIiSpaMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-16 0001622879 MDCL:DyeCannIiSpaMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-18 0001622879 MDCL:DyeCannIiSpaMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-22 0001622879 MDCL:DyeCannIiSpaMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-02-03 0001622879 MDCL:DyeCannIiSpaMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-02 0001622879 MDCL:DyeCannIiSpaMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-30 0001622879 MDCL:DyeCannIiSpaMember 2021-01-01 2021-03-30 0001622879 MDCL:DyeCapitalMember 2020-12-16 0001622879 MDCL:DyeCapitalMember 2021-01-01 2021-02-26 0001622879 MDCL:DyeCapitalMember MDCL:WarrantsMember 2021-01-01 2021-02-26 0001622879 MDCL:CrwSpaMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-02-26 0001622879 MDCL:StarBudsMember 2020-12-19 2021-03-02 0001622879 MDCL:StarBudsMember 2021-03-02 0001622879 MDCL:StarBudsMember us-gaap:SeriesAPreferredStockMember 2020-12-19 2021-03-02 0001622879 MDCL:StarBudsMember MDCL:WarrantsMember 2020-12-19 2021-03-02 0001622879 MDCL:StarBudsMember MDCL:SellerNotesMember 2021-03-31 0001622879 MDCL:StarBudsMember MDCL:SellerNotesMember 2021-01-01 2021-03-31 0001622879 MDCL:StarBudsMember MDCL:BrianRudenMember 2020-12-19 2021-03-02 0001622879 MDCL:StarBudsMember us-gaap:SeriesAPreferredStockMember MDCL:BrianRudenMember 2020-12-19 2021-03-02 0001622879 MDCL:StarBudsMember MDCL:WarrantsMember MDCL:BrianRudenMember 2020-12-19 2021-03-02 0001622879 MDCL:StarBudsMember MDCL:SellerNotesMember MDCL:BrianRudenMember 2021-01-01 2021-03-31 0001622879 MDCL:SuccessAndPonoMember 2017-01-01 2017-06-03 0001622879 MDCL:DenverConsultingMember 2017-01-01 2017-07-21 0001622879 MDCL:BigTomatoMember 2018-09-17 0001622879 MDCL:MesaOrganicsMember 2020-01-01 2020-04-20 0001622879 MDCL:PrivatePlacementsMember 2020-01-01 2020-12-31 0001622879 MDCL:SBUDLLCMember us-gaap:PreferredStockMember 2021-01-01 2021-03-03 0001622879 MDCL:SBUDLLCMember MDCL:WarrantsMember 2021-01-01 2021-03-31 0001622879 MDCL:SBUDLLCMember MDCL:WarrantsMember MDCL:AccreditedInvestorMember 2021-01-01 2021-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Medicine Man Technologies, Inc. 0001622879 2021-03-31 false --12-31 Yes Q1 2021

200456

1796386

250000000

0.001

Non-accelerated Filer true true true

2705445

8298446

24958

1402814

6870674

26826

1154887

1523732

42601773

42819815

42169041

42331595

Yes NV 000-55450

-3649507

-1379310

-3649507

1398651

2814014

-7862172

446499

-1825809

false

432732

488220

10-Q

7253004

1054599

4315443

2962571

-25010

633705

421894

19340115

3203134

11816200

7446265

2528931

77650

674203

11816200

7446265

77650

2528931

674203

12087111

2148535

7500757

4483694

102660

1896226

252309

42331595

20240

1933329

2554750

2862

6404

2319

29500

5531250

9152

1715936

7000000

2258065

2554750

17921

3793530

20240000

20239980

4167253

2861994

6403987

2318998

17920982

-1484906

-4111075

8737910

5165674

1869358

1997036

2195108

1248988

3189638

666919

12087111

2148535

42601773

42819815

432732

488220

19716

87266

39952628

257732

41774859

109304698

42602

42820

85357835

157530563

-42099098

-46823076

-1332500

-1445696

39953

50356469

51609200

-22816477

-24195787

-1000000

26579945

26453366

47310

57700

1500000

9287500

7700

1450

1300

3100

3800

4000

21350

25350

187500

50449207

50449160

218042

406895

444806

218

444588

497301

1039000

1252731

1039000

-113196

55488

-3649507

-1379310

42616309

39952628

-0.09

-0.03

-1707987

2731765

-1253814

1191963

-961282

48042

0 1462636 4462636

1483806

1252731

50282798

57700000

65109039

44250000

13727490

2609500

10000000

0.001

872579

1032211

70682601

181019152

1332500

1445696

-42293098

-46823076

85357835

157530563

42602

42820

28907742

71714454

16547356

58592018

2645597

4342018

13901759

54250000

12360386

13122436

5000000

50000

1047481

2301295

48982

41123

3508478

2481572

70682601

181019152

64685236

149432265

2579036

4242124

51879

423710

3063968

276782

491412

3082044

97589114

53046729

40532910

6301080

3003226

2147613

6301080

3003226

3000000

2147613

26080991

3000000

2584798

3089027

5997365

31586887

614200

627016

181911

40231

2619145

5588257

80494

1270380

2365063

1231235

22966320

9075427

214630

-129992

19716

87266

19716

87266

456614

-3192893

-1379310

292479

880471

897247

1237235

11853627

21729085

-2778200

85631039

-5000000

40348241

-65600473

-307178

633114

307178

1698519

-2471022

-50000

2224092

572827

371831

178290

12816

-225878

-42251

1483806

1252731

214630

29124

-1253814

1191963

1790568

6113

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">2.</td> <td style="text-align: justify">Critical Accounting Policies and Estimates</td></tr> </table>   Management’s Representation of Interim Financial Statements   The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of the Company’s financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of December 31, 2020 and 2019, as presented in the Company’s Annual Report on Form 10-K filed on March 31, 2021 with the SEC.   Basis of Presentation   These accompanying financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the SEC for interim financial statements. All intercompany accounts and transactions are eliminated in consolidation.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.   Reclassifications   During the quarter ended March 31, 2021, we changed our segments based on the way management discusses and reviews financial information. Certain prior year amounts have been reclassified to conform to the current year presentation. These reclassifications had no impact on the Company’s net (loss) earnings and financial position.   Fair Value Measurements   Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:   Level 1 – Quoted prices in active markets for identical assets or liabilities.   Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.   Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.   The Company’s financial instruments include cash, accounts receivable, notes receivable, accounts payables and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. The Company’s derivative liability was adjusted to fair market value at the end of the year, using Level 3 inputs.   The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2021 and December 31, 2020, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Level 1 – Marketable Securities Available-for-Sale – Recurring</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">491,412</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">276,782</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>   Marketable Securities at Fair Value on a Recurring Basis   Certain assets are measured at fair value on a recurring basis. The Level 1 position consists of an investment in equity securities held in Canada House Wellness Group, Inc., a publicly-traded company whose securities are actively quoted on the Toronto Stock Exchange.   Fair Value of Financial Instruments   The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available-for-sale securities are recorded at current market value as of the date of this report.   Accounts Receivable   The Company extends unsecured credit to its customers in the ordinary course of business. This accounts receivable relates to the Company’s wholesale and other revenue segments. Accounts receivable is recorded when a milestone is reached at point in time resulting in funds being due for delivered goods or services, and where payment is reasonably assured. Wholesale revenues are generally collected within 14 to 30 days after invoice is sent. Consulting revenues are generally collected from 30 to 60 days after the invoice is sent.   The following table depicts the composition of our accounts receivable as of March 31, 2021, and December 31, 2020:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: justify">Accounts receivable – trade</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,524,718</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,315,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts receivable – related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80,494</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Accounts receivable – litigation, non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,063,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,063,968</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(159,656</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(44,808</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total accounts receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,429,031</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,414,842</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The Company establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade receivables. A considerable amount of judgment is required in assessing the amount of the allowance. The Company makes judgments about the creditworthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the customers were to deteriorate, resulting in their inability to make payments, a specific allowance will be required. As of March 31, 2021 and December 31, 2020, the Company recorded an allowance for doubtful accounts of $159,656 and $44,808, respectively.   Notes Receivable   On July 17, 2018, the Company entered into an intellectual property license agreement with Abba Medix Corp. (“AMC”), a wholly owned subsidiary of publicly traded Canada House Wellness Group, Inc.. The Company agreed to provide a lending facility to AMC in CAD$125,000 increments of up to CAD$500,000. The lending facility is for a term of 36 months and bears interest at a rate of 2%. As of March 31, 2021 and December 31, 2020, the outstanding balance, including accrued interest, on the notes receivable with AMC totaled $248,025 and $246,765, respectively. As of March 31, 2021 and December 31, 2020, the Company has recorded a full allowance on the note receivable balance.   Other Assets (Current and Non-Current)   Other assets as of March 31, 2021 and December 31, 2020 were $1,050,726 and $666,079, respectively. As of March 31, 2021, this balance included $627,016 in prepaid expenses and $423,710 in security deposits. As of December 31, 2020, other assets included $345,777 in prepaid expenses, $268,423 in tax receivable, and $51,879 in security deposits. Prepaid expenses were primarily comprised of insurance premiums, membership dues, conferences and seminars, and other general and administrative costs.   Goodwill and Intangible Assets   Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from the Company’s acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. The Company’s amortizable intangible assets consist of licensing agreements, product licenses and registrations, and intellectual property or trade secrets. Their estimated useful lives range from 10 to 15 years.   Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. The Company performs an annual impairment assessment for goodwill during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, the Company determines fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, the Company relies on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, the Company’s risk relative to the overall market, the Company’s size and industry and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.   Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that the Company’s estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause the Company to perform an impairment test prior to scheduled annual impairment tests.   The Company performed its annual fair value assessment as of December 31, 2020, on its subsidiaries with material goodwill and intangible asset amounts on their respective balance sheets and determined that no impairment exists. No additional factors or circumstances existed as of March 31, 2021 that would indicate impairment.   Long-Lived Assets   The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances have indicated that an asset may not be recoverable. The long-lived asset is grouped with other assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows is less than the carrying value of the assets, the assets are written down to the estimated fair value.   The Company evaluated the recoverability of its long-lived assets on December 31, 2020 on its subsidiaries with material amounts on their respective balance sheets and determined that no impairment exists.   Accounts Payable   Accounts payable as of March 31, 2021 and December 31, 2020 were $2,522,695 and $3,557,460, respectively and were comprised of trade payables for various purchases and services rendered during the ordinary course of business.   Accrued Expenses and Other Liabilities   Accrued expenses and other liabilities as of March 31, 2021 and December 31, 2020 were $8,298,446 and $2,705,445, respectively. As of March 31, 2021, this was comprised of customer deposits of $24,958, accrued payroll of $1,402,814, and operating expenses of $6,870,674. As of December 31, 2020, accrued expenses and other liabilities was comprised of customer deposits of $26,826, accrued payroll of $1,154,887, and operating expenses of $1,523,732.   Revenue Recognition and Related Allowances   The Company’s revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until is the criteria are met. When consideration is received in advance of the delivery of goods or services, a contract liability is recorded. Revenue contracts are identified when accepted from customers and represent a single performance obligation to sell the Company’s products to a customer.   The Company has three main revenue streams: retail; wholesale; and other.   Retail and wholesale sales are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, the Company considers several indicators, including significant risks and rewards of products, its right to payment, and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to customers.   Other revenue consists of other income and expenses, including related to, licensing and consulting services, facility design services, facility management services, the Company’s Three A Light™ publication, and corporate operations. Revenue is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved and target harvest yields are exceeded or earned upon the completion of the seminar. The Company also recognizes expense reimbursement from clients as revenue for expenses incurred during certain jobs.   Costs of Goods and Services Sold   Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of the Company’s products and services.   General and Administrative Expenses   General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.   Advertising and Marketing Costs   Advertising and marketing costs are expensed as incurred and were $111,685 and $129,267 during the quarter ended March 31, 2021 and 2020, respectively.   Stock Based Compensation   The Company accounts for share-based payments pursuant to ASC 718, Stock Compensation and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model.    Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and Emerging Issues Task Force (“EITF”) 96-18 when stock or options are awarded for previous or current service without further recourse.    Share-based expense paid to through direct stock grants is expensed as occurred. Since the Company’s common stock is publicly traded, the value is determined based on the number of shares of common stock issued and the trading value of the common stock on the date of the transaction.   On June 20, 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-07 which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. Previously, share-based payment arrangements to nonemployees were accounted for under ASC 718, while nonemployee share-based payments issued for goods and services were accounted for under ASC 505-50. Before the amendment, the major difference for the Company (but not limited to) was the determination of measurement date, which generally is the date on which the measurement of equity classified share-based payments becomes fixed. Equity classified share-based payments for employees was fixed at the time of grant. Equity-classified nonemployee share-based payment awards are no longer measured at the earlier of the date which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. They are now measured at the grant date of the award, which is the same as share-based payments for employees. The Company adopted the requirements of the new rule as of January 1, 2019, the effective date of the new guidance.   The Company recognized $1,483,806 in expense for stock-based compensation from common stock options and common stock issued to employee, officers, and directors during the three months ended March 31, 2021, and $1,252,731 in expense for stock-based compensation from common stock options issued to employees during the three months ended March 31, 2020.   Income Taxes   ASC 740, Income Taxes requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.   Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.   The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability, and the tax benefit to be recognized is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.   As the Company operates in the cannabis industry, it is subject to the limits of the Internal Revenue Code (IRC) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.   Right of Use Assets and Lease Liabilities   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard requires lessees to recognize almost all leases on the balance sheet as a Right-of-Use (“ROU”) asset and a lease liability and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840. The Company elected the package of practical expedients permitted under the standard, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.   Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in determining the present value of lease payments. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.   Operating leases are included in operating lease ROU assets and operating lease liabilities, current and non-current, on the Company's consolidated balance sheets.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 42px">10.</td> <td style="text-align: justify">Leases</td></tr> </table>   Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Leases with a term greater than one year are recognized on the balance sheet at the time of lease commencement or modification of an ROU operating lease asset and a lease liability, initially measured at the present value of the lease payments. Lease costs are recognized in the income statement over the lease term on a straight-line basis. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.   The Company's leases consist of real estate leases for office spaces. The Company elected to combine the lease and related non-lease components for its operating leases.   The Company’s operating leases include options to extend or terminate the lease, which are not included in the determination of the ROU asset or lease liability unless reasonably certain to be exercised. The Company's operating leases have remaining lease terms of less than two years. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.   As the Company's leases do not provide an implicit rate, we used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The discount rate used in the computations ranged between 6% and 12%.   Balance Sheet Classification of Operating Lease Assets and Liabilities   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Balance Sheet Line</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Asset</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 61%; text-align: left; padding-left: 10pt">Operating lease right of use assets</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: left">Noncurrent assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,242,124</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Liabilities</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Lease liabilities</td><td> </td> <td style="text-align: left">Noncurrent liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,342,018</td><td style="text-align: left"> </td></tr> </table>   Lease Costs   The table below summarizes the components of lease costs for the three months ended March 31, 2021.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended March 31, 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; width: 83%">Operating lease costs</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 13%">278,117</td><td style="text-align: left; width: 1%"> </td></tr> </table>   Maturities of Lease Liabilities   Maturities of lease liabilities as of March 31, 2021 are as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">2021 fiscal year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,418,867</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(76,848</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,342,018</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The following table presents the Company’s future minimum lease obligation under ASC 840 as of March 31, 2021:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">2021 fiscal year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">1,109,215</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,479,393</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">2023 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,354,595</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">723,590</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">2025 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333,356</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178,648</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,178,796</td><td style="text-align: left"> </td></tr></table>

The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2021 and December 31, 2020, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Level 1 – Marketable Securities Available-for-Sale – Recurring</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">491,412</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">276,782</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr></table>

The following table depicts the composition of our accounts receivable as of March 31, 2021, and December 31, 2020:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: justify">Accounts receivable – trade</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,524,718</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,315,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts receivable – related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80,494</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Accounts receivable – litigation, non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,063,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,063,968</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(159,656</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(44,808</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total accounts receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,429,031</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,414,842</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">294,204</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">228,451</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">656,314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,314</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Machinery and Tools</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,401,752</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,456,752</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69,983</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104,059</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,308,387</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,308,387</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Work in process</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">390,598</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">269,414</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,121,239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,457,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less:  Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,032,211</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(872,579</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total property and equipment, net of depreciation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,089,027</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,584,798</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.    <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 67%">Furniture and fixtures</td> <td style="width: 33%">3 years</td></tr> <tr style="vertical-align: bottom"> <td>Leasehold improvements</td> <td>Lesser of the lease term or estimated useful life</td></tr> <tr style="vertical-align: bottom"> <td>Vehicles</td> <td>3 years</td></tr> <tr style="vertical-align: bottom"> <td>Office equipment</td> <td>3 years</td></tr></table>

Intangible assets as of March 31, 2021 and December 31, 2020 were comprised of the following:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Licenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">88,745,700</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,667,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Tradename</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,270,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">350,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,055,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Non-compete</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,130,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Product license and registration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Trade secret – intellectual property</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">99,385,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,282,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,796,386</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(200,456</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net of amortization</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97,589,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,082,044</td></tr></table>

Balance Sheet Classification of Operating Lease Assets and Liabilities   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Balance Sheet Line</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Asset</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 61%; text-align: left; padding-left: 10pt">Operating lease right of use assets</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: left">Noncurrent assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,242,124</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Liabilities</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Lease liabilities</td><td> </td> <td style="text-align: left">Noncurrent liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,342,018</td><td style="text-align: left"> </td></tr></table>

The table below summarizes the components of lease costs for the three months ended March 31, 2021.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended March 31, 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; width: 83%">Operating lease costs</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 13%">278,117</td><td style="text-align: left; width: 1%"> </td></tr></table>

Maturities of lease liabilities as of March 31, 2021 are as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">2021 fiscal year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,418,867</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(76,848</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,342,018</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The following table presents the Company’s future minimum lease obligation under ASC 840 as of March 31, 2021:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">2021 fiscal year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">1,109,215</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,479,393</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">2023 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,354,595</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">723,590</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">2025 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333,356</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026 fiscal year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178,648</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,178,796</td><td style="text-align: left"> </td></tr></table>

The following table reflects the change in common stock purchase warrants for the three months ended March 31, 2021.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%">Balance as of January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">11,725,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Warrants forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,293,530</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">17,018,750</td></tr></table>

1014189

107426

-141680 0

1248

The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended March 31, 2021 and March 31, 2020:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Income (Loss) before Income Taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(3,192,891</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(1,379,310</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income Tax Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">456,614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Effective Tax Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-14.30%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0%</td><td style="text-align: left"> </td></tr></table>

5000000

491412

276782

4414842

5429031

2524718

3063968

1315188

80494

3063968

44808

159656

28074

810887

111824

241711

247272

248025

246765

666079

1050726

627016

423710

345777

268423

51879

P10Y

P15Y

111685

129267

3457377

4121239

294204

656314

1401752

69983

1308387

390598

228451

90314

1456752

104059

1308387

269414

P3Y

Lesser of the lease term or estimated useful life

194637

4465

84298

3641

106699

1233

3232

3282500

99385500

88745700

4270000

5150000

57300

32500

1130000

1667000

350000

1055000

120000

57300

32500

1595931

1648

500000

1000000

997262

73557

14605

16125

16605

52244

72109

5885

31250 93944

767695

2090887

3345353

27342

1331658

500917

911246

4418867

76848

4342018

278117

1109215

1479393

1354595

723590

333356

178648

5178796

0.06

0.12

11725220

17018750

5293530

P5Y

0.0046

0.0075

1.9271

1.9500

1595931

1648

1594302

1497

133

1513

135

181019151 30029291 132931035 21326258 26761858 0 12935074 17094217

-3192891

-1379310

-0.1430

0.00

The following information represents segment activity for the three-month periods ended March 31, 2021 and March 31, 2020:    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="30" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Retail</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Wholesale</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Retail</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Wholesale</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 20%">Revenues</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,816,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">7,446,265</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">77,650</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 7%; text-align: right">19,340,115</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">2,528,931</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">674,203</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">3,203,134</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of goods and services</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(7,500,757</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,483,694</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(102,660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12,087,111</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,896,226</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(252,309</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,148,535</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,315,443</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,962,571</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,010</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,253,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">633,705</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">421,894</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,054,599</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,594,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,497</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,595,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,513</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">135</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,648</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Depreciation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">84,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,641</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,699</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">194,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,233</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,465</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,398,651</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,814,014</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,862,172</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,649,507</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">446,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,825,809</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,379,310</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Segment assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">132,931,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,326,258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,761,858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,019,151</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,935,074</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">17,094,217</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">30,029,291</td><td style="text-align: left"> </td></tr></table>

1500000 9287500 187500 1500000

2.50

1.20

Management’s Representation of Interim Financial Statements   The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of the Company’s financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of December 31, 2020 and 2019, as presented in the Company’s Annual Report on Form 10-K filed on March 31, 2021 with the SEC.

Basis of Presentation   These accompanying financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the SEC for interim financial statements. All intercompany accounts and transactions are eliminated in consolidation.

Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Reclassifications   During the quarter ended March 31, 2021, we changed our segments based on the way management discusses and reviews financial information. Certain prior year amounts have been reclassified to conform to the current year presentation. These reclassifications had no impact on the Company’s net (loss) earnings and financial position.

Fair Value Measurements   Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:   Level 1 – Quoted prices in active markets for identical assets or liabilities.   Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.   Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.   The Company’s financial instruments include cash, accounts receivable, notes receivable, accounts payables and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. The Company’s derivative liability was adjusted to fair market value at the end of the year, using Level 3 inputs.   The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2021 and December 31, 2020, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Level 1 – Marketable Securities Available-for-Sale – Recurring</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">491,412</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">276,782</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr></table>

Marketable Securities at Fair Value on a Recurring Basis   Certain assets are measured at fair value on a recurring basis. The Level 1 position consists of an investment in equity securities held in Canada House Wellness Group, Inc., a publicly-traded company whose securities are actively quoted on the Toronto Stock Exchange.

Fair Value of Financial Instruments   The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available-for-sale securities are recorded at current market value as of the date of this report.

Notes Receivable   On July 17, 2018, the Company entered into an intellectual property license agreement with Abba Medix Corp. (“AMC”), a wholly owned subsidiary of publicly traded Canada House Wellness Group, Inc.. The Company agreed to provide a lending facility to AMC in CAD$125,000 increments of up to CAD$500,000. The lending facility is for a term of 36 months and bears interest at a rate of 2%. As of March 31, 2021 and December 31, 2020, the outstanding balance, including accrued interest, on the notes receivable with AMC totaled $248,025 and $246,765, respectively. As of March 31, 2021 and December 31, 2020, the Company has recorded a full allowance on the note receivable balance.

Goodwill and Intangible Assets   Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from the Company’s acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. The Company’s amortizable intangible assets consist of licensing agreements, product licenses and registrations, and intellectual property or trade secrets. Their estimated useful lives range from 10 to 15 years.   Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. The Company performs an annual impairment assessment for goodwill during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, the Company determines fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, the Company relies on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, the Company’s risk relative to the overall market, the Company’s size and industry and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.   Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that the Company’s estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause the Company to perform an impairment test prior to scheduled annual impairment tests.   The Company performed its annual fair value assessment as of December 31, 2020, on its subsidiaries with material goodwill and intangible asset amounts on their respective balance sheets and determined that no impairment exists. No additional factors or circumstances existed as of March 31, 2021 that would indicate impairment.

Long-Lived Assets   The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances have indicated that an asset may not be recoverable. The long-lived asset is grouped with other assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows is less than the carrying value of the assets, the assets are written down to the estimated fair value.   The Company evaluated the recoverability of its long-lived assets on December 31, 2020 on its subsidiaries with material amounts on their respective balance sheets and determined that no impairment exists.

Revenue Recognition and Related Allowances   The Company’s revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until is the criteria are met. When consideration is received in advance of the delivery of goods or services, a contract liability is recorded. Revenue contracts are identified when accepted from customers and represent a single performance obligation to sell the Company’s products to a customer.   The Company has three main revenue streams: retail; wholesale; and other.   Retail and wholesale sales are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, the Company considers several indicators, including significant risks and rewards of products, its right to payment, and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to customers.   Other revenue consists of other income and expenses, including related to, licensing and consulting services, facility design services, facility management services, the Company’s Three A Light™ publication, and corporate operations. Revenue is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved and target harvest yields are exceeded or earned upon the completion of the seminar. The Company also recognizes expense reimbursement from clients as revenue for expenses incurred during certain jobs.

Costs of Goods and Services Sold   Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of the Company’s products and services.

General and Administrative Expenses   General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.

Advertising and Marketing Costs   Advertising and marketing costs are expensed as incurred and were $111,685 and $129,267 during the quarter ended March 31, 2021 and 2020, respectively.

Stock Based Compensation   The Company accounts for share-based payments pursuant to ASC 718, Stock Compensation and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model.    Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and Emerging Issues Task Force (“EITF”) 96-18 when stock or options are awarded for previous or current service without further recourse.    Share-based expense paid to through direct stock grants is expensed as occurred. Since the Company’s common stock is publicly traded, the value is determined based on the number of shares of common stock issued and the trading value of the common stock on the date of the transaction.   On June 20, 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-07 which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. Previously, share-based payment arrangements to nonemployees were accounted for under ASC 718, while nonemployee share-based payments issued for goods and services were accounted for under ASC 505-50. Before the amendment, the major difference for the Company (but not limited to) was the determination of measurement date, which generally is the date on which the measurement of equity classified share-based payments becomes fixed. Equity classified share-based payments for employees was fixed at the time of grant. Equity-classified nonemployee share-based payment awards are no longer measured at the earlier of the date which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. They are now measured at the grant date of the award, which is the same as share-based payments for employees. The Company adopted the requirements of the new rule as of January 1, 2019, the effective date of the new guidance.   The Company recognized $1,483,806 in expense for stock-based compensation from common stock options and common stock issued to employee, officers, and directors during the three months ended March 31, 2021, and $1,252,731 in expense for stock-based compensation from common stock options issued to employees during the three months ended March 31, 2020.

Income Taxes   ASC 740, Income Taxes requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.   Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.   The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability, and the tax benefit to be recognized is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.   As the Company operates in the cannabis industry, it is subject to the limits of the Internal Revenue Code (IRC) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.

Right of Use Assets and Lease Liabilities   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard requires lessees to recognize almost all leases on the balance sheet as a Right-of-Use (“ROU”) asset and a lease liability and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840. The Company elected the package of practical expedients permitted under the standard, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.   Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in determining the present value of lease payments. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.   Operating leases are included in operating lease ROU assets and operating lease liabilities, current and non-current, on the Company's consolidated balance sheets.

Other Assets (Current and Non-Current)   Other assets as of March 31, 2021 and December 31, 2020 were $1,050,726 and $666,079, respectively. As of March 31, 2021, this balance included $627,016 in prepaid expenses and $423,710 in security deposits. As of December 31, 2020, other assets included $345,777 in prepaid expenses, $268,423 in tax receivable, and $51,879 in security deposits. Prepaid expenses were primarily comprised of insurance premiums, membership dues, conferences and seminars, and other general and administrative costs. Accounts Payable   Accounts payable as of March 31, 2021 and December 31, 2020 were $2,522,695 and $3,557,460, respectively and were comprised of trade payables for various purchases and services rendered during the ordinary course of business. Accrued Expenses and Other Liabilities   Accrued expenses and other liabilities as of March 31, 2021 and December 31, 2020 were $8,298,446 and $2,705,445, respectively. As of March 31, 2021, this was comprised of customer deposits of $24,958, accrued payroll of $1,402,814, and operating expenses of $6,870,674. As of December 31, 2020, accrued expenses and other liabilities was comprised of customer deposits of $26,826, accrued payroll of $1,154,887, and operating expenses of $1,523,732.

33334

5053

Organization and Nature of Operations   Medicine Man Technologies, Inc. (“we,” “us,” “our” or the “Company”) was incorporated in Nevada on March 20, 2014. On May 1, 2014, we entered into a non-exclusive Technology License Agreement with Futurevision, Inc., f/k/a Medicine Man Production Corp., dba Medicine Man Denver (“Medicine Man Denver”) pursuant to which Medicine Man Denver granted us a license to use all of the proprietary processes that they had developed, implemented and practiced at their cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future) (the “License Agreement”) for 10 years.   In 2017, the Company acquired additional cultivation intellectual property through the acquisition of Success Nutrients™ and Pono Publications, including the rights to the book titled “Three A Light” and its associated cultivation techniques, which have been part of the Company’s products and services offerings since the acquisition. The Company acquired Two J’s LLC d/b/a The Big Tomato (“The Big Tomato”) in 2018, which operates a retail location in Aurora, Colorado. It has been a leading supplier of hydroponics and indoor gardening supplies in the metro Denver area since May 2001. The Company was focused on cannabis dispensary and cultivation consulting and providing equipment and nutrients to cannabis cultivators until its first plant touching acquisition in April of 2020. In 2019, due to the changes in Colorado law permitting non-Colorado resident and publicly traded investment into “plant-touching” cannabis companies, the Company made a strategic decision to move toward direct plant-touching operations. The Company developed a plan to roll up a number of direct plant-touching dispensaries, manufacturing facilities, and cannabis cultivations with a target to be one of the largest seed to sale cannabis businesses in Colorado. In April 2020, the Company acquired its first plant-touching business, Mesa Organics Ltd. (“Mesa Organics”), which consists of four dispensaries and one manufacturing infused products facility (“MIP”), d/b/a Purplebee’s.   On April 20, 2020, the Company rebranded and conducts its business under the trade name, Schwazze. The corporate name of the Company continues to be Medicine Man Technologies, Inc. Effective April 21, 2020, the Company commenced trading under the OTC ticker symbol SHWZ.   On December 17, 2020, the Company closed on the acquisition of (i) Starbuds Pueblo LLC; and (ii) Starbuds Alameda LLC. On December 18, 2020, the Company closed on the acquisition of (i) Starbuds Commerce City LLC; (ii) Lucky Ticket LLC; (iii) Starbuds Niwot LLC; and (iv) LM MJC LLC under the applicable Asset Purchase Agreements (“APAs”).   On February 4, 2021, the Company acquired the assets of Colorado Health Consultants LLC and Mountain View 44th LLC under the applicable APAs.   On March 2, 2021, the Company acquired the assets of (i) Starbuds Aurora LLC, (ii) SB Arapahoe LLC; (iii) Citi-Med LLC; (iv) Starbuds Louisville LLC; and (v) KEW LLC under the applicable APAs.   From December 2020 through March 2021 the Company completed a private placement of Series A Cumulative Convertible Preferred Stock (“Series A Preferred Stock”) for aggregate gross proceeds of $57.7 million dollars. In the private placement, the Company issued and sold an aggregate of 57,700 shares of Series A Preferred Stock at a price of $1,000 per share under securities purchase agreement with Dye Capital Cann Holdings II, LLC (“Dye Cann II”) and CRW Cann Holdings, LLC (“CRW”) as well as subscription agreements with unaffiliated investors. Among other terms, each share of Series A Preferred Stock (i) earns an annual dividend of 8% on the “preference amount,” which initially is equal to the $1,000 per-share purchase price and subject to increase, by having such dividends automatically accrete to, and increase, the outstanding preference amount; (ii) is entitled to a liquidation preference under certain circumstances, (iii) is convertible into shares of the Company’s common stock by dividing the preference amount by $1.20 per share under certain circumstances, and (iv) is subject to a redemption right or obligation under certain circumstances.   In addition, on December 16, 2020, the Company issued and sold a Convertible Promissory Note and Security Agreement in the original principal amount of $5,000,000 to Dye Capital & Company, LLC (“Dye Capital”). On February 26, 2021, Dye Capital converted all outstanding amounts under the note into 5,060 shares of Preferred Stock.   The Company is focused on growing through internal growth, acquisition, and new licenses in the Colorado cannabis market. The Company is focused on building the premier vertically integrated cannabis company in Colorado. The company's leadership team has deep expertise in mainstream consumer packaged goods, retail, and product development at Fortune 500 companies as well as in the cannabis sector. The Company has a high-performance culture and a focus on analytical decision making, supported by data. Customer-centric thinking inspires the Company’s strategy and provides the foundation for the Company’s operational playbooks.   The Company’s operations are organized into three different segments as follows: (i) retail, consisting of retail locations for sale of cannabis products, (ii) wholesale, consisting of manufacturing and sale of wholesale cannabis products, nutrients for cannabis, and hydroponics and indoor gardening supplies, and (iii) other, consisting of all other income and expenses, including those related to licensing and consulting services, facility design services, facility management services, and corporate operations.

Accounts Receivable   The Company extends unsecured credit to its customers in the ordinary course of business. This accounts receivable relates to the Company’s wholesale and other revenue segments. Accounts receivable is recorded when a milestone is reached at point in time resulting in funds being due for delivered goods or services, and where payment is reasonably assured. Wholesale revenues are generally collected within 14 to 30 days after invoice is sent. Consulting revenues are generally collected from 30 to 60 days after the invoice is sent.   The following table depicts the composition of our accounts receivable as of March 31, 2021, and December 31, 2020:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: justify">Accounts receivable – trade</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,524,718</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,315,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts receivable – related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80,494</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Accounts receivable – litigation, non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,063,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,063,968</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(159,656</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(44,808</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total accounts receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,429,031</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,414,842</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The Company establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade receivables. A considerable amount of judgment is required in assessing the amount of the allowance. The Company makes judgments about the creditworthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the customers were to deteriorate, resulting in their inability to make payments, a specific allowance will be required. As of March 31, 2021 and December 31, 2020, the Company recorded an allowance for doubtful accounts of $159,656 and $44,808, respectively.

1000

5000000

5060

3557460

2522695

40231

767695

181911

47161

100000

175000

3000000

18575000

21350000

25350000

375000

5000000

60250 231

170119

66264

118000000

44250000

13727490

44250000

425162

EX-101.SCH 8 mdcl-20210331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statement of Comprehensive (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement Of Changes in Stockholders Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 1. Liquidity and Capital Resources link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 2. Critical Accounting Policies and Estimates link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 3. Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 4. Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 5. Intangible Asset link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 6. Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 7. Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 8. Inventory link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 9. Goodwill link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 10. Leases link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 11. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 12. Segment Information link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 13. Tax Provision link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 14. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 2. Critical Accounting Policies and Estimates (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 2. Critical Accounting Policies and Estimates (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 4. Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 5. Intangible Asset (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 10. Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 11. Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 12. Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 13. Tax Provision (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Organization and Nature of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 1. Liquidity and Capital Resources (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 2. Critical Accounting Policies and Estimates (Details - Level 3) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 2. Critical Accounting Policies and Estimates (Details Receivables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 2. Critical Accounting Policies and Estimates (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 4. Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 4. Property and Equipment (Details - Expected life) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 4. Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 5. Intangible Asset (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - 5. Intangible Asset (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - 6. Derivative Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - 7. Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - 8. Inventory (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - 9. Goodwill (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - 10. Leases (Details - Balance Sheet Classification) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - 10. Leases (Details - Operating lease cost) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - 10. Leases (Details - Lease maturities) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - 10. Leases (Details - Minimum lease obligation) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - 10. Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - 11. Stockholders' Equity (Details Warrant Activity) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - 11. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - 13. Segment Information (Details- Segment Information) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - 14. Tax Provision (Details - Components of Income Tax) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 mdcl-20210331_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 mdcl-20210331_def.xml XBRL DEFINITION FILE EX-101.LAB 11 mdcl-20210331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital Accumulated Deficit Treasury Stock Product and Service [Axis] Retail [Member] Wholesale [Member] Other [Member] Preferred Stock Long-term Debt, Type [Axis] Convertible Promissory Note [Member] Counterparty Name [Axis] Dye Capital [Member] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Inputs Level 1 [Member] Measurement Frequency [Axis] Fair Value Measurements Recurring [Member] Financial Instrument [Axis] Marketable Securities [Member] Accounts Notes Loans And Financing Receivable By Receivable Type [Axis] Trade Accounts Receivable [Member] Accounts receivable - related party [Member] Accounts receivable - litigation [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Abba Medix [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Balance Sheet Location [Axis] Customer Deposits [Member] Accrued Payroll [Member] Operating Expenses [Member] Prepaid Expenses [Member] Security Deposits [Member] Tax Receivable [Member] Property, Plant and Equipment, Type [Axis] Furniture and Fixtures [Member] Leasehold Improvements [Member] Machinery and Tools [Member] Office Equipment [Member] Software [Member] Work In Progress [Member] Vehicles [Member] Finite-Lived Intangible Assets by Major Class [Axis] License [Member] Trade Names [Member] Customer Relationships [Member] Product License and Registration [Member] Trade Secret [Member] Noncompete [Member] Officer And Director [Member] Class of Stock [Axis] Restricted Stock [Member] An Officer [Member] Related Party [Axis] Med Man Denver [Member] Med Pharm Holdings [Member] Baseball 18 LLC [Member] Farm Boy [Member] Emerald Fields [Member] Los Suenos [Member] Tella Digital [Member] Business Acquisition [Axis] Success Nutrients and Pono Publications [Member] Denver Consulting Group [Member] Big Tomato [Member] Mesa Organics [Member] Derivative Instrument [Axis] Warrants [Member] Employees, Officers and Directors [Member] Mesa Organics, Ltd [Member] SBUD LLC [Member] Preferred Stock [Member] Award Type [Axis] Accredited Investors [Member] Segments [Axis] Products [Member] Licensing and Consulting [Member] Corporate, Infrastructure and Other [Member] of Series A Cumulative Convertible Preferred Stock [Member] Dye Cann II and CRW [Member] Nonmonetary Transaction Type [Axis] Director Resignation [Member] Andrew Williams [Member] Transaction Type [Axis] Securities Purchase Agreement [Member] Dye Cann I SPA [Member] Warrants [Member] Dye Cann II SPA [Member] Series A Preferred Stock [Member] CRW SPA [Member] Star Buds [Member] Seller Notes [Member] Brian Ruden [Member] Private Placements [Member] Accredited Investor [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Shell Company Entity Ex Transition Period Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Interactive Data Current Entity Incorporation State Country Code Entity File Number Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts Accounts receivable - related party Inventory Notes receivable - related party Prepaid expenses Total current assets Non-current assets Fixed assets, net accumulated depreciation of $1,032,211 and $872,579, respectively Goodwill Intangible assets, net accumulated amortization of $1,796,386 and $200,456, respectively Marketable securities, net of unrealized gain (loss) of $214,630 and ($129,992), respectively Accounts receivable - litigation Other noncurrent assets Operating lease right of use assets Total non-current assets Total assets Liabilities and Stockholders' Equity Current liabilities Accounts payable Accounts payable - related party Accrued expenses Derivative liabilities Deferred revenue Notes payable - related party Total current liabilities Long-term liabilities Long term debt Lease liabilities Total long-term liabilities Total liabilities Shareholders' equity Common stock $0.001 par value. 250,000,000 authorized, 42,819,815 shares issued and 42,331,595 outstanding as of March 31, 2021 and 42,601,773 shares issued and 42,169,041 outstanding as of December 31, 2020, respectively. Preferred stock $0.001 par value. 10,000,000 authorized. 87,266 shares issued and outstanding as of March 31, 2021 and 19,716 shares issued and outstanding as of December 31, 2020, respectively. Additional paid-in capital Accumulated deficit Common stock held in treasury, at cost, 488,220 shares held as of March 31, 2021 and 432,732 shares held as of December 31, 2020. Total shareholders' equity Total liabilities and stockholders' equity Accumulated depreciation Accumulated amortization Marketable securities, unrealized gain (loss) Common stock authorized Common stock par value Common stock issued Common stock outstanding Preferred stock authorized Preferred stock par value Preferred stock issued Preferred stock outstanding Treasury Stock, Common, Shares Statement [Table] Statement [Line Items] Operating revenues Total revenue Cost of goods and services Cost of goods and services Total cost of goods and services Gross profit Operating expenses Selling, general and administrative Professional services Salaries Stock-based compensation Total operating expenses Loss from operations Other income (expense) Interest income (expense), net Gain on forfeiture of contingent consideration EX-101.PRE 12 mdcl-20210331_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 10, 2021
Cover [Abstract]
Entity Registrant Name	Medicine Man Technologies, Inc.
Entity Central Index Key	0001622879
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Shell Company	false
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		42,331,595
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NV
Entity File Number	000-55450

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 22,966,320	$ 1,231,235
Accounts receivable, net of allowance for doubtful accounts	2,365,063	1,270,380
Accounts receivable - related party	0	80,494
Inventory	5,588,257	2,619,145
Notes receivable - related party	40,231	181,911
Prepaid expenses	627,016	614,200
Total current assets	31,586,887	5,997,365
Non-current assets
Fixed assets, net accumulated depreciation of $1,032,211 and $872,579, respectively	3,089,027	2,584,798
Goodwill	40,532,910	53,046,729
Intangible assets, net accumulated amortization of $1,796,386 and $200,456, respectively	97,589,114	3,082,044
Marketable securities, net of unrealized gain (loss) of $214,630 and ($129,992), respectively	491,412	276,782
Accounts receivable - litigation	3,063,968	3,063,968
Other noncurrent assets	423,710	51,879
Operating lease right of use assets	4,242,124	2,579,036
Total non-current assets	149,432,265	64,685,236
Total assets	181,019,152	70,682,601
Current liabilities
Accounts payable	2,481,572	3,508,478
Accounts payable - related party	41,123	48,982
Accrued expenses	8,298,446	2,705,445
Derivative liabilities	2,301,295	1,047,481
Deferred revenue	0	50,000
Notes payable - related party	0	5,000,000
Total current liabilities	13,122,436	12,360,386
Long-term liabilities
Long term debt	54,250,000	13,901,759
Lease liabilities	4,342,018	2,645,597
Total long-term liabilities	58,592,018	16,547,356
Total liabilities	71,714,454	28,907,742
Shareholders' equity
Common stock $0.001 par value. 250,000,000 authorized, 42,819,815 shares issued and 42,331,595 outstanding as of March 31, 2021 and 42,601,773 shares issued and 42,169,041 outstanding as of December 31, 2020, respectively.	42,820	42,602
Preferred stock $0.001 par value. 10,000,000 authorized. 87,266 shares issued and outstanding as of March 31, 2021 and 19,716 shares issued and outstanding as of December 31, 2020, respectively.	87	20
Additional paid-in capital	157,530,563	85,357,835
Accumulated deficit	(46,823,076)	(42,293,098)
Common stock held in treasury, at cost, 488,220 shares held as of March 31, 2021 and 432,732 shares held as of December 31, 2020.	(1,445,696)	(1,332,500)
Total shareholders' equity	109,304,698	41,774,859
Total liabilities and stockholders' equity	$ 181,019,152	$ 70,682,601

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 1,032,211		$ 872,579
Accumulated amortization	1,796,386		$ 200,456
Marketable securities, unrealized gain (loss)	$ 214,630	$ (129,992)
Common stock authorized	250,000,000		250,000,000
Common stock par value	$ 0.001		$ 0.001
Common stock issued	42,819,815		42,601,773
Common stock outstanding	42,331,595		42,169,041
Preferred stock authorized	10,000,000		10,000,000
Preferred stock par value	$ 0.001		$ 0.001
Preferred stock issued	87,266		19,716
Preferred stock outstanding	87,266		19,716
Treasury Stock, Common, Shares	488,220		432,732

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Statement of Comprehensive (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating revenues
Total revenue	$ 19,340,115	$ 3,203,134
Cost of goods and services
Cost of goods and services	12,087,111	2,148,535
Total cost of goods and services	12,087,111	2,148,535
Gross profit	7,253,004	1,054,599
Operating expenses
Selling, general and administrative	3,189,638	666,919
Professional services	2,195,108	1,248,988
Salaries	1,869,358	1,997,036
Stock-based compensation	1,483,806	1,252,731
Total operating expenses	8,737,910	5,165,674
Loss from operations	(1,484,906)	(4,111,075)
Other income (expense)
Interest income (expense), net	(961,282)	48,042
Gain on forfeiture of contingent consideration	0	1,462,636
Unrealized gain (loss) on derivative liabilities	(1,253,814)	1,191,963
Gain (loss) on sale of assets	292,479	0
Unrealized gain (loss) on investment	214,630	29,124
Total other income (expense)	(1,707,987)	2,731,765
Loss before income taxes	(3,192,893)	(1,379,310)
Provision for income tax (benefit) expense	456,614	0
Net loss	$ (3,649,507)	$ (1,379,310)
Loss per share attributable to common shareholders
Basic and diluted loss per share	$ (0.09)	$ (0.03)
Weighted average number of shares outstanding, basic and diluted	42,616,309	39,952,628
Comprehensive loss	$ (3,649,507)	$ (1,379,310)
Retail [Member]
Operating revenues
Total revenue	11,816,200	0
Wholesale [Member]
Operating revenues
Total revenue	7,446,265	2,528,931
Other [Member]
Operating revenues
Total revenue	$ 77,650	$ 674,203

XML 17 R5.htm IDEA: XBRL DOCUMENT

Statement Of Changes in Stockholders Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock [Member]	Treasury Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Dec. 31, 2019		39,952,628	257,732
Beginning balance, value at Dec. 31, 2019		$ 39,953	$ (1,000,000)	$ 50,356,469	$ (22,816,477)	$ 26,579,945
Net income (loss)					(1,379,310)	(1,379,310)
Stock based compensation expense related to stock options				1,252,731		1,252,731
Ending balance, shares at Mar. 31, 2020		39,952,628	257,732
Ending balance, value at Mar. 31, 2020		$ 39,953	$ (1,000,000)	51,609,200	(24,195,787)	26,453,366
Beginning balance, shares at Dec. 31, 2019		39,952,628	257,732
Beginning balance, value at Dec. 31, 2019		$ 39,953	$ (1,000,000)	50,356,469	(22,816,477)	26,579,945
Ending balance, shares at Dec. 31, 2020	19,716	42,601,773	432,732
Ending balance, value at Dec. 31, 2020	$ 20	$ 42,602	$ (1,332,500)	85,357,835	(42,099,098)	41,774,859
Net income (loss)					(3,649,507)	(3,649,507)
Issuance of stock as payment for acquisitions, shares	20,240
Issuance of stock as payment for acquisitions, value	$ 20			20,239,980		20,240,000
Return of common stock as compensation to employees, officers and/or directors
Issuance of common stock as compensation to employees, officers, and/or directors , shares		218,042
Issuance of common stock as compensation to employees, officers, and/or directors , value		$ 218		444,588		444,806
Issuance of common stock in connection with sales made under private of public offerings, shares	47,310
Issuance of common stock in connection with sales made under private of public offerings, value	$ 47			50,449,160		50,449,207
Dividends declared					(880,471)	(880,471)
Return of common stock, shares			55,488
Return of common stock, value			$ (113,196)			(113,196)
Stock based compensation expense related to stock options				1,039,000		1,039,000
Ending balance, shares at Mar. 31, 2021	87,266	42,819,815	488,220
Ending balance, value at Mar. 31, 2021	$ 87	$ 42,820	$ (1,445,696)	$ 157,530,563	$ (46,823,076)	$ 109,304,698

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss for the period	$ (3,649,507)	$ (1,379,310)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,790,568	6,113
Gain on forfeiture of contingent consideration	0	(1,462,636)
(Gain) loss on change in derivative liabilities	1,253,814	(1,191,963)
(Gain) loss on investment, net	(214,630)	(29,124)
Stock based compensation	1,483,806	1,252,731
Changes in operating assets and liabilities
Accounts receivable	(1,014,189)	(107,426)
Accrued interest receivable	0	(1,248)
Inventory	225,878	42,251
Prepaid expenses and other current assets	(12,816)	0
Other assets	(371,831)	(178,290)
Operating lease right of use assets and liabilities	33,334	5,053
Accounts payable and other liabilities	2,224,092	572,827
Deferred revenue	(50,000)	0
Net cash provided by (used in) operating activities	1,698,519	(2,471,022)
Cash flows from investing activities
Purchase of fixed assets	(633,114)	(307,178)
Cash consideration for acquisition of business	(65,109,039)	0
Issuance of notes receivable	141,680	0
Net cash (used in) investing activities	(65,600,473)	(307,178)
Cash flows from financing activities
Proceeds from issuance of debt, net	40,348,241	0
Repayment of notes payable	(5,000,000)	0
Proceeds from issuance of stock, net of issuance costs	50,282,798	0
Net cash provided by financing activities	85,631,039	0
Net (decrease) increase in cash and cash equivalents	21,729,085	(2,778,200)
Cash and cash equivalents at beginning of period	1,237,235	11,853,627
Cash and cash equivalents at end of period	22,966,320	9,075,427
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 897,247	$ 0

XML 19 R7.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description

Organization and Nature of Operations

On February 4, 2021, the Company acquired the assets of Colorado Health Consultants LLC and Mountain View 44th LLC under the applicable APAs.

On March 2, 2021, the Company acquired the assets of (i) Starbuds Aurora LLC, (ii) SB Arapahoe LLC; (iii) Citi-Med LLC; (iv) Starbuds Louisville LLC; and (v) KEW LLC under the applicable APAs.

XML 20 R8.htm IDEA: XBRL DOCUMENT

1. Liquidity and Capital Resources

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity and Capital Resources

1.	Liquidity and Capital Resources:

During the quarters ended March 31, 2021 and 2020, the Company primarily used revenues from its operations to fund its operations.

XML 21 R9.htm IDEA: XBRL DOCUMENT

2. Critical Accounting Policies and Estimates

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Critical Accounting Policies and Estimates

2.	Critical Accounting Policies and Estimates

Management’s Representation of Interim Financial Statements

Basis of Presentation

Use of Estimates

Reclassifications

Fair Value Measurements

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

March 31,

2021

December 31,

2020

Level 1 – Marketable Securities Available-for-Sale – Recurring

491,412

276,782

Marketable Securities at Fair Value on a Recurring Basis

Fair Value of Financial Instruments

Accounts Receivable

The following table depicts the composition of our accounts receivable as of March 31, 2021, and December 31, 2020:

	March 31, 2021			December 31, 2020
Accounts receivable – trade	$	2,524,718		$	1,315,188
Accounts receivable – related party		–			80,494
Accounts receivable – litigation, non-current		3,063,968			3,063,968
Allowance for doubtful accounts		(159,656	)		(44,808	)
Total accounts receivable	$	5,429,031		$	4,414,842

Notes Receivable

Other Assets (Current and Non-Current)

Goodwill and Intangible Assets

Long-Lived Assets

Accounts Payable

Accrued Expenses and Other Liabilities

Revenue Recognition and Related Allowances

The Company has three main revenue streams: retail; wholesale; and other.

Costs of Goods and Services Sold

Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of the Company’s products and services.

General and Administrative Expenses

General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred and were $111,685 and $129,267 during the quarter ended March 31, 2021 and 2020, respectively.

Stock Based Compensation

Income Taxes

Right of Use Assets and Lease Liabilities

Operating leases are included in operating lease ROU assets and operating lease liabilities, current and non-current, on the Company's consolidated balance sheets.

XML 22 R10.htm IDEA: XBRL DOCUMENT

3. Recent Accounting Pronouncements

3 Months Ended

Mar. 31, 2021

Accounting Standards Update and Change in Accounting Principle [Abstract]

Recent Accounting Pronouncements

3.	Recent Accounting Pronouncements

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

4. Property and Equipment

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment

4.	Property and Equipment

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:

	March 31, 2021			December 31, 2020
Furniture and fixtures	$	294,204		$	228,451
Leasehold improvements		656,314			90,314
Machinery and Tools		1,401,752			1,456,752
Office equipment		69,983			104,059
Software		1,308,387			1,308,387
Work in process		390,598			269,414
	$	4,121,239		$	3,457,377
Less: Accumulated depreciation		(1,032,211	)		(872,579	)
Total property and equipment, net of depreciation	$	3,089,027		$	2,584,798

Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.

Furniture and fixtures	3 years
Leasehold improvements	Lesser of the lease term or estimated useful life
Vehicles	3 years
Office equipment	3 years

Depreciation expense for the three months ended March 31, 2021 and 2020 was $194,637 and $4,465 respectively.

XML 24 R12.htm IDEA: XBRL DOCUMENT

5. Intangible Asset

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Asset

5.	Intangible Asset

Intangible assets as of March 31, 2021 and December 31, 2020 were comprised of the following:

	March 31, 2021			December 31, 2020
Licenses	$	88,745,700		$	1,667,000
Tradename		4,270,000			350,000
Customer relationships		5,150,000			1,055,000
Non-compete		1,130,000			120,000
Product license and registration		57,300			57,300
Trade secret – intellectual property		32,500			32,500
	$	99,385,500		$	3,282,500
Less: accumulated amortization		(1,796,386	)		(200,456	)
Total intangible assets, net of amortization	$	97,589,114		$	3,082,044

Amortization expense for the three months ended March 31, 2021 and 2020 was $1,595,931 and $1,648, respectively.

XML 25 R13.htm IDEA: XBRL DOCUMENT

6. Derivative Liability

3 Months Ended

Mar. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Liability

6.	Derivative Liability

XML 26 R14.htm IDEA: XBRL DOCUMENT

7. Related Party Transactions

3 Months Ended

Mar. 31, 2021

Related Party Transactions

7.	Related Party Transactions

Transactions Involving Former Directors, Executive Officers or Their Affiliated Entities

Transactions with Entities Affiliated with Justin Dye

Transactions with CRW and Affiliated Entities

Transactions with Entities Affiliated with Brian Ruden

In connection with the Star Buds acquisitions, the Company granted Mr. Ruden and Naser Joudeh the right designate individuals for election or appointment to the Board.

XML 27 R15.htm IDEA: XBRL DOCUMENT

8. Inventory

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Inventory

8.	Inventory

XML 28 R16.htm IDEA: XBRL DOCUMENT

9. Goodwill

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

9.	Goodwill

XML 29 R17.htm IDEA: XBRL DOCUMENT

10. Leases

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Leases

10.	Leases

The Company's leases consist of real estate leases for office spaces. The Company elected to combine the lease and related non-lease components for its operating leases.

Balance Sheet Classification of Operating Lease Assets and Liabilities

	Balance Sheet Line	March 31, 2021
Asset
Operating lease right of use assets	Noncurrent assets	$	4,242,124
Liabilities
Lease liabilities	Noncurrent liabilities	$	4,342,018

Lease Costs

The table below summarizes the components of lease costs for the three months ended March 31, 2021.

		Three Months Ended March 31, 2021
Operating lease costs		$	278,117

Maturities of Lease Liabilities

Maturities of lease liabilities as of March 31, 2021 are as follows:

2021 fiscal year	$	4,418,867
Less: Interest		(76,848	)
Present value of lease liabilities	$	4,342,018

The following table presents the Company’s future minimum lease obligation under ASC 840 as of March 31, 2021:

2021 fiscal year			1,109,215
2022 fiscal year			1,479,393
2023 fiscal year			1,354,595
2024 fiscal year			723,590
2025 fiscal year			333,356
2026 fiscal year			178,648
Total			5,178,796

XML 30 R18.htm IDEA: XBRL DOCUMENT

11. Stockholders' Equity

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Stockholders' Equity

11.	Stockholders’ Equity

The Company is authorized to issue two classes of stock, designated preferred stock and common stock.

Preferred Stock

Common Stock

Common Stock Issued in Private Placements

During the year ended December 31, 2020, the Company issued 187,500 shares of common stock and warrants to purchase 187,500 shares of common stock, for gross proceeds of $375,000.

Common Stock Issued as Compensation to Employees, Officers, and Directors

During the year ended December 31, 2020, the Company issued 406,895 shares of common stock valued at $497,301 to employees, officers, and directors as compensation.

During the quarter ended March 31, 2021, the Company issued 218,042 shares of common stock valued at $444,806 to employees, and directors as compensation.

Common and Preferred Stock Issued as Payment for Acquisitions

On April 20, 2020, the Company issued 2,554,750 shares of common stock valued at $4,167,253 for the acquisition of Mesa Organics, Ltd.

Warrants

The following table reflects the change in common stock purchase warrants for the three months ended March 31, 2021.

	Number of shares
Balance as of January 1, 2021		11,725,220
Warrants exercised		–
Warrants forfeited		–
Warrants issued		5,293,530
Balance as of March 31, 2021		17,018,750

Option Repricing

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 31 R19.htm IDEA: XBRL DOCUMENT

12. Segment Information

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Segment Information

12.	Segment Information

The following information represents segment activity for the three-month periods ended March 31, 2021 and March 31, 2020:

	For the Three Months Ended March 31,
	2021												2020
	Retail			Wholesale			Other			Total			Retail		Wholesale			Other			Total

Revenues	$	11,816,200			7,446,265			77,650			19,340,115		$	–	$	2,528,931		$	674,203		$	3,203,134
Cost of goods and services	$	(7,500,757	)		(4,483,694	)		(102,660	)		(12,087,111	)	$	–	$	(1,896,226	)	$	(252,309	)	$	(2,148,535	)
Gross profit	$	4,315,443			2,962,571			(25,010	)		7,253,004		$	–	$	633,705		$	421,894		$	1,054,599
Intangible assets amortization	$	1,594,302			1,497			133			1,595,931		$	–	$	1,513		$	135		$	1,648
Depreciation	$	84,298			3,641			106,699			194,637		$	–	$	1,233		$	3,232		$	4,465
Net income (loss)	$	1,398,651			2,814,014			(7,862,172	)		(3,649,507	)	$	–	$	446,499		$	(1,825,809	)	$	(1,379,310	)
Segment assets	$	132,931,035			21,326,258			26,761,858			181,019,151		$	–	$	12,935,074		$	17,094,217		$	30,029,291

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 32 R20.htm IDEA: XBRL DOCUMENT

13. Tax Provision

3 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Tax Provision

13.	Tax Provision

The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended March 31, 2021 and March 31, 2020:

	Three Months Ended March 31,
	2021			2020
Income (Loss) before Income Taxes		(3,192,891	)		(1,379,310	)
Income Tax Expense		456,614			–
Effective Tax Rate		-14.30%			0%

The Federal statute of limitation remains open for the 2017 tax year to present. The state statute of limitation remains open for the 2016 tax year to present.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 33 R21.htm IDEA: XBRL DOCUMENT

14. Subsequent Events

3 Months Ended

Mar. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

14.	Subsequent Events

XML 34 R22.htm IDEA: XBRL DOCUMENT

2. Critical Accounting Policies and Estimates (Policies)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Management's Representation of Interim Financial Statements

Management’s Representation of Interim Financial Statements

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Reclassifications

Reclassifications

Fair Value Measurements

Fair Value Measurements

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

March 31,

2021

December 31,

2020

Level 1 – Marketable Securities Available-for-Sale – Recurring

491,412

276,782

Marketable Securities at Fair Value on a Recurring Basis

Marketable Securities at Fair Value on a Recurring Basis

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Accounts receivable

Accounts Receivable

The following table depicts the composition of our accounts receivable as of March 31, 2021, and December 31, 2020:

	March 31, 2021			December 31, 2020
Accounts receivable – trade	$	2,524,718		$	1,315,188
Accounts receivable – related party		–			80,494
Accounts receivable – litigation, non-current		3,063,968			3,063,968
Allowance for doubtful accounts		(159,656	)		(44,808	)
Total accounts receivable	$	5,429,031		$	4,414,842

Notes receivable

Notes Receivable

Other assets (current and non-current)

Other Assets (Current and Non-Current)

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Long-Lived Assets

Long-Lived Assets

Accounts payable

Accounts Payable

Accrued expenses and other liabilities

Accrued Expenses and Other Liabilities

Revenue recognition and related allowances

Revenue Recognition and Related Allowances

The Company has three main revenue streams: retail; wholesale; and other.

Cost of Goods and Services Sold

Costs of Goods and Services Sold

Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of the Company’s products and services.

General and Administrative Expenses

General and Administrative Expenses

General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.

Advertising and Marketing Costs

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred and were $111,685 and $129,267 during the quarter ended March 31, 2021 and 2020, respectively.

Stock-Based Compensation

Stock Based Compensation

Income Taxes

Income Taxes

Right of Use Assets and Lease Liabilities

Right of Use Assets and Lease Liabilities

Operating leases are included in operating lease ROU assets and operating lease liabilities, current and non-current, on the Company's consolidated balance sheets.

XML 35 R23.htm IDEA: XBRL DOCUMENT

2. Critical Accounting Policies and Estimates (Tables)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Schedule of fair value measurement

March 31,

2021

December 31,

2020

Level 1 – Marketable Securities Available-for-Sale – Recurring

491,412

276,782

Schedule of Accounts Receivable

The following table depicts the composition of our accounts receivable as of March 31, 2021, and December 31, 2020:

	March 31, 2021			December 31, 2020
Accounts receivable – trade	$	2,524,718		$	1,315,188
Accounts receivable – related party		–			80,494
Accounts receivable – litigation, non-current		3,063,968			3,063,968
Allowance for doubtful accounts		(159,656	)		(44,808	)
Total accounts receivable	$	5,429,031		$	4,414,842

XML 36 R24.htm IDEA: XBRL DOCUMENT

4. Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Property and equipment table

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:

	March 31, 2021			December 31, 2020
Furniture and fixtures	$	294,204		$	228,451
Leasehold improvements		656,314			90,314
Machinery and Tools		1,401,752			1,456,752
Office equipment		69,983			104,059
Software		1,308,387			1,308,387
Work in process		390,598			269,414
	$	4,121,239		$	3,457,377
Less: Accumulated depreciation		(1,032,211	)		(872,579	)
Total property and equipment, net of depreciation	$	3,089,027		$	2,584,798

Schedule of property and equipment useful lives

Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.

Furniture and fixtures	3 years
Leasehold improvements	Lesser of the lease term or estimated useful life
Vehicles	3 years
Office equipment	3 years

XML 37 R25.htm IDEA: XBRL DOCUMENT

5. Intangible Asset (Tables)

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible assets

Intangible assets as of March 31, 2021 and December 31, 2020 were comprised of the following:

	March 31, 2021			December 31, 2020
Licenses	$	88,745,700		$	1,667,000
Tradename		4,270,000			350,000
Customer relationships		5,150,000			1,055,000
Non-compete		1,130,000			120,000
Product license and registration		57,300			57,300
Trade secret – intellectual property		32,500			32,500
	$	99,385,500		$	3,282,500
Less: accumulated amortization		(1,796,386	)		(200,456	)
Total intangible assets, net of amortization	$	97,589,114		$	3,082,044

XML 38 R26.htm IDEA: XBRL DOCUMENT

10. Leases (Tables)

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Balance Sheet Classification Table

Balance Sheet Classification of Operating Lease Assets and Liabilities

	Balance Sheet Line	March 31, 2021
Asset
Operating lease right of use assets	Noncurrent assets	$	4,242,124
Liabilities
Lease liabilities	Noncurrent liabilities	$	4,342,018

Operating Lease Costs

The table below summarizes the components of lease costs for the three months ended March 31, 2021.

		Three Months Ended March 31, 2021
Operating lease costs		$	278,117

Maturities of Lease Liabilities

Maturities of lease liabilities as of March 31, 2021 are as follows:

2021 fiscal year	$	4,418,867
Less: Interest		(76,848	)
Present value of lease liabilities	$	4,342,018

Future minimum lease obligations

The following table presents the Company’s future minimum lease obligation under ASC 840 as of March 31, 2021:

2021 fiscal year			1,109,215
2022 fiscal year			1,479,393
2023 fiscal year			1,354,595
2024 fiscal year			723,590
2025 fiscal year			333,356
2026 fiscal year			178,648
Total			5,178,796

XML 39 R27.htm IDEA: XBRL DOCUMENT

11. Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Schedule of warrant activity

The following table reflects the change in common stock purchase warrants for the three months ended March 31, 2021.

	Number of shares
Balance as of January 1, 2021		11,725,220
Warrants exercised		–
Warrants forfeited		–
Warrants issued		5,293,530
Balance as of March 31, 2021		17,018,750

XML 40 R28.htm IDEA: XBRL DOCUMENT

12. Segment Information (Tables)

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following information represents segment activity for the three-month periods ended March 31, 2021 and March 31, 2020:

	For the Three Months Ended March 31,
	2021												2020
	Retail			Wholesale			Other			Total			Retail		Wholesale			Other			Total

Revenues	$	11,816,200			7,446,265			77,650			19,340,115		$	–	$	2,528,931		$	674,203		$	3,203,134
Cost of goods and services	$	(7,500,757	)		(4,483,694	)		(102,660	)		(12,087,111	)	$	–	$	(1,896,226	)	$	(252,309	)	$	(2,148,535	)
Gross profit	$	4,315,443			2,962,571			(25,010	)		7,253,004		$	–	$	633,705		$	421,894		$	1,054,599
Intangible assets amortization	$	1,594,302			1,497			133			1,595,931		$	–	$	1,513		$	135		$	1,648
Depreciation	$	84,298			3,641			106,699			194,637		$	–	$	1,233		$	3,232		$	4,465
Net income (loss)	$	1,398,651			2,814,014			(7,862,172	)		(3,649,507	)	$	–	$	446,499		$	(1,825,809	)	$	(1,379,310	)
Segment assets	$	132,931,035			21,326,258			26,761,858			181,019,151		$	–	$	12,935,074		$	17,094,217		$	30,029,291

XML 41 R29.htm IDEA: XBRL DOCUMENT

13. Tax Provision (Tables)

3 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Components of income tax expense

The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended March 31, 2021 and March 31, 2020:

	Three Months Ended March 31,
	2021			2020
Income (Loss) before Income Taxes		(3,192,891	)		(1,379,310	)
Income Tax Expense		456,614			–
Effective Tax Rate		-14.30%			0%

XML 42 R30.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended		4 Months Ended
	Feb. 26, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Dec. 16, 2020
Proceeds from issuance of stock		$ 50,282,798	$ 0
Dye Capital [Member] \| Convertible Promissory Note [Member]
Debt face amount					$ 5,000,000
Debt converted, amount converted	$ 5,000,000
of Series A Cumulative Convertible Preferred Stock [Member] \| Dye Cann II and CRW [Member]
Proceeds from issuance of stock				$ 57,700,000
Stock issued new, shares				57,700
Share Price		$ 1,000		$ 1,000
of Series A Cumulative Convertible Preferred Stock [Member] \| Dye Capital [Member] \| Convertible Promissory Note [Member]
Debt converted, shares issued	5,060

XML 43 R31.htm IDEA: XBRL DOCUMENT

1. Liquidity and Capital Resources (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 22,966,320	$ 1,231,235	$ 9,075,427

XML 44 R32.htm IDEA: XBRL DOCUMENT

2. Critical Accounting Policies and Estimates (Details - Level 3) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Fair Value Inputs Level 1 [Member] \| Fair Value Measurements Recurring [Member] \| Marketable Securities [Member]
Fair value assets	$ 491,412	$ 276,782

XML 45 R33.htm IDEA: XBRL DOCUMENT

2. Critical Accounting Policies and Estimates (Details Receivables) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Total accounts receivable	$ 5,429,031	$ 4,414,842
Allowance for doubtful accounts	(159,656)	(44,808)
Trade Accounts Receivable [Member]
Total accounts receivable	2,524,718	1,315,188
Accounts receivable - related party [Member]
Total accounts receivable	0	80,494
Accounts receivable - litigation [Member]
Total accounts receivable	$ 3,063,968	$ 3,063,968

XML 46 R34.htm IDEA: XBRL DOCUMENT

2. Critical Accounting Policies and Estimates (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Allowance for doubtful accounts	$ 159,656		$ 44,808
Debt expense	28,074	$ 0
Notes receivable	247,272		241,711
Other assets	1,050,726		666,079
Intangible assets impairment	0
Accounts payable	2,522,695		3,557,460
Accrued expenses and other liabilities	8,298,446		2,705,445
Advertising and marketing expense	111,685	129,267
Stock based compensation expense	1,483,806	$ 1,252,731
Customer Deposits [Member]
Accrued expenses and other liabilities	24,958		26,826
Accrued Payroll [Member]
Accrued expenses and other liabilities	1,402,814		1,154,887
Operating Expenses [Member]
Accrued expenses and other liabilities	6,870,674		1,523,732
Prepaid Expenses [Member]
Other assets	627,016		345,777
Security Deposits [Member]
Other assets	$ 423,710		51,879
Tax Receivable [Member]
Other assets			268,423
Minimum [Member]
Intangible assets useful lives	10 years
Maximum [Member]
Intangible assets useful lives	15 years
Abba Medix [Member]
Notes receivable	$ 248,025		$ 246,765

XML 47 R35.htm IDEA: XBRL DOCUMENT

4. Property and Equipment (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property and Equipment, gross	$ 4,121,239	$ 3,457,377
Less: Accumulated Depreciation	(1,032,211)	(872,579)
Property and equipment, net	3,089,027	2,584,798
Furniture and Fixtures [Member]
Property and Equipment, gross	294,204	228,451
Leasehold Improvements [Member]
Property and Equipment, gross	656,314	90,314
Machinery and Tools [Member]
Property and Equipment, gross	1,401,752	1,456,752
Office Equipment [Member]
Property and Equipment, gross	69,983	104,059
Software [Member]
Property and Equipment, gross	1,308,387	1,308,387
Work In Progress [Member]
Property and Equipment, gross	$ 390,598	$ 269,414

XML 48 R36.htm IDEA: XBRL DOCUMENT

4. Property and Equipment (Details - Expected life)	3 Months Ended
4. Property and Equipment (Details - Expected life)	Mar. 31, 2021
Furniture and Fixtures [Member]
Estimated useful life	3 years
Leasehold Improvements [Member]
Estimated useful life	Lesser of the lease term or estimated useful life
Vehicles [Member]
Estimated useful life	3 years
Office Equipment [Member]
Estimated useful life	3 years

XML 49 R37.htm IDEA: XBRL DOCUMENT

4. Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
4. Property and Equipment (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 194,637	$ 4,465

XML 50 R38.htm IDEA: XBRL DOCUMENT

5. Intangible Asset (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Intangible assets, gross	$ 99,385,500	$ 3,282,500
Less: accumulated amortization	(1,796,386)	(200,456)
Intangible assets, net	97,589,114	3,082,044
License [Member]
Intangible assets, gross	88,745,700	1,667,000
Trade Names [Member]
Intangible assets, gross	4,270,000	350,000
Customer Relationships [Member]
Intangible assets, gross	5,150,000	1,055,000
Noncompete [Member]
Intangible assets, gross	1,130,000	120,000
Product License and Registration [Member]
Intangible assets, gross	57,300	57,300
Trade Secret [Member]
Intangible assets, gross	$ 32,500	$ 32,500

XML 51 R39.htm IDEA: XBRL DOCUMENT

5. Intangible Asset (Details Narrative) - USD ($)	3 Months Ended
5. Intangible Asset (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 1,595,931	$ 1,648

XML 52 R40.htm IDEA: XBRL DOCUMENT

6. Derivative Liability (Details Narrative) - USD ($)		2 Months Ended	3 Months Ended		4 Months Ended	5 Months Ended
6. Derivative Liability (Details Narrative) - USD ($)	Jan. 08, 2019	Feb. 25, 2020	Mar. 31, 2021	Mar. 31, 2020	Apr. 23, 2019	Jun. 11, 2019	Dec. 31, 2020
Fair value of derivative liabilities			$ 2,301,295				$ 1,047,481
Unrealized gain (loss) on derivative liabilities			(1,253,814)	$ 1,191,963
Gain on forfeiture of contingent consideration			$ 0	$ 1,462,636
Officer And Director [Member] \| Restricted Stock [Member]
Restricted stock granted, shares	500,000				1,000,000
Officer And Director [Member] \| Restricted Stock [Member] \| Director Resignation [Member]
Gain on forfeiture of contingent consideration		$ 4,462,636
An Officer [Member] \| Restricted Stock [Member]
Restricted stock granted, shares						1,000,000

XML 53 R41.htm IDEA: XBRL DOCUMENT

7. Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	2 Months Ended			3 Months Ended			5 Months Ended	7 Months Ended	8 Months Ended	12 Months Ended					22 Months Ended
	Feb. 03, 2021	Mar. 02, 2021	Mar. 02, 2021	Feb. 26, 2021	Mar. 31, 2021	Mar. 30, 2021	Mar. 31, 2020	Jun. 05, 2019	Jul. 31, 2020	Sep. 04, 2020	Dec. 31, 2020	Dec. 22, 2020	Dec. 18, 2020	Dec. 16, 2020	Dec. 31, 2019	Mar. 31, 2021	Aug. 01, 2020
Cash paid at closing					$ 65,109,039		$ 0
Interest paid					28,074		$ 0
Star Buds [Member]
Consideration transferred			$ 118,000,000
Cash paid at closing			44,250,000
Deferred cash			$ 44,250,000
Dye Capital [Member]
Convertible note														$ 5,000,000
Debt converted, amount converted				$ 5,000,000
Debt converted, interest converted				$ 60,250
Seller Notes [Member] \| Star Buds [Member]
Note payable balance					44,250,000											$ 44,250,000
Accrued interest payable					425,162											425,162
Interest paid					810,887
Warrants [Member] \| Star Buds [Member]
Stock issued			5,531,250
Warrants [Member] \| Dye Capital [Member]
Debt converted, shares issued				5,060
Cash paid on conversion of debt				$ 231
Series A Preferred Stock [Member] \| Star Buds [Member]
Stock issued			29,500
Dye Cann II SPA [Member]
Stock issued new, shares						21,350
Proceeds from sale of equity						$ 21,350,000
Dye Cann II SPA [Member] \| Series A Preferred Stock [Member]
Stock issued new, shares	3,100	3,800				4,000						1,300	1,450	7,700
CRW SPA [Member] \| Series A Preferred Stock [Member]
Stock issued new, shares				25,350
Proceeds from sale of equity				$ 25,350,000
Med Man Denver [Member]
Revenue from related parties											$ 997,262
Accounts receivable from related parties											72,109
Med Pharm Holdings [Member]
Revenue from related parties											73,557
Accounts receivable from related parties											5,885
Notes receivable issued															$ 767,695
Note receivable balance					40,231					$ 181,911						40,231	$ 767,695
Proceeds from note receivable									$ 100,000
Accrued interest receivable																	$ 47,161
Med Pharm Holdings [Member] \| Andrew Williams [Member]
Shares returned for payment of note receivable										175,000
Baseball 18 LLC [Member]
Revenue from related parties											14,605
Accounts payable from related party											31,250
Farm Boy [Member]
Revenue from related parties											16,125
Accounts payable from related party											93,944
Emerald Fields [Member]
Revenue from related parties											16,605
Los Suenos [Member]
Revenue from related parties											52,244
Dye Cann I SPA [Member] \| Securities Purchase Agreement [Member]
Proceeds from sale of equity								$ 3,000,000								$ 18,575,000
Dye Cann I SPA [Member] \| Securities Purchase Agreement [Member] \| Common Stock [Member]
Stock issued new, shares								1,500,000								9,287,500
Dye Cann I SPA [Member] \| Securities Purchase Agreement [Member] \| Warrants [Member]
Warrants issued								1,500,000								9,287,500
Tella Digital [Member]
Costs and expenses to related party					170,119						$ 66,264
Brian Ruden [Member] \| Star Buds [Member]
Cash paid at closing			$ 13,727,490
Deferred cash			$ 13,727,490
Brian Ruden [Member] \| Seller Notes [Member] \| Star Buds [Member]
Interest paid					$ 111,824
Brian Ruden [Member] \| Warrants [Member] \| Star Buds [Member]
Stock issued			1,715,936
Brian Ruden [Member] \| Series A Preferred Stock [Member] \| Star Buds [Member]
Stock issued			9,152

XML 54 R42.htm IDEA: XBRL DOCUMENT

8. Inventory (Details Narrative) - USD ($)	3 Months Ended
8. Inventory (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Inventory Disclosure [Abstract]
Finished goods inventory	$ 3,345,353		$ 2,090,887
Raw materials inventory	1,331,658		27,342
Inventory work in process	911,246		$ 500,917
Inventory obsolescence	$ 0	$ 0

XML 55 R43.htm IDEA: XBRL DOCUMENT

9. Goodwill (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended		4 Months Ended	5 Months Ended	7 Months Ended	9 Months Ended
9. Goodwill (Details Narrative) - USD ($)	Mar. 02, 2021	Mar. 31, 2021	Mar. 31, 2020	Apr. 20, 2020	Jun. 03, 2017	Jul. 21, 2017	Sep. 17, 2018	Dec. 31, 2020
Goodwill		$ 40,532,910						$ 53,046,729
Cash paid for acquisition		65,109,039	$ 0
Success Nutrients and Pono Publications [Member]
Stock issued for acquisition, shares					7,000,000
Goodwill		6,301,080			$ 6,301,080
Denver Consulting Group [Member]
Stock issued for acquisition, shares						2,258,065
Goodwill		3,003,226				$ 3,003,226
Big Tomato [Member]
Stock issued for acquisition, shares							1,933,329
Goodwill		3,000,000					$ 3,000,000
Mesa Organics [Member]
Stock issued for acquisition, shares				2,554,750
Goodwill		$ 2,147,613		$ 2,147,613
Cash paid for acquisition				$ 2,609,500
Star Buds [Member]
Goodwill	$ 26,080,991
Cash paid for acquisition	44,250,000
Consideration transferred	$ 118,000,000

XML 56 R44.htm IDEA: XBRL DOCUMENT

10. Leases (Details - Balance Sheet Classification) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease asset - non-current	$ 4,242,124	$ 2,579,036
Operating lease liability - non-current	$ 4,342,018	$ 2,645,597

XML 57 R45.htm IDEA: XBRL DOCUMENT

10. Leases (Details - Operating lease cost)	3 Months Ended
10. Leases (Details - Operating lease cost)	Mar. 31, 2021 USD ($)
Leases [Abstract]
Operating lease costs	$ 278,117

XML 58 R46.htm IDEA: XBRL DOCUMENT

10. Leases (Details - Lease maturities)	Mar. 31, 2021 USD ($)
Leases [Abstract]
2021 fiscal year	$ 4,418,867
Less: interest	(76,848)
Present value of lease liabilities	$ 4,342,018

XML 59 R47.htm IDEA: XBRL DOCUMENT

10. Leases (Details - Minimum lease obligation)	Mar. 31, 2021 USD ($)
Leases [Abstract]
2021 fiscal year	$ 1,109,215
2022 fiscal year	1,479,393
2023 fiscal year	1,354,595
2024 fiscal year	723,590
2025 fiscal year	333,356
2026 fiscal year	178,648
Total	$ 5,178,796

XML 60 R48.htm IDEA: XBRL DOCUMENT

10. Leases (Details Narrative)	Mar. 31, 2021
Minimum [Member]
Weighted average lease discount rate	6.00%
Maximum [Member]
Weighted average lease discount rate	12.00%

XML 61 R49.htm IDEA: XBRL DOCUMENT

11. Stockholders' Equity (Details Warrant Activity) - Warrants [Member]	3 Months Ended
	Mar. 31, 2021 shares
Warrants outstanding, beginning balance	11,725,220
Warrants exercised	0
Warrants forfeited	0
Warrants issued	5,293,530
Warrants outstanding, ending balance	17,018,750

XML 62 R50.htm IDEA: XBRL DOCUMENT

11. Stockholders' Equity (Details Narrative) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended	4 Months Ended	12 Months Ended
11. Stockholders' Equity (Details Narrative) - USD ($)	Feb. 03, 2021	Mar. 03, 2021	Mar. 31, 2021	Apr. 20, 2020	Dec. 31, 2020	Dec. 18, 2020	Dec. 17, 2020
Preferred stock authorized			10,000,000		10,000,000
Preferred stock par value			$ 0.001		$ 0.001
Preferred stock issued			87,266		19,716
Preferred stock outstanding			87,266		19,716
Common stock authorized			250,000,000		250,000,000
Common stock par value			$ 0.001		$ 0.001
Common stock issued			42,819,815		42,601,773
Common stock outstanding			42,331,595		42,169,041
Stock issued for compensation, value			$ 444,806
Shares issued for acquisition, value			$ 20,240,000
Accredited Investors [Member] \| Warrants [Member]
Contractual term			5 years
Accredited Investors [Member] \| Warrants [Member] \| Maximum [Member]
Risk-free interest rate			0.75%
Expected volatility rate			195.00%
Stock price			$ 2.50
Accredited Investors [Member] \| Warrants [Member] \| Minimum [Member]
Risk-free interest rate			0.46%
Expected volatility rate			192.71%
Stock price			$ 1.20
Employees, Officers and Directors [Member]
Stock issued for compensation, shares					406,895
Stock issued for compensation, value					$ 497,301
Mesa Organics, Ltd [Member]
Stock issued for acquisition, shares				2,554,750
Shares issued for acquisition, value				$ 4,167,253
SBUD LLC [Member] \| Preferred Stock
Stock issued for acquisition, shares	2,319	17,921				6,404	2,862
Shares issued for acquisition, value	$ 2,318,998	$ 17,920,982				$ 6,403,987	$ 2,861,994
SBUD LLC [Member] \| Warrants [Member]
Stock issued for acquisition, shares			3,793,530
SBUD LLC [Member] \| Warrants [Member] \| Accredited Investor [Member]
Warrants issued			1,500,000
Private Placements [Member]
Stock issued new, shares					187,500
Warrants issued					187,500
Proceeds from sale of equity					$ 375,000

XML 63 R51.htm IDEA: XBRL DOCUMENT

13. Segment Information (Details- Segment Information) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues	$ 19,340,115	$ 3,203,134
Cost of goods and services	(12,087,111)	(2,148,535)
Gross profit	7,253,004	1,054,599
Intangible assets amortization	1,595,931	1,648
Depreciation	194,637	4,465
Net income (loss)	(3,649,507)	(1,379,310)
Segment assets	181,019,151	30,029,291
Products [Member]
Revenues	11,816,200	0
Cost of goods and services	(7,500,757)	0
Gross profit	4,315,443	0
Intangible assets amortization	1,594,302	0
Depreciation	84,298	0
Net income (loss)	1,398,651	0
Segment assets	132,931,035	0
Licensing and Consulting [Member]
Revenues	7,446,265	2,528,931
Cost of goods and services	(4,483,694)	(1,896,226)
Gross profit	2,962,571	633,705
Intangible assets amortization	1,497	1,513
Depreciation	3,641	1,233
Net income (loss)	2,814,014	446,499
Segment assets	21,326,258	12,935,074
Corporate, Infrastructure and Other [Member]
Revenues	77,650	674,203
Cost of goods and services	(102,660)	(252,309)
Gross profit	(25,010)	421,894
Intangible assets amortization	133	135
Depreciation	106,699	3,232
Net income (loss)	(7,862,172)	(1,825,809)
Segment assets	$ 26,761,858	$ 17,094,217

XML 64 R52.htm IDEA: XBRL DOCUMENT

14. Tax Provision (Details - Components of Income Tax) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income (Loss) before Income Taxes	$ (3,192,891)	$ (1,379,310)
Income Tax Expense	$ 456,614	$ 0
Effective Tax Rate	(14.30%)	0.00%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 185 317 1 false 79 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://medicineman.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://medicineman.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://medicineman.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statement of Comprehensive (Loss) (Unaudited) Sheet http://medicineman.com/role/StatementOfComprehensiveLoss Condensed Statement of Comprehensive (Loss) (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statement Of Changes in Stockholders Equity (Unaudited) Sheet http://medicineman.com/role/StatementOfChangesInStockholdersEquity Statement Of Changes in Stockholders Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://medicineman.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Nature of Operations Sheet http://medicineman.com/role/OrganizationAndNatureOfOperations Organization and Nature of Operations Notes 7 false false R8.htm 00000008 - Disclosure - 1. Liquidity and Capital Resources Sheet http://medicineman.com/role/LiquidityAndCapitalResources 1. Liquidity and Capital Resources Notes 8 false false R9.htm 00000009 - Disclosure - 2. Critical Accounting Policies and Estimates Sheet http://medicineman.com/role/CriticalAccountingPoliciesAndEstimates 2. Critical Accounting Policies and Estimates Notes 9 false false R10.htm 00000010 - Disclosure - 3. Recent Accounting Pronouncements Sheet http://medicineman.com/role/RecentAccountingPronouncements 3. Recent Accounting Pronouncements Notes 10 false false R11.htm 00000011 - Disclosure - 4. Property and Equipment Sheet http://medicineman.com/role/PropertyAndEquipment 4. Property and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - 5. Intangible Asset Sheet http://medicineman.com/role/IntangibleAsset 5. Intangible Asset Notes 12 false false R13.htm 00000013 - Disclosure - 6. Derivative Liability Sheet http://medicineman.com/role/DerivativeLiability 6. Derivative Liability Notes 13 false false R14.htm 00000014 - Disclosure - 7. Related Party Transactions Sheet http://medicineman.com/role/RelatedPartyTransactions 7. Related Party Transactions Notes 14 false false R15.htm 00000015 - Disclosure - 8. Inventory Sheet http://medicineman.com/role/Inventory 8. Inventory Notes 15 false false R16.htm 00000016 - Disclosure - 9. Goodwill Sheet http://medicineman.com/role/Goodwill 9. Goodwill Notes 16 false false R17.htm 00000017 - Disclosure - 10. Leases Sheet http://medicineman.com/role/Leases 10. Leases Notes 17 false false R18.htm 00000018 - Disclosure - 11. Stockholders' Equity Sheet http://medicineman.com/role/StockholdersEquity 11. Stockholders' Equity Notes 18 false false R19.htm 00000019 - Disclosure - 12. Segment Information Sheet http://medicineman.com/role/SegmentInformation 12. Segment Information Notes 19 false false R20.htm 00000020 - Disclosure - 13. Tax Provision Sheet http://medicineman.com/role/TaxProvision 13. Tax Provision Notes 20 false false R21.htm 00000021 - Disclosure - 14. Subsequent Events Sheet http://medicineman.com/role/SubsequentEvents 14. Subsequent Events Notes 21 false false R22.htm 00000022 - Disclosure - 2. Critical Accounting Policies and Estimates (Policies) Sheet http://medicineman.com/role/CriticalAccountingPoliciesAndEstimatesPolicies 2. Critical Accounting Policies and Estimates (Policies) Policies http://medicineman.com/role/CriticalAccountingPoliciesAndEstimates 22 false false R23.htm 00000023 - Disclosure - 2. Critical Accounting Policies and Estimates (Tables) Sheet http://medicineman.com/role/CriticalAccountingPoliciesAndEstimatesTables 2. Critical Accounting Policies and Estimates (Tables) Tables http://medicineman.com/role/CriticalAccountingPoliciesAndEstimates 23 false false R24.htm 00000024 - Disclosure - 4. Property and Equipment (Tables) Sheet http://medicineman.com/role/PropertyAndEquipmentTables 4. Property and Equipment (Tables) Tables http://medicineman.com/role/PropertyAndEquipment 24 false false R25.htm 00000025 - Disclosure - 5. Intangible Asset (Tables) Sheet http://medicineman.com/role/IntangibleAssetTables 5. Intangible Asset (Tables) Tables http://medicineman.com/role/IntangibleAsset 25 false false R26.htm 00000026 - Disclosure - 10. Leases (Tables) Sheet http://medicineman.com/role/LeasesTables 10. Leases (Tables) Tables http://medicineman.com/role/Leases 26 false false R27.htm 00000027 - Disclosure - 11. Stockholders' Equity (Tables) Sheet http://medicineman.com/role/StockholdersEquityTables 11. Stockholders' Equity (Tables) Tables http://medicineman.com/role/StockholdersEquity 27 false false R28.htm 00000028 - Disclosure - 12. Segment Information (Tables) Sheet http://medicineman.com/role/SegmentInformationTables 12. Segment Information (Tables) Tables http://medicineman.com/role/SegmentInformation 28 false false R29.htm 00000029 - Disclosure - 13. Tax Provision (Tables) Sheet http://medicineman.com/role/TaxProvisionTables 13. Tax Provision (Tables) Tables http://medicineman.com/role/TaxProvision 29 false false R30.htm 00000030 - Disclosure - Organization and Nature of Operations (Details Narrative) Sheet http://medicineman.com/role/OrganizationAndNatureOfOperationsDetailsNarrative Organization and Nature of Operations (Details Narrative) Details http://medicineman.com/role/OrganizationAndNatureOfOperations 30 false false R31.htm 00000031 - Disclosure - 1. Liquidity and Capital Resources (Details Narrative) Sheet http://medicineman.com/role/LiquidityAndCapitalResourcesDetailsNarrative 1. Liquidity and Capital Resources (Details Narrative) Details http://medicineman.com/role/LiquidityAndCapitalResources 31 false false R32.htm 00000032 - Disclosure - 2. Critical Accounting Policies and Estimates (Details - Level 3) Sheet http://medicineman.com/role/CriticalAccountingPoliciesAndEstimatesDetails-Level3 2. Critical Accounting Policies and Estimates (Details - Level 3) Details http://medicineman.com/role/CriticalAccountingPoliciesAndEstimatesTables 32 false false R33.htm 00000033 - Disclosure - 2. Critical Accounting Policies and Estimates (Details Receivables) Sheet http://medicineman.com/role/CriticalAccountingPoliciesAndEstimatesDetailsReceivables 2. Critical Accounting Policies and Estimates (Details Receivables) Details http://medicineman.com/role/CriticalAccountingPoliciesAndEstimatesTables 33 false false R34.htm 00000034 - Disclosure - 2. Critical Accounting Policies and Estimates (Details Narrative) Sheet http://medicineman.com/role/CriticalAccountingPoliciesAndEstimatesDetailsNarrative 2. Critical Accounting Policies and Estimates (Details Narrative) Details http://medicineman.com/role/CriticalAccountingPoliciesAndEstimatesTables 34 false false R35.htm 00000035 - Disclosure - 4. Property and Equipment (Details) Sheet http://medicineman.com/role/PropertyAndEquipmentDetails 4. Property and Equipment (Details) Details http://medicineman.com/role/PropertyAndEquipmentTables 35 false false R36.htm 00000036 - Disclosure - 4. Property and Equipment (Details - Expected life) Sheet http://medicineman.com/role/PropertyAndEquipmentDetails-ExpectedLife 4. Property and Equipment (Details - Expected life) Details http://medicineman.com/role/PropertyAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - 4. Property and Equipment (Details Narrative) Sheet http://medicineman.com/role/PropertyAndEquipmentDetailsNarrative 4. Property and Equipment (Details Narrative) Details http://medicineman.com/role/PropertyAndEquipmentTables 37 false false R38.htm 00000038 - Disclosure - 5. Intangible Asset (Details) Sheet http://medicineman.com/role/IntangibleAssetDetails 5. Intangible Asset (Details) Details http://medicineman.com/role/IntangibleAssetTables 38 false false R39.htm 00000039 - Disclosure - 5. Intangible Asset (Details Narrative) Sheet http://medicineman.com/role/IntangibleAssetDetailsNarrative 5. Intangible Asset (Details Narrative) Details http://medicineman.com/role/IntangibleAssetTables 39 false false R40.htm 00000040 - Disclosure - 6. Derivative Liability (Details Narrative) Sheet http://medicineman.com/role/DerivativeLiabilityDetailsNarrative 6. Derivative Liability (Details Narrative) Details http://medicineman.com/role/DerivativeLiability 40 false false R41.htm 00000041 - Disclosure - 7. Related Party Transactions (Details Narrative) Sheet http://medicineman.com/role/RelatedPartyTransactionsDetailsNarrative 7. Related Party Transactions (Details Narrative) Details http://medicineman.com/role/RelatedPartyTransactions 41 false false R42.htm 00000042 - Disclosure - 8. Inventory (Details Narrative) Sheet http://medicineman.com/role/InventoryDetailsNarrative 8. Inventory (Details Narrative) Details http://medicineman.com/role/Inventory 42 false false R43.htm 00000043 - Disclosure - 9. Goodwill (Details Narrative) Sheet http://medicineman.com/role/GoodwillDetailsNarrative 9. Goodwill (Details Narrative) Details http://medicineman.com/role/Goodwill 43 false false R44.htm 00000044 - Disclosure - 10. Leases (Details - Balance Sheet Classification) Sheet http://medicineman.com/role/LeasesDetails-BalanceSheetClassification 10. Leases (Details - Balance Sheet Classification) Details http://medicineman.com/role/LeasesTables 44 false false R45.htm 00000045 - Disclosure - 10. Leases (Details - Operating lease cost) Sheet http://medicineman.com/role/LeasesDetails-OperatingLeaseCost 10. Leases (Details - Operating lease cost) Details http://medicineman.com/role/LeasesTables 45 false false R46.htm 00000046 - Disclosure - 10. Leases (Details - Lease maturities) Sheet http://medicineman.com/role/LeasesDetails-LeaseMaturities 10. Leases (Details - Lease maturities) Details http://medicineman.com/role/LeasesTables 46 false false R47.htm 00000047 - Disclosure - 10. Leases (Details - Minimum lease obligation) Sheet http://medicineman.com/role/LeasesDetails-MinimumLeaseObligation 10. Leases (Details - Minimum lease obligation) Details http://medicineman.com/role/LeasesTables 47 false false R48.htm 00000048 - Disclosure - 10. Leases (Details Narrative) Sheet http://medicineman.com/role/LeasesDetailsNarrative 10. Leases (Details Narrative) Details http://medicineman.com/role/LeasesTables 48 false false R49.htm 00000049 - Disclosure - 11. Stockholders' Equity (Details Warrant Activity) Sheet http://medicineman.com/role/StockholdersEquityDetailsWarrantActivity 11. Stockholders' Equity (Details Warrant Activity) Details http://medicineman.com/role/StockholdersEquityTables 49 false false R50.htm 00000050 - Disclosure - 11. Stockholders' Equity (Details Narrative) Sheet http://medicineman.com/role/StockholdersEquityDetailsNarrative 11. Stockholders' Equity (Details Narrative) Details http://medicineman.com/role/StockholdersEquityTables 50 false false R51.htm 00000051 - Disclosure - 13. Segment Information (Details- Segment Information) Sheet http://medicineman.com/role/SegmentInformationDetails-SegmentInformation 13. Segment Information (Details- Segment Information) Details 51 false false R52.htm 00000052 - Disclosure - 14. Tax Provision (Details - Components of Income Tax) Sheet http://medicineman.com/role/TaxProvisionDetails-ComponentsOfIncomeTax 14. Tax Provision (Details - Components of Income Tax) Details 52 false false All Reports Book All Reports mdcl-20210331.xml mdcl-20210331.xsd mdcl-20210331_cal.xml mdcl-20210331_def.xml mdcl-20210331_lab.xml mdcl-20210331_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true ZIP 70 0001683168-21-001967-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-21-001967-xbrl.zip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end